The sHsp expression signature in the
brain and modulation in models of
chronic neurodegeneration by Quraishe, Shmma
University of Southampton Research Repository
ePrints Soton
Copyright © and Moral Rights for this thesis are retained by the author and/or other 
copyright owners. A copy can be downloaded for personal non-commercial 
research or study, without prior permission or charge. This thesis cannot be 
reproduced or quoted extensively from without first obtaining permission in writing 
from the copyright holder/s. The content must not be changed in any way or sold 
commercially in any format or medium without the formal permission of the 
copyright holders.
  
 When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given e.g.
AUTHOR (year of submission) "Full thesis title", University of Southampton, name 
of the University School or Department, PhD Thesis, pagination
http://eprints.soton.ac.uk 
The sHsp expression signature in the 




Shmma Quraishe BSc (Hons) 
 
 
A thesis presented for the degree of 
Doctor of Philosophy 
of the 
University of Southampton 
in the 
Faculty of Medicine, Health and Life Sciences 









   2 
UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
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Doctor of Philosophy 
The sHsp expression signature in the mouse brain and modulation in models of 
chronic neurodegeneration 
 
Intrinsic protein folding pathways are modulated by molecular chaperones, such as the diverse 
group of heat shock proteins (Hsps).  Among these is the small heat shock protein (sHsp) 
family which in the mammalian genome consists of 10 low molecular weight (15 30kDa) 
members.  The sHsps have classical chaperone functions but additionally contribute to 
pathways that protect against cellular stresses, maintain the cytoskeleton, prevent protein 
aggregation and regulate apoptosis.  They contain a characteristic C terminal α crystallin 
domain, which is exclusive to the sHsp family.  In addition to their constitutive expression 
under physiological (non disease) conditions, they are also induced under conditions of 
stress/heat shock which is thought to play a role in response to protein misfolding that 
underpins disease.  There are a wide range of diseases in which the sHsps function or are 
dysfunctional by mutations, such as neurodegenerative disorders, cataract, and desmin related 
myopathy.  
  Each of the 10 sHsps is believed to have a unique expression profile.  Seven of the sHsps are 
expressed in heart and muscle, but little is known about their precise expression and/or 
physiological role in the CNS.  In the present study the expression of the mammalian sHsps in 
various mouse tissues including the brain was investigated.  This provided evidence for the 
constitutive expression of 4 sHsps in the brain.  In situ hybridization using naïve adult mice 
revealed a distinct white matter (oligodendrocyte) specific expression pattern for HspB5 (αB 
crystallin).  HspB1 (Hsp25) and HspB8 (Hsp22) demonstrated overlapping expression in the 
lateral and dorsal ventricles of the brain, as well as expression in a distinct set of motor 
neurons in the ventral horn of the spinal cord.  Further, cellular immunostaining and sub 
fractionation of brain tissue supports a distinct cellular and subcellular protein expression of 
HspB1, HspB5, HspB6 (Hsp20) and HspB8 in the brain.  Both HspB5 and HspB6 were 
enriched in the myelin fraction.  In view of the potential for induction of these sHsps by stress 
and modulation in chronic brain diseases we systematically investigated the sHsp signature in 
two distinct models of intracellular (R6/2) and extracellular (ME7) proteinopathies.  These 
models recapitulate key features of Huntington’s and prion disease, respectively.  
  Analysis of the sHsps in the R6/2 Huntington’s disease (HD) mouse model showed a specific 
down regulation of HspB5 in the white matter at all time points analyzed.  All other sHsps 
investigated did not change in this model of HD.  Analysis of the sHsps in ME7 prion disease 
showed up regulation of HspB1, HspB5 and HspB8 in the hippocampus.  For HspB1, this was 
selective to an anatomically defined sub population of astrocytes distributed in the stratum 
radiatum.  In contrast, all GFAP positive astrocytes throughout the hippocampus exhibited 
induced expression of HspB5 and HspB8.  Based on QT PCR data, the changes in expression 
of the sHsps in either model was not under transcriptional control, suggesting translation/post 
translational regulation.  The differing results in the two models suggest that the presence of 
intracellular (R6/2) or extracellular (ME7) aggregates may dictate the sHsp response 
associated with non neuronal cells. In view of the emerging significance of non neuronal cells 
in chronic diseases the data supports adaptive and differential responses that might contribute 
to and/or provide a route to therapy of distinct aspects of neurodegeneration.  3 
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Chapter 1 – Introduction   21 
  The functions of proteins rely upon their characteristic native three dimensional structure 
(Morange, 2006).  The native structure is the most thermodynamically stable state and is 
adopted via a number of distinct intermediate states (Pande and Rokhsar, 1999).  These 
intermediates transiently expose hydrophobic regions on their surface that have the 
potential to form inappropriate interactions with themselves or other cellular components 
leading to protein aggregation (Mogk et al., 2002).  Native proteins undergoing 
conformational changes and proteins that have become unfolded have the potential to form 
protein aggregates due to exposed hydrophobic surfaces.  This potential is further 
heightened by the high concentrations of macromolecules and proteins that are present in 
cells (Minton, 1983).  However, this is normally regulated and kept under control by 
molecular chaperones that have evolved to assist proteins to fold efficiently by shielding 
exposed hydrophobic surfaces and promote refolding of the substrate protein (Ellis, 2001).  
The many states that a protein can encompass have been exploited by the cell for selective 
targeting of proteins to relevant cellular compartments (Radford and Dobson, 1999).  For 
example, unfolded and partially folded protein states are known to be important for 
translocation across membranes, trafficking of proteins and in targeting proteins that are no 
longer needed, for destruction (Dunker and Obradovic, 2001).  In addition to the protein 
folding machinery involving molecular chaperones, other sophisticated mechanisms of 
protein quality control exist to monitor whether proteins are correctly folded, and to target 
them for destruction if they are not.  For example, the unfolded protein response (UPR) has 
evolved to encounter the stresses associated with the endoplasmic reticulum (ER) as a 
result of misfolded proteins.  Folding processes in the ER are assisted by molecular 
chaperones such as Bip/Grp78.  Bip is directly involved in the UPR response as it binds to 
the ER stress sensors, however when unfolded protein concentrations rise, it preferentially 
binds unfolded proteins, thus freeing the stress sensors and triggering a cascade of events 
to either slow protein synthesis, increase chaperone content or increase protein degradation 
(Sitia and Braakman, 2003, Boot Handford and Briggs, 2010).   The ubiquitin/proteasome 
degradation system is a complex system involving the ubiquitination of proteins selected 
for removal, followed by their degradation to peptides in the cytosol by the proteasome 
(Goldberg, 2003).  This process not only regulates the amount of intracellular proteins, but 
is also involved in their quality control.   22 
   Although all the above mentioned mechanisms are in place to prevent protein 
aggregation, it is inevitable that mistakes can be made leading to the formation and 
deposition of abnormal protein aggregates and disease.  Increasingly a large number of 
diseases are associated with a misfolding stress.  For example, in neurodegenerative 
diseases such as Alzheimer’s disease (AD), normally soluble amyloid β peptides (Aβ) 
accumulate in the extracellular compartment as insoluble deposits rich in β structure 
(Selkoe, 2003).   
  Interestingly the ability to form aggregates is not a unique feature of proteins associated 
with disease but is thought to be a general property of all polypeptide chains (Dobson, 
2001).  For example, myoglobin, a compact and highly soluble protein with most of its 
sequence arranged in α helices is able to form fibrillar structures under conditions that 
substantially destabilize its native fold (Fandrich et al., 2001).  Additionally two normally 
harmless protein domains, the SH3 domain from bovine phosphatidyl inositol 3 kinase 
(PI3 SH3) and the N terminal (‘acylphosphatase like’) domain of the Escherichia coli 
(E.coli) HypF protein (HypF N) are also able to form fibrillar aggregates in vitro under 
appropriate conditions (Guijarro et al., 1998, Chiti et al., 2001).    
  The key features involved in protein homeostasis as described above include protein 
folding by molecular chaperones, protein folding in the endoplasmic reticulum pathway 
and protein degradation pathways.  For the purposes of this thesis, molecular chaperones 
will be discussed more extensively below, followed by a brief description of protein 
degradation pathways.   
1.1.  Molecular Chaperones 
    Molecular chaperones, including the heat shock proteins (Hsps), are able to bind 
specifically and non covalently to interactive protein surfaces that are transiently exposed 
during cellular processes (Thulasiraman et al., 1999).  The controlled binding and release 
of substrate proteins facilitates the correct fate of the protein in the cell, whether this be 
correct folding, assembly into oligomers, transport to a specific subcellular compartment, 
membrane translocation, or even degradation (Saibil, 2000).  Molecular chaperones protect 
the cell against a variety of stresses by preventing abnormal protein aggregation and by 
keeping proteins in a state competent for either refolding or degradation (Bryantsev et al.,   23 
2007).  Some chaperones interact with a variety of polypeptide chains, whereas others act 
on specific targets via substrate specific binding domains.  For example the 70 kDa Hsps 
recognise hydrophobic protein surfaces or amino acid residues that are generally exposed 
by non native proteins and newly synthesized polypeptide chains (Rudiger et al., 1997).  
An example of the specificity of some molecular chaperones can be illustrated by the 
ClpX/Hsp100 family.  Proteins of this family form ring like subunit architectures and are 
able to disassemble multimeric or aggregated forms of certain proteins in an ATP 
dependent fashion (Schirmer et al., 1996).  Two members of this family, (ClpX and ClpA) 
recognize specific C terminal sequences on target proteins.  This property has been 
extensively characterized for the interaction between E.coli ClpX and the transposase of 
phage Mu (MuA protein) (Levchenko et al., 1997).  
  Molecular chaperones were originally termed heat shock proteins (Hsps) due to their 
initial discovery in Drosophila melanogaster cells exposed to elevated temperatures.  
However, the Hsps are also known to be induced by a wide variety of environmental or 
metabolic stresses including anoxia, ischemia and viral agents (Whitley et al., 1999, Haak 
and Kregel, 2008).  Hsps can be divided into ATP dependent and ATP independent 
families as well as being subdivided into families according to molecular weight.  The 
ATP dependent molecular chaperones require ATP hydrolysis to facilitate the folding 
process (Saibil, 2000).  Each of the distinct Hsp (molecular chaperone) families will be 
described below. 
1.1.1.  Hsps (molecular chaperone) families  
  The name of each chaperone family (Table 1.1) is derived from the molecular weight of 
the main representative protein (Lindquist, 1986, Sghaier et al., 2004).  Additionally the 
nomenclature is based on the systematic gene symbols that have been assigned by the 


























Table 1.1. Structure and function of the Hsp families.  Only the major Hsp chaperone 
families are described.  Examples of prokaryotic and eukaryotic members are given with 
brief functional descriptions (Mogk et al., 2002). 
 
 
Hsp100 (Clp family in E. coli).  The human genome encodes four Hsp100 genes 
(Kampinga et al., 2009) which encode a family of proteins with high homology to the 
Hsp70 family (described below).  The primary distinction arises from the existence of a 
long linker domain between the N terminal ATPase domain and the C terminal peptide 
binding domain (Shaner et al., 2006).  This family of Hsps targets and unfolds proteins 
tagged for degradation and misfolded proteins.  Although this family of Hsps is able to 
function independently, co operation with the Hsp70 family forms an efficient system to 
reverse protein aggregation and promote folding (Mogk et al., 2008).  Some of the Hsp100 
chaperones are associated with peptidases (e.g. ClpP) via a conserved P element (Neuwald 
et al., 1999).  Protein substrates containing specific degradation tags are unfolded and 
threaded through the axial channel of the hexameric complex in an ATP dependent   25 
process. The substrate is then threaded into the proteolytic chamber of the peptidase for 
degradation (Wang et al., 2001).  Hsp110 is ubiquitously expressed and is abundant in the 
brain with the exception of the cerebellum (Hylander et al., 2000).   
 
Hsp90 (HtpG in E. coli).  The Hsp90 family consisting of 5 members are also ubiquitously 
expressed, ATP dependent molecular chaperones (Chen et al., 2005, Kampinga et al., 
2009), with a molecular weight of approximately 90 kDa.  Hsp90 is one of the most 
abundant proteins in eukaryotic cells accounting for 1 2% of all cellular proteins 
(Csermely et al., 1998).  Isoforms of Hsp90 are found in the cytosol (Hsp90 α, inducible 
and Hsp90 β, constitutive), endoplasmic reticulum (ER) (Grp48) and mitochondria 
(TRAP) (Csermely et al., 1998, Krishna and Gloor, 2001).  This family of chaperones is 
involved in signal transduction, protein folding, protein degradation and they are necessary 
for viability.  Hsp90 binds, stabilizes and regulates steroid hormone receptor function and 
protein kinases and is therefore essential in cellular signal transduction networks (Young et 
al., 2001).  In addition to these roles Hsp90 is thought to play an important role in 
evolutionary capacitance (Bergman and Siegal, 2003).  Stressful events leading to 
developmental remodelling by Hsp90 could allow variations in several processes to occur, 
leading to productive changes in multiple systems (Rutherford et al., 2007). 
   
Hsp70 (BiP, DnaK in E. coli).  13 members of the Hsp70 chaperone family are encoded by 
the human genome (Kampinga et al., 2009).  Key members of this family include inducible 
Hsp70, constitutively expressed cognate Hsc70, the ER localised Grp78 (Bip) and 
mitochondrial MtHsp75.  Hsp70 proteins interact with Hsp40 proteins (DnaJ in E. coli) to 
increase their chaperone activity by increasing the ATP consumption rate.  The Hsp70 
family recognizes short hydrophobic sequences which become exposed in misfolded 
proteins and proteins emerging from the ribosome.  They are also involved in membrane 
translocation and regulation of the heat shock response (Saibil, 2000). 
  
Hsp60 (GroEL/GroES complex in E. coli) can be found in a large (~ 1 MDa) chaperone 
complex that forms a barrel shaped structure.  GroES which acts as a protein cap binds to 
GroEL in the presence of ATP confining the enclosed substrate protein in the barrel, thus   26 
allowing the protein to fold in a favourable environment.  Members of the Hsp60 family 
are located in both the cytoplasm and the mitochondria where they are involved in protein 
folding and assembly after synthesis (Horwich et al., 2007). 
 
Hsp40 (DNAJ).  The Hsp40 family are co chaperone proteins that regulate complex 
formation between Hsp70 and substrate proteins by driving the conversion of ATP to ADP 
(Fewell et al., 2004).  The Hsp40 family is probably the largest Hsp family in humans and 
is identified by the conserved J domain which regulates Hsp70 ATPase activity (Kampinga 
et al., 2009).  The Hsp40 family can be divided into 3 different subtypes.  Type I and type 
II proteins function as ATP dependent chaperones that bind non native polypeptides and 
protect cells from stress by preventing protein aggregation.  Type III proteins do not appear 
to be general chaperones and have evolved to contain polypeptide binding domains that 
recognize specific substrates (Fan et al., 2004). 
 
Small heat shock proteins (sHsps) are low molecular weight chaperone proteins (Taylor 
and Benjamin, 2005).  They form large dynamic oligomeric structures and are able to bind 
several non native proteins per oligomeric complex (Haslbeck et al., 2008).  They have 
been suggested to be involved in the inhibition of apoptosis, organization of the 
cytoskeleton and also in preventing protein aggregation (Haslbeck, 2002, Sun and 
MacRae, 2005b).  In contrast to other Hsp families, the sHsps do not require ATP for their 
chaperone function (Jakob et al., 1993, Ganea, 2001).  The tissue specific expression, 
general characteristics and properties of the sHsps will be discussed in section 1.3 and in 
detail in Chapter 3.   
1.2.  Protein degradation 
  In addition to protein folding processes, protein degradation is important in regulating 
protein quality control and turnover.  This highly regulated process involves two major 
pathways; the ubiquitin proteasome pathway (UPP) and the autophagic lysosomal 
pathway.   27 
1.2.1.  The ubiquitin proteasome pathway 
  The eukaryotic proteasome consists of the 20S catalytic core proteasome.  This can be 
bound by different regulators such as the 11S and 19S subunits.  These can modify the 
activity and selectivity of the degradation process (Volker and Lupas, 2002).  The 20S core 
proteasomal particle is an enzymatic hollow barrel made up of 4 stacked rings.  Each ring 
consists of 7 subunits with the outer rings being composed of homologous alpha subunits 
and the inner rings of beta subunits.  Catalytic activity resides in 3 of the beta subunits in 
each ring, giving 6 catalytically active sites in the core of the proteasomal structure 
(Zwickl et al., 2001).  Binding of the 11S and 19S subunits to the 20S core proteasome 
leads to differing proteasomal protease activity, substrate specificity and degradation.  For 
example the 26S proteasome, consisting of the core with a 19S regulatory subunit on each 
side, is mainly responsible for the recognition and degradation of poly ubiquitinated 
proteins (Glickman and Maytal, 2002).  However, addition of two 11S regulatory subunits 
on each side leads to increased peptidase activity and generation of small peptide products 
for antigen presentation by the MHC I complex (Hill et al., 2002). 
  Proteins targeted for degradation by the proteasome via the addition of ubiquitin (ub) 
typically involves three enzymes: E1 (ub activating enzyme) which hydrolyses ATP and 
forms a thioester bond with ub; E2 (ub  conjugating enzyme) removes ub from E1 and 
forms a similar thioester bond with it; and E3 (ub ligase) binds both the substrate protein 
and E2/ub complex and transfers the ub molecule to the substrate protein (Figure 1.1).  
Chains of four or more ub molecules form the recognition signal for targeting/shuttling to 

























Figure 1.1. The ubiquitin proteasome system.  Proteins targeted for proteasomal 
degradation are covalently modified with ub.  Typically, three enzymes are involved in this 
process; E1 (ub activating), E2 (ub conjugating) and E3 (ub ligase) enzymes.  Proteins 
tagged with four or more ub molecules are shuttled to the proteasome where they are 
reduced to peptides.  Peptides are further broken down by peptidases in the cytosol (Burger 
and Seth, 2004). 
 
1.2.2.  The autophagic lysosomal pathway 
  Proteins and protein aggregates that are not targeted to the proteasome or are poor 
substrates for proteasomal processing can be processed by autophagy (Rubinsztein, 2006).  
Three pathways exist that can target proteins for lysosomal degradation (Figure 1.2).  In 
microautophagy, small areas of the cytosol are engulfed via lysosomal invaginations, and 
proteins are degraded in the lumen of this organelle.  During macroautophagy the 
cytoplasm is sequestered into double membrane vesicles or autophagosomes.  
Autophagosomes fuse with lysosomes and the vacuolar contents are enzymatically 
degraded by acidic lysosomal hydrolases (Yorimitsu and Klionsky, 2005).  The third 
pathway for cytosolic protein clearance is chaperone mediated autophagy (CMA).  This 
pathway does not require any vesicular trafficking (Majeski and Dice, 2004), but involves 
the recognition of a pentapeptide motif (KFERQ) by the cognate molecular chaperone 
Hsc70, which then translocates the protein across the lysosomal membrane through   29 
binding with the receptor lysosome associated membrane protein 2A (LAMP 2A) (Zhou et 













Figure 1.2.  Multiple pathways of protein degradation in lysosomes.  In 
microautophagy, portions of the cytosol are continuously internalized via lysosomal 
invaginations.  In macroautophagy, the cytoplasm is sequestered into double membrane 
structures, known as autophagosomes, which fuse with lysosomes.  In CMA, specific 
cytosolic proteins are transported into lysosomes via a molecular chaperone receptor 
complex composed of Hsp70 and LAMP 2 (Crotzer and Blum, 2005). 
   
 
  Previously it was thought that protein folding by molecular chaperones and protein 
degradation pathways were distinct and opposing processes, but it has been suggested that 
molecular chaperones cooperate directly with the UPP and the autophagic pathways (Esser 
et al., 2004).  An example of cooperation with the UPP is given by the co chaperone CHIP 
(C terminus of Hsp70 Interacting protein), which facilitates poly ubiquitination of target 
proteins and shuttles misfolded proteins from Hsp70 to the UPP.  CHIP inhibits Hsp70 
refolding activity through tetratricopeptide repeat (TPR) domains at its N terminal, and 
facilitates ubiquitination of the substrate protein through its ubiquitin ligase (U box) 
domain (Kabashi and Durham, 2006).  An example of the involvement of molecular 
chaperones in autophagy can be illustrated by HspB8.  It has recently been shown to 
associate with Bag3, a stimulator of autophagy.  The ability of HspB8 to prevent the   30 
accumulation of aggregation prone proteins (huntingtin containing 43 glutamines) was 
found to be dependent on its interaction with Bag3 (Carra et al., 2008).  
1.3.  The small Heat Shock Protein (sHsp) family 
1.3.1.  Structures of the sHsps 
  sHsps represent a diverse family of proteins that are grouped together based on their 
structural homology and low molecular weight.  The homology and number of sHsps in 
different species varies considerably, with up to 19 in Arabidopsis thaliana and 10 in 
mammals (Kappe et al., 2003, Waters and Rioflorido, 2007).  They share significant 
sequence similarity within the approximately 90 residue C terminal α crystallin domain, 
which is the characteristic region of these sHsps (Figure 1.3).  They have a more variable 
N terminal region and a short and variable C terminal tail. 
  The sHsps form high oligomeric, globular structures.  However the number of subunits 
and flexibility of the complex varies in different species.  For three members the structure 
of the oligomeric complexes have been solved (Figure 1.4).  HspB5 oligomers are 
structurally variable due to the continuous exchange of subunits (Haley et al., 1998).  
However, the quaternary structure of Hsp16.5 from Methanococcus jannaschii, a 
hyperthermophilic organism, is well defined.  The building block is a dimer interacting via 
β sheets in each monomer.  The oligomer forms a hollow barrel of 24 monomers (Kim et 
al., 1998).  The wheat Hsp16.9 assembles into a dodecameric double disk.   The structures 
that have been solved so far support the idea that the dimer is the smallest exchangeable 























Figure 1.3.  Schematic showing the domain structure of different sHsps.                                     
The N terminal is of variable length and is not conserved throughout the sHsp family.  The 
α crystallin domain folds into an anti parallel β sheet sandwich (conserved region in 
sHsps).  The C terminal is variable in length and is moderately conserved. 
(A) General domain structure.  (B) Comparison of different sHsps.  Black regions indicate 
Phe Pro rich regions (Haslbeck, 2002).  
 
   
 
 
Figure 1.4. Three dimensional structures of the sHsps.  (A) Cryoelectron microscopy 
structure of α crystallin shows a 32mer with an outer diameter of 18nm (Haley et al., 
1998).  (B) Crystal structure of Hsp16.5 from Methanococcus jannaschii shows a 24mer 
with an outer diameter of 12nm (Kim et al., 1998).  (C) Crystal structure of wheat Hsp16.9 




     32 
  Mammalian sHsps are found as homo  or heteromeric complexes, consisting of 2 40 
subunits (Bova et al., 2000, Sugiyama et al., 2000).  The α crystallin domain consists of 
two layers of three and five anti parallel strands, respectively, connected by a short inter 
domain loop, forming the β sheet (Haslbeck et al., 2005).  The α crystallin domains of 2 
monomers interact tightly to form the dimeric building block of the sHsp oligomers.  The 
N terminal region contains α helical components and is variable in structure (Kappe et al., 
2003).  The N terminal of many of the sHsps contains a small prolinephenylalanine rich 
region with one or two WD/EPF motifs.  This region seems to be important in oligomeric 
complex formation and also for chaperone activity (Kim et al., 1998, Theriault et al., 2004, 
Stamler et al., 2005).  The C terminal tail is highly motile and flexible, and is also involved 
in stabilizing the oligomeric structure through contacts between a conserved motif in the 
C terminal region and a hydrophobic patch in the α crystallin domain of a neighbouring 
subunit (Haslbeck et al., 2005).  The structure of the sHsps is important for its functional 
role as will be described below. 
1.3.2.  Functions of the sHsps 
  The sHsps prevent stress induced irreversible aggregation of unfolded and damaged 
proteins (Van Montfort et al., 2001).  Expression of most sHsps is developmentally 
regulated, and increases in response to heat stress (Basha et al., 2004), oxidative stress 
(Volkov et al., 2006), ischemia (Golenhofen et al., 2004) and environmental stresses 
(Siddique et al., 2008).  Cytoskeletal rearrangement, redox homeostasis, inflammation and 
apoptosis are amongst the cellular processes in which the sHsps are involved, as will be 
described below (Kappe et al., 2003, Verschuure et al., 2003, van Noort, 2008).  These 
processes are also modulated in disease conditions therefore the potential modulation of 
these processes by the sHsps during disease will be discussed in section 1.6.3. 
  sHsps associate with non native substrate proteins to form stable sHsp substrate 
complexes (Basha et al., 2006).  This allows efficient prevention of irreversible substrate 
aggregation.  Release of active substrate proteins from these complexes occurs 
spontaneously or requires cooperation with proteins from ATP dependent chaperone 
families such as Hsp70 Hsp40 and Hsp100.  Although Hsp70 Hsp40 can act directly on   33 
protein aggregates, the presence of sHsps increases the efficiency of the process (Cashikar 
et al., 2005). 
  As described above the sHsps normally exist as large oligomers, which change dynamic 
properties (shape and size) on exposure to stress and/or a substrate (Haslbeck et al., 2005).  
The exact mechanism involved in binding of misfolded proteins is unclear, however three 
modes of action have been proposed for the sHsps: (1) substrates are directly bound by the 
large chaperone oligomer (Kim et al., 2003), (2) the oligomer dissociates into smaller 
subunits exposing hydrophobic surfaces which can bind unfolded substrates.  Then large 
soluble complexes are formed which are processed by the ATP dependent refolding 
machinery (Haslbeck et al., 1999, Van Montfort et al., 2001), or (3) sHsp molecules 
combine with insoluble protein aggregates, which allows disaggregation and refolding by 
the ATP dependent refolding machinery (Stamler et al., 2005, Cashikar et al., 2005). 
  The function of the sHsps is intricately linked to their phosphorylation states.  They can 
be reversibly phosphorylated at several serine residues by a multitude of kinases.  
Phosphorylation results in a change in the oligomerisation status of several sHsps (Bukach 
et al., 2009).  For example, phosphorylation of HspB1 reduces the large HspB1 oligomeric 
complexes to much smaller oligomers and additionally shifts chaperone function to actin 
stabilization (Figure 1.5) (Arrigo et al., 2007).  
 










Figure 1.5. Biochemical properties of the sHsps.  Large sHsp oligomeric structures are favoured 
under conditions of stress and associate with unfolded proteins.  Phosphorylation decreases the size 
of the oligomers.  Large non phosphorylated oligomers of sHsp (>300 kDa) can protect cells 
through their chaperone activity (Rogalla et al., 1999) and small oligomers may act at the level of 
F actin polymerization/depolymerization (Benndorf et al., 1994).   34 
 
  HspB1 is able to cap the barbed end of the actin filament in its monomeric and/or non 
phosphorylated form, preventing the addition of monomers and subsequent filament 
growth (Williams et al., 2005).  The degree of phosphorylation and the structural 
organization of the sHsps dictate the modulatory activity on actin polymerization/ 
stabilisation.   
1.3.3.  The mammalian sHsp family.  
  The mammalian sHsp family comprises of 10 members, HspB1 HspB10 (Table 1.2) 
which have varying expression patterns with some being ubiquitously expressed and others 
specific to certain tissues such as the lens and testis (Verschuure et al., 2003, de Wit et al., 
2004).  Heart and muscle are the two tissues in which up to seven sHsps are expressed at 
the same time and at relatively high levels (Verschuure et al., 2003).  The general and 
selective expression may reflect the particular needs of certain tissues and the potential, 
selective use of their activities in protection against physiological stress particularly 
associated with a cell type.  Each member of the mammalian sHsp family will be described 
below.  For clarity, physiological stress encompasses the normal homeostatic mechanisms 
which are able to buffer changes for example in levels of misfolded proteins and oxidative 
stress as a result of normal cellular functions.  However pathological stress refers to an 
abnormal acute and/or chronic stress conditions such as the presence of misfolded protein 
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Formal name  Alternative name  Distribution 
HspB1  Hsp27/Hsp25  Ubiquitous (a) 
HspB2  MKBP  Cardiac and Skeletal muscle (b) 
HspB3     Cardiac and Skeletal muscle (c) 
HspB4  αA crystallin  Lens (d) 
HspB5  αB crystallin  Ubiquitous (a) 
HspB6  Hsp20  Ubiquitous (b) 
HspB7  cvHsp  Cardiac and Skeletal muscle (e) 
HspB8  Hsp22/H11  Ubiquitous (b) 
HspB9     Testis (b) 
HspB10  ODF1  Testis (f) 
 
Table 1.2.  sHsps nomenclature and distribution.  Currently accepted nomenclature, 
alternative names and tissue distribution are described.  Highlighted names are the 
preferred use in this thesis.  HspB1, HspB5, HspB6 and HspB8 are ubiquitously expressed 
whereas HspB4, HspB9 and HspB10 show selective expression.  (a) (Tallot et al., 2003); 
(b) (Verschuure et al., 2003); (c) (Sugiyama et al., 2000); (d) (Brady et al., 1997); e). 




HspB1/Hsp25/27 is a ubiquitously expressed protein with high levels in cardiac and 
skeletal muscle.  HspB1 is one of the most efficient thermo protective Hsps when over 
expressed alone.  It is found in large oligomers with a molecular mass of about 700kDa 
(Theriault et al., 2004).  It is involved in cytoskeleton rearrangement and stabilization by 
its interaction with actin and the intermediate filaments in a phosphorylation dependent 
manner as described above (Perng et al., 1999).  Mitogen activated protein kinases 
associated protein kinases (MAPKAP kinase 2, 3) are involved in the phosphorylation of 
HspB1 on three serine residues (Figure 1.6).  Phosphorylation of Ser
82 allows HspB1 
oligomers to dissociate and  phosphorylation on Ser
15 allows HspB1 to perform its thermo 
protective role (Theriault et al., 2004).   
 
 






Figure 1.6. Domain structure of HspB1.  Light box: conserved region in N terminus; 
black box: α crystallin domain; grey box: WDPF domain; ^^^^: flexible domain; P: 
phosphorylated serine residues of human protein.  Position 137 corresponds to the only 
cysteine residue in the protein sequence.  If deleted, dimer formation and the protective 
capacity of HspB1 are eliminated.  Positions of point mutations that are responsible for 
pathologies are indicated by arrows (Arrigo et al., 2007). 
 
 
  HspB1 is involved in intracellular redox homeostasis proposed to occur via its 
interactions with enzymes (e.g. glutathione reductase) involved in keeping glutathione 
(GSH), an antioxidant, in its reduced form.  Additionally HspB1 expression correlates with 
a decrease in iron levels, a catalyser of hydroxyl radical production (Arrigo et al., 2005a). 
  HspB1 is also involved in the signalling pathways that modulate the inflammatory 
response; however there is conflicting evidence on the role of HspB1 in inflammation.  For 
example HspB1 is a component of the p38 MAPK signalling pathway, which has 
important functions in the inflammatory response.  It has been shown to regulate a pro 
inflammatory response in HeLa cells and fibroblasts (Alford et al., 2007), however in 
keratinocytes, HspB1 was found to have a protective effect against pro  inflammatory 
mediator release.  Interestingly this was associated with the NF kB signalling pathway and 
not MAPK (Sur et al., 2008). 
  HspB1 plays a further significant role in apoptosis via its interactions with and inhibition 
of caspase 3 and  9 (Theriault et al., 2004).  It has also been shown to inhibit Bax 
activation, oligomerisation, and translocation to mitochondria, reducing cytochrome c 
release by promoting Akt activation, an anti apoptotic serine/threonine kinase (Havasi et 
al., 2008).  The protective activity of HspB1 may be cell type specific as it was shown to 
protects against apoptotic stimuli in neuronal and other cell types (Wyttenbach et al., 
2002), but not in cardiomyocytes (Kamradt et al., 2002). 
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HspB2/MKBP (myotonic dystrophy protein kinase binding protein) expression is 
restricted to the heart and muscle (Verschuure et al., 2003).  HspB2 binds and activates 
myotonic dystrophy protein kinase (DMPK), an enzyme that when absent results in 
myotonic dystrophy.  DMPK plays an essential role in maintaining muscle structure and 
function and HspB2 protects DMPK from heat/stress induced inactivation.  HspB2 is 
localized to the neuromuscular junction in skeletal muscle cells where DMPK is 
concentrated, but also at the Z bands of myofibrils (Suzuki et al., 1998).  There is limited 
information regarding the role of this sHsp in regulation of the cytoskeleton, oxidative 
stress and inflammation.  However, HspB2 has been shown to interact with the actin 
cytoskeleton in cell lines subjected to proteasomal inhibition (Verschuure et al., 2002).  A 
functional relationship between HspB2 and the mitochondria has also been suggested by 
its association with the outer mitochondrial membrane.  HspB2 may play a protective role 
here under stress conditions or it may mediate the transfer of proteins from the cytosol to 
the mitochondria (Nakagawa et al., 2001).  Although not previously implicated in the 
regulation of apoptosis, HspB2 has recently been described as a novel inhibitor of caspase 
activation by TRAIL (TNF related apoptosis inducing ligand) and TNF α (tumour necrosis 
factor) in the extrinsic apoptotic pathway by suppressing caspase 8 and  10 activation 
(Oshita et al., 2010). 
  The restricted expression of this sHsp has been ascribed to its gene location.  HspB2 and 
HspB5 genes are located in a head to head manner in the human, mouse and rat genomes 
(Doerwald et al., 2004) and are transcribed in opposite directions.  An intergenic enhancer 
region preferentially activates the HspB5 promoter, additionally 2 cis elements that 
interact with glucocorticoid receptor (GR) and SP1, differentially regulate the promoters of 
both genes (Swamynathan and Piatigorsky, 2007). 
 
HspB3 is expressed in muscle cells along with HspB2.  It is induced during muscle 
differentiation under the control of MyoD.  HspB3 and HspB2 form oligomeric complexes 
of approximately 150 kDa (Suzuki et al., 1998).  This complex is independent of the 
complexes formed by HspB1, HspB5 and HspB6.  It has been proposed that HspB3/HspB2 
complexes represent an additional stress response system to that observed by HspB1 and 
HspB5 in muscle (Sugiyama et al., 2000).  HspB3 was also shown to interact with the actin   38 
cytoskeleton in the same study showing HspB2 association in cell lines subjected to 
proteasomal inhibition (Verschuure et al., 2002).  There is currently no information 
regarding the involvement of HspB3 in oxidative stress, inflammation and apoptosis. 
 
HspB4/αA crystallin was thought to be specifically expressed in the lens, but non 
lenticular expression has been reported in the rat in significant amounts in the spleen and 
thymus whereas low levels were found in retina, intestines, liver, kidney, adrenal, 
cerebellum and brainstem (Kato et al., 1991).  HspB4 (and HspB5) play structural roles 
and are important in maintaining the transparent properties of the lens (Peterson et al., 
2005).  They display chaperone activity, thereby preventing proteins from forming light 
scattering aggregates.  The two isoforms make up one third of the proteins in the eye lens 
(Yan and Hui, 2000). 
  HspB4 is thought to be important in microtubule integrity and assembly in lens epithelial 
cells by maintaining a pool of unassembled tubulin (Xi et al., 2006).  The contribution of 
HspB4 to redox homeostasis has been demonstrated in knockout studies showing increased 
susceptibility of retinal pigment epithelium to apoptosis induced by hydrogen peroxide 
treatment (Yaung et al., 2007).  HspB4 inhibits apoptosis by inhibiting the caspase3/6 
pathway (Morozov and Wawrousek, 2006). 
 
HspB5/αB crystallin is a ubiquitously expressed protein (Verschuure et al., 2003) and is a 
major constituent of the eye lens.  It is associated with cytoskeleton proteins, for example 
HspB5 modulates the assembly of the intermediate filament protein vimentin and stabilizes 
actin filaments in a phosphorylation dependent manner (Singh et al., 2007).  HspB5 also 
associates with tubulin, and microtubule associated protein (MAP) (Sakurai et al., 2005).  
This is mediated through the alpha crystallin domain (Ohto Fujita et al., 2007). 
  HspB5 has been found to interact with FBX4, an F box containing protein that is a 
component of the ubiquitin protein isopeptide ligase SCF (SKP1/CUL1/F box).  This 
interaction is dependent on phosphorylation of HspB5 (den Engelsman et al., 2003).  It is 
phosphorylated at three serine sites by protein kinases (Figure 1.7).  At least two pathways 
are implicated in HspB5 phosphorylation; the MAPKAPK2 kinases phosphorylate serine   39 
59 whereas serine 45 is thought to be regulated by p42/p44 MAPK.  The kinase involved 
in the phosphorylation of serine 19 is still unknown (Rouse et al., 1994).  
  
 
Figure 1.7. Domain structure of HspB5.  Light box: conserved region in N terminus; 
black box: α crystallin domain; grey box: WDPF domain; ^^^^: flexible domain; P: 
phosphorylated serine residues.  Positions of point mutations that are responsible for 
pathologies are indicated by arrows (Arrigo et al., 2007).  
 
 
  HspB5 is reported to bind Cu
2+ with close to picomolar affinity, and has been shown to 
inhibit Cu
2+ induced oxidation of ascorbate and hence the production of reactive oxygen 
species (ROS) (Ahmad et al., 2008).  HspB5 is directly involved in inflammatory 
processes in multiple sclerosis (MS); however this will be discussed in section 1.6.3 in the 
context of modulation of disease processes by sHsps. 
  HspB5 has anti apoptotic functions through its potential interactions with the p53 and 
caspase 3 pathway (Kamradt et al., 2002, Liu et al., 2007).  HspB5 was able to reduce the 
levels of hydrogen peroxide induced apoptosis in C6 astroglioma cell lines (Shin et al., 
2009).  Its expression is also correlated with TRAIL resistance in a number of human 
cancer cell lines (Kamradt et al., 2005, Liu et al., 2007). 
   
HspB6/Hsp20 is a ubiquitously expressed protein, with varying expression levels during 
development (Verschuure et al., 2003).  It plays a role in the relaxation of vascular muscle 
and in the inhibition of platelet aggregation (Bukach et al., 2004).  HspB6 interacts with 
itself, HspB1, HspB5 and HspB8 (Fontaine et al., 2005), however it is not heat inducible 
and has been shown to have a much lower chaperone activity than HspB5 (van de Klundert 
et al., 1998).  It is regulated by several cellular pathways for example the cyclic nucleotide 
(cAMP) dependent protein kinase (PK) pathways involving PKA and PKG eliciting 
functions such as smooth muscle relaxation (Komalavilas et al., 2008).  HspB6 is   40 
phosphorylated at Ser16 by PKA (Brophy et al., 1997).  Although limited, there is 
evidence for HspB6 binding to actin in a phosphorylation dependent manner and a 
potential role in cytoskeletal stabilization (Dreiza et al., 2005). 
  HspB6 over expression in cells exposed to doxorubicin (DOX) a widely used anti tumour 
drug was found to enhance cardiac function by improving cell contraction, attenuating 
DOX induced oxidative stress and was cardioprotective by interacting with Bax, a pro 
apoptotic protein, thereby exerting anti apoptotic actions.  These effects were mediated by 
the Akt kinase pathway (Fan et al., 2005, Fan et al., 2008). 
   
HspB7/cvHsp is abundantly expressed in the heart and muscle (Verschuure et al., 2003).  
HspB7 mRNA is over expressed in insulin sensitive tissue in obese rats, suggesting that 
HspB7 may be associated with obesity and related metabolic disorders.  It binds to the 
cytoskeletal protein α filamin (an actin binding protein) in the heart (Krief et al., 1999). 
  
HspB8/Hsp22 is a ubiquitously expressed protein (Verschuure et al., 2003).  HspB8 
interacts with itself, HspB2, HspB5, HspB6 and HspB7 (Sun et al., 2004, Fontaine et al., 
2005) as well as with other chaperones, such as the Hsp70 family.  It is thought to have 
kinase activity in vitro (Kim et al., 2004) and potentially has a direct link to the Akt/PKB 
kinase pathway (Sui et al., 2009).  HspB8 forms a stable complex with the co chaperone 
Bag3 in vitro and is thought to facilitate the removal of abnormal proteins by the 
stimulation of autophagy (Carra et al., 2008).  Although HspB8 has not been shown to 
interact directly with intermediate filaments, it is possible it does via interactions with 
HspB1 (Der Perng and Quinlan, 2004, Sun et al., 2004).  
  HspB8 has recently been suggested to play a role during the inflammatory process in 
autoimmune diseases such as rheumatoid arthritis, by the activation of dendritic cells via 
Toll like receptor 4 (TLR 4) (Roelofs et al., 2006). 
   HspB8 is an anti apoptotic protein, regulating its pro survival effects via activation of the 
phosphatidylinositol 3 kinase (PI3K)/Akt pathway thus promoting cell growth and survival 
(Sui et al., 2009). 
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HspB9 is expressed in the testis, and in various types of cancer.  HspB9 interacts with 
TCTELI, a light chain component of dynein (tubulin motor protein), which may transport 
it to the nucleus.  It is found in the seminiferous tubuli, specifically in the nuclei of 
spermatogonia and early spermatids (de Wit et al., 2004; Kappe et al., 2001). 
 
HspB10/ODF1 is also expressed in testis.  It has a C terminal tail that is similar to some 
keratins and possibly serves a cytoskeletal structural role in the sperm tail (Fontaine et al., 
2003). 
  As described above and in addition to their chaperone functions, the sHsps are important 
in regulating a variety of cellular functions such as cytoskeleton homeostasis, oxidative 
stress and pro/anti survival pathways.  Interestingly these cellular functions are perturbed 
in many diseases, particularly protein misfolding diseases (also called “proteinopathies”) 
which will be discussed below. 
1.4.  Protein misfolding, proteinopathies and sHsps 
  Protein aggregates and deposits do not accumulate at steady state suggesting that the 
cellular machinery regulating protein folding and degradation, including the sHsps is 
sufficient to prevent accumulation of misfolded proteins.  In contrast protein homeostasis 
becomes disrupted in disease and misfolding and aggregation are recognized as common 
molecular events for a large number of human diseases (proteinopathies) (Chiti et al., 
2001; Chiti and Dobson, 2006; Perutz, 1999). 
  The characteristic abnormal protein deposits in proteinopathies can be found 
extracellularly and are referred to as ‘amyloids’ or ‘plaques’, or they can be present 
intracellularly and are referred to as Lewy bodies (LBs) or inclusion bodies, (IBs).  Among 
these diseases are severe neurodegenerative disorders, such as AD, Huntington’s disease 
(HD), Parkinson’s disease (PD) and spongiform encephalopathies or Prion disease (Table 
1.3) (Stefani and Dobson, 2003).  HD and prion disease will be discussed in detail in 
section 1.7 and 1.8 respectively to represent an intracellular misfolding (HD) and an 
extracellular misfolding (prion) disease.  Neurodegeneration is a general term used to 
describe the progressive loss of structure and function of neurons and their demise. 
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Alzheimer’s   APP and Tau  Both Plaques (Aβ1 40/42),  and 
NFT (hyper phosphorylated tau) 
Cortex 
Prion   Prion (PrP
c)  Extracellular (PrP





Intracellular (mtHtt inclusions)  Cortex, Striatum 
Parkinson’s  α synuclein 
 
Intracellular (Lewy bodies)  Substantia nigra, 
Putamen 
Table 1.3. Examples of proteinopathies characterized by intracellular/ extracellular 
aggregates. The proteins associated with each disease are given along with the location of 
aggregates.  The most vulnerable brain regions are noted.   
  
  
  The accumulation of protein aggregates of normal cellular proteins (tau , huntingtin (htt), 
prion (PrP
c)) that have become misfolded or modified in these diseases suggests the 
involvement of common molecular pathways and pathogenic mechanisms leading to 
neurodegeneration (Bucciantini et al., 2002).  These include abnormal protein dynamics 
and degradation, ROS generation, impaired bioenergetics, disruption of cellular transport 
and a neuro inflammatory response.  These mechanisms are extensively discussed in the 
context of commonalities in neurodegenerative diseases in the recent review by (Jellinger, 
2009).  All of these diseases (proteinopathies) have differing region and cell specific 
vulnerabilities/ pathologies in the CNS.  This may be indicative of molecular differences 
between cell types and brain regions as well as the misfolded protein and location of 
aggregates, providing a context for disease (Chung et al., 2005).  
  Although it is still unclear whether the presence of microscopically visible protein 
aggregates is a cause or a consequence of pathology, it is clear that the process of protein 
misfolding and aggregation can affect cellular function and cause cytotoxicity (Esser et al., 
2004).   
  Misfolded proteins aggregate into fibrillar structures or amyloids.  However amyloid 
fibrils appear to be less toxic than pre fibrillar structures/precursors (Figure 1.8).  Soluble 
levels of Aβ more closely correlate with pathology than insoluble, fibrillar amyloid plaques 
(Walsh et al., 2002).  These intermediate species that form different structures (annular and 
spherical) as determined by atomic force microscopy (Wacker et al., 2004) are thought to   43 
confer toxicity by their intrinsic ability to impair fundamental cellular processes (Stefani 
and Dobson, 2003).  It may be speculated that chaperones act at the level of protofibrils 
promoting the generation of amorphous, non toxic aggregates, thus protecting against 















Figure 1.8.  A model for molecular chaperone suppression of neurotoxicity.  Fibril 
formation is a multi step process involving a number of intermediate structures that are 
thought to mediate neurotoxicity.  Chaperone proteins may prevent neurotoxicity by 
preventing the conversion of native proteins to abnormal toxic conformations, (A) by 
preventing the formation of pre fibrillar intermediates, (B) by preventing the conversion to 
mature fibrils, (C) and/or by facilitating the conversion of toxic intermediates to non toxic 
amorphous aggregates (D). (Muchowski, 2002; Wacker et al., 2004). 
 
 
  The current body of evidence suggests expression of the sHsps in neurodegenerative 
conditions is predominantly associated with non neuronal cells (Wyttenbach et al, 2010 in 
press).  Whether abnormal protein aggregates are localized to neurons or glial cells, up 
regulation of the sHsps during disease occurs predominantly in glial cells (section 1.6.2) 
and implies distinct pathological mechanisms for both cell types.  Cultured neurons and 
astrocytes show different expression levels and compositions of individual sHsps.  HspB1 
and HspB5 are predominantly expressed in unstressed cells, and even after stress, sHsp 
levels are increased in glial cells but remain low in neurons (Schwarz et al., 2010).    44 
Oligodendrocytes similarly respond to oxidative and proteasomal stress by inducing the 
endogenously expressed HspB5 (Goldbaum and Richter Landsberg, 2001).  As all brain 
cell types (neurons and glia) are potentially involved in neurodegenerative processes, these 
cell types will be described below.  
1.5.  The central nervous system (CNS) and vulnerability to proteinopathies  
  The mammalian CNS is subdivided into many regions and interconnected circuits.  This 
requires highly specialized cell types such as neurons involved in information processing 
and storage, immuno reactive microglial cells, astrocytes that interact with synapses and 
blood vessels regulating key aspects of brain bioenergetics and oligodendrocytes the 
myelin producing cells of the CNS. 
1.5.1.  Neuronal cells  
  Neuronal cells are highly compartmentalized structures, with distinct functional roles 
(Somogyi et al., 1998).  For example, neuronal dendrites are involved in plastic adaptation 
including long term potentiation and depression and homeostatic plasticity which allows 
neuronal cells to stabilize synaptic strength and intrinsic excitability (Yu and Goda, 2009).  
The spatial organization of neurons with presynaptic terminals often a great distance from 
the cell body makes it crucial for this sub compartment to be partially independent of the 
cell body for certain processes, such as regulating the manufacture of proteins needed for 
specialized function at the synapse (Chicurel et al., 1993).  Indeed protein synthesis has 
been shown to occur in axons and nerve terminals (Macara et al., 2009).  This local 
synthesis and availability of crucial proteins would allow neurons to respond promptly to 
environmental stimuli (Giuditta et al., 2008).  Increasingly, synaptic changes, dysfunction 
and death are reported in neurodegenerative diseases, preceding loss of cell bodies (Gray et 
al., 2009, Nimmrich and Ebert, 2009).  The cell autonomous properties of the synapse may 
underlie the vulnerability of this region to neurodegeneration and misfolded protein insult. 
  The initial loss of neurons in CNS neurodegenerative diseases is selective to specific 
brain regions and neuronal sub types in each individual proteinopathy.  For example in AD 
there is selective loss of large pyramidal neurons in layer III and V of the cortex (Hampel 
et al., 2002).  In HD, an early loss of medium spiny neurons and a relative sparing of 
interneurons (Cowan and Raymond, 2006) occurs in the severely affected basal ganglia   45 
(caudate and putamen).  In PD, dopaminergic neuronal cell loss is most prominent in the 
substantia nigra pars compacta (Gasser, 2009).  In prion disease neuronal loss in the CNS 
is more extensive.  In variant Creutzfeldt Jacob disease (vCJD) neuronal death occurs in 
the cerebral cortex with the primary visual cortex most severely affected, the thalamus and 
midbrain structures are also affected (Liberski and Ironside, 2004).   
  Although neurons seem to be particularly vulnerable to stress (e.g. protein misfolding, 
oxidative stress), they are known to respond to such insult by up regulating protective 
proteins such as the sHsps under conditions of acute stress (e.g. ischemia) and chronic 
stress.  Such up regulation is more widely known for the non neuronal astrocytes and 
microglia cells with limited information about the response in oligodendrocytes.  These 
cell types will be discussed below, particularly as the broad cellular responses during 
disease highlight the potential for cell autonomous neuroprotective mechanisms in specific 
cell types and/or indeed a concerted, multifaceted response involving cell cell interaction.   
  Glial cells are classified into three main groups: microglia, astrocytes and 
oligodendrocytes  (Garcia Marin et al., 2007).  
1.5.2.  Microglia 
  Microglial cells are the resident mononuclear phagocytes and immune cells of the 
nervous system.  They possess highly ramified processes under normal “physiological” 
conditions (Napoli and Neumann, 2009).  Microglia are activated in response to insult or 
injury to the brain, resulting in retraction of their processes and a transformation into an 
amoeboid morphology (Lynch, 2009).  The response that is taken by the activated 
microglia depends on the pathological stimulus and is termed microgliosis.  Microglia may 
up regulate distinct profiles of cell surface markers, become motile and mediate an 
inflammatory response (Chan et al., 2007, Pocock and Kettenmann, 2007).  The activation 
of microglia is graded and when fully activated may contribute to and increase damage to 
neurons by the release of cytokines and ROS (Streit et al., 1999).  The microglial response 
has been attributed to the interaction of neurotransmitters and cytokines with cognate 
receptors that are expressed on the microglia (Pocock and Kettenmann, 2007).   46 
1.5.3.  Astrocytes 
  Astrocytes provide structural and metabolic support in the CNS.  They are involved in 
neurotransmitter re uptake and release, supplying nutrients to neurons, removing toxic 
waste products of neuronal metabolism, regulating cerebral blood flow and synaptic 
activity (Maragakis and Rothstein, 2006, Garcia Marin et al., 2007).  The astrocytic 
response to any form of injury to the CNS is referred to as astrocytosis or astrogliosis.  
Changes in glial fibrillary acidic protein (GFAP) an intermediate filament protein localised 
to astrocytes is generally used as an indicator of astrogliosis (Correa Cerro and Mandell, 
2007). 
  Astrogliosis can be both beneficial and deleterious.  Astrocytes can mediate repair at the 
site of injury by the secretion of neurotrophic factors (Jean et al., 2008).  They can also 
minimize damage and neuronal death by maintaining neurotransmitter homeostasis.  
Detrimental effects are seen when the presence of glial scars inhibit neurite outgrowth as 
well as remyelination of axons in white mater lesions (Carmen et al., 2007).  Despite this 
prohibitive nature of glial scars, non reactive astrocytes have been shown to be important 
for oligodendrocyte maturation and myelin formation (Carmen et al., 2007).  
  Perisynaptic astrocytes are intimately associated with the synaptic compartment.  The 
processes of these astrocytes enwrap synapses, forming a ‘tripartite’ synapse (Todd et al., 
2006, Bains and Oliet, 2007).  This proximity allows astrocytes to sense neuronal activity 
and modulate synaptic transmission thereby contributing to neural plasticity (Reichenbach 
et al., 2010). 
1.5.4.  Oligodendrocytes    
  Oligodendrocytes form one of the most highly specialised cellular structures in the body, 
the myelin sheath.  The myelin sheath is formed by the spiral wrapping of plasma 
membrane extensions around the axon, followed by the extrusion of cytoplasm and 
compaction of the stacked membrane bilayers.  These membrane stacks provide electrical 
insulation around nerve fibres to minimize metabolic expense and maximize conductance 
velocity (Simons and Trajkovic, 2006).  The myelin membrane has biochemically distinct 
domains.  Proteins such as myelin basic protein (MBP) and proteolipid protein (PLP) are 
localised to ‘compact’ myelin, which as the name suggests, consists of tightly packed   47 
membranous structures from which the cytoplasmic content has been extruded.  2’, 3’ 
cyclic nucleotide 3’ phosphodiesterase (CNP) and myelin associated protein (MAG) are 
localised to non compact myelin, this sub compartment is involved in cell signalling 
events and forms contacts with the ensheathed axon.  MBP is responsible for adhesion of 
the cytosolic surfaces of these membrane stacks.  It may also interact with the cytoskeleton 
and participate in signalling events (Ahmed et al., 2009).  There are many size isoforms of 
MBP due to differential splicing of a single mRNA transcript (Boggs, 2006).   Neurons 
control the development of oligodendrocytes by regulating their proliferation, 
differentiation and survival.  The timing of signals between neurons and oligodendrocytes 
is crucial in coordinating myelin biogenesis (Simons and Trajkovic, 2006).   
1.6.  sHsps in Diseases 
1.6.1.  Mutation in the sHsps and disease 
  Mutations in the sHsps have been reported in a number of human diseases. In particular 
four members of the sHsp family (HspB1, HspB4, HspB5 and HspB8) have been found as 
genes responsible for human degenerative myopathy, neuropathy and congenital cataract 
(Table 1.4).  The majority of mutations in the sHsps are contained in the conserved α 
crystallin domain, suggesting that oligomerisation and chaperone function of the sHsps is 
impaired (Dierick et al., 2005).   
  Mutations in HspB1 and HspB8 overlap in their disease outcomes (Der Perng and 
Quinlan, 2004).  Mutations in both of these sHsps result in either Charcot Marie Tooth 
(CMT2) disease, a sensory and motor neuropathy, characterised by premature axonal 
degeneration; or distal hereditary motor neuropathy (DHMN), resulting in premature 
axonal loss, neuronal degeneration and death.  These diseases result in progressive 
weakness and wasting of the limbs, hands and feet (Irobi et al., 2004, Tang et al., 2005a, 
Tang et al., 2005b).  CMT can be divided into two major classes; the demyelinating forms 
(CMT1) and axonal forms (CMT2).  Mutations in the sHsps give rise to axonal forms of 
this disease which is selective to a population of large motor neurons in the spinal cord 
(Evgrafov et al., 2004, Tang et al., 2005a).   
  The cellular effect of the HspB1 mutant P182L was demonstrated in primary neuronal 
cultures.  Mutant HspB1 protein resulted in the formation of insoluble intracellular   48 
aggregates (Ackerley et al., 2006).  Cellular components including intermediate 
neurofilament middle chain subunit (NF M) and p150 subunit of dynactin were 
sequestered into these aggregates, thus disruption of axonal transport and structure were 
suggested as possible pathogenic mechanisms of mutant HspB1 (Ackerley et al., 2006).    
  Missense mutations in both HspB4 (R116C) and HspB5 were found in familial congenital 
cataracts (Litt et al., 1998).  The normal function of these proteins as chaperones and their 
involvement in maintaining the refractive properties of the lens suggests mutation and 
aggregation has a two fold effect, firstly in loss of the normal function, indeed the R116C 
mutation has been shown to have a lower actin binding affinity compared to wild type 
HspB4 (Brown et al., 2007), and secondly an increase in light diffraction by aggregates.   
  HspB5 has been linked to inclusion based diseases involving the cytoskeleton, in 
particular desmin related myopathy.  The R120G mutation in HspB5 induces intermediate 
filament aggregation in skeletal muscle (Sun and MacRae, 2005a).  The same mutation 
induces desmin related cardiomyopathy in the hearts of transgenic mice (Sanbe et al., 
2005).  HspB5 may play a nuclear role during cardiomyopathy as the R120G mutant 
inhibits the formation of inter chromatin granule clusters by the wild type HspB5 protein. 
These granules are thought to be involved in RNA transcription and splicing (van den et 
al., 2003).    
  The K141N mutation in HspB8 occurs in families with distal hereditary motor 
neuropathy.  This mutation is in the α crystallin domain and is equivalent to the HspB4 
R116C and HspB5  R120G mutations (Irobi et al., 2004). 
  Interestingly, it is increasingly apparent that these mutations perturb the normal function 
of the cytoskeleton, as described in the above examples.  The formation of protein 
aggregates by proteins inherently involved in preventing such misfolding processes 
suggests this may be attributed to either a loss of function of the sHsps in their normal 
cellular and protein homeostatic processes, or indeed a gain of function by formation of 
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sHsp  Mutation  Disease  Reference 
R127W  CMT2, DHMN  (Evgrafov et al., 2004; Liu et al., 2005) 
S135F  CMT2, DHMN  (Evgrafov et al., 2004) 
R136W  CMT2  (Evgrafov et al., 2004) 
T151I  DHMN  (Evgrafov et al., 2004) 
P182S  DHMN  (Kijima et al., 2005) 
HspB1 
P182L  DHMN  (Evgrafov et al., 2004) 
W9X  CC  (Pras et al., 2000) 
R49C  CC  (Mackay et al., 2002) 
R116C  CC  (Litt et al., 1998) 
R116H  CC  (Gu et al., 2008) 
HspB4 
G98R  CC  (Santhiya et al., 2004) 
R120G  DRM, CC, MM  (Vicart et al., 1998) 
Q151X  MM  (Selcen and Engel, 2003) 
R157H  CM   (Inagaki et al., 2006) 
P20S  CC  (Liu et al., 2006) 
HspB5 
D140N  CC  (Berry et al., 2001) 
K141N  CMT2, DHMN  (Irobi et al., 2004, Tang et al., 2005b)  HspB8 
K141E  DHMN  (Irobi et al., 2004) 
Table 1.4.  Human mutations in sHsps associated with degenerative disease.  
Abbreviations: CC, congenital cataract; CM, cardiomyopathy; CMT2, Charcot Marie 
Tooth disease type 2; DHMN, distal hereditary motor neuropathy; DRM, desmin related 
myopathy;  MM, myofibrillar myopathy. 
 
1.6.2.  Induction of the sHsps associated with disease  
  Increased expression of the sHsps has also been associated with a number of acute and 
chronic conditions such as stroke (ischemia), and neurodegenerative diseases.   
1.6.2.1.  Acute stress (ischemia) 
  Ischemic/reperfusion injury to cells during stroke involves a complex sequence of 
neurochemical events such as cellular bioenergetic failure and excitotoxicity by glutamate 
release, oxidative stress by the generation of free radicals, post ischemic inflammation 
resulting in death of neurons, glia and endothelial cells (reviewed in (Brouns and De Deyn,   50 
2009).  The sHsps are involved in several of these events under basal conditions and could 
therefore potentially provide a protective mechanism in such conditions.  Indeed, in a rat 
model of middle cerebral artery occlusion (MCAO), HspB1 was induced in microglia at 
the site of ischemic insult after 4 hours.  This was followed by induction in reactive 
astrocytes for an extended period of 1 day to 2 weeks (Kato et al., 1995).  Lowe et al. 
(1992) reported increased HspB5 expression in a small proportion of ballooned neurons at 
the edges of areas with cerebral infarction (CI) in CI patients.  Up regulation of this 
otherwise non neuronal sHsp under basal conditions was suggested to represent 
regenerating neurons (Lowe et al., 1992).  In another study of MCAO in the rat brain, 
HspB5 was also shown to be transiently expressed only 4 hours after MCAO in pyramidal 
neurons in the vicinity of ischemic insult.  Induction was localized to astrocytes, 2 days 
after MCAO in the penumbra and was sustained for a number of days.  This induction was 
associated with up regulation and co localisation with MAPKAP 2 (Piao et al., 2005). 
1.6.2.2.  Chronic stress (neurodegenerative diseases) 
  Increased expression of the sHsps has been observed in several chronic 
neurodegenerative diseases, such as AD and PD.   
1.6.2.2.a.  sHsp expression in AD  
  AD is characterized by deposition of Aβ in senile plaques (SPs) and tau in neurofibrillary 
tangles (NFTs).  HspB1 and HspB5 are up regulated in AD brains and are localized to 
astrocytes and degenerating neurons (Bjorkdahl et al., 2008).  HspB6 reactivity was also 
found in astrocytes surrounding these sites, whereas HspB8 expression was localized to 
oligodendrocytes and microglia based on morphological criteria (Wilhelmus et al., 2006b, 
Wilhelmus et al., 2006c).  HspB1 and  HspB5 were associated with extracellular Aβ SPs 
(Iwaki et al., 1992, Renkawek et al., 1994, Dabir et al., 2004), and elevated levels of 
HspB2, HspB6 and HspB8 immunoreactivity were also associated with SPs in AD 
(Wilhelmus et al., 2006b, Wilhelmus et al., 2006c).  Interestingly the sHsps were not found 
to associate with NFTs suggesting a non neuronal induction and involvement in this 
protein misfolding disease.   51 
1.6.2.2.b.  sHsp expression in PD 
  PD is characterized by LBs, comprised of intraneuronal α synuclein aggregates and 
ubiquitin (Spillantini et al., 1997).  Although induction of some of the sHsps has been 
reported in PD it is not as pronounced as observed in AD with extracellular aggregates 
(Renkawek et al., 1999). However, increased expression of HspB1 and HspB5 was 
associated with reactive glial cells in degenerating regions (Renkawek et al., 1999). 
Additionally a 2/3 fold up regulation of HspB1 mRNA and protein were reported in 
patients with dementia with LBs (DML) (Outeiro et al., 2006).   
  HspB5 staining has also been described in neurons of the cerebral cortex and amygdala in 
PD patients.  The immuno positive cells did not develop LBs suggesting a neuroprotective 
role for HspB5 (Braak et al., 2001). 
1.6.2.2.c.  sHsp expression in polyQ diseases 
  HspB1 expression also increased in post mortem brains of spinocerebellar ataxia 3 (SCA 
3) patients.  This disease is one of a repertoire of poly glutamine (polyQ) disorders 
characterized by proteins containing pathologically long polyQ repeats within the protein 
(Chang et al., 2005).  However HspB1 expression has also been shown to be decreased in 
patients with SCA 7 and in SCA 17 transgenic (tg) mice (Tsai et al., 2005, Friedman et al., 
2007), suggesting modulation of the sHsps depending on the disease context (discussed 
below).  
  Induction of the sHsps in disease conditions in neuronal and non neuronal cells as 
described above and their involvement in cellular processes in addition to protein folding 
as described for each sHsp in section 1.3.3 suggest the sHsps could play an important 
modulatory role during disease as many of these cellular processes are also perturbed or 
abnormally activated in disease.  This aspect of sHsp function will be discussed below. 
1.6.3.  Modulation of disease mechanisms and pathways 
1.6.3.a.  Modulation of aggregation 
  The capacity of the sHsps to modulate disease processes has been demonstrated in a 
number of studies.  As described above the sHsp co localise with Aβ deposits in SPs, 
therefore an in vitro investigation using cerebrovascular cells was conducted to investigate   52 
the binding capacity of the sHsps (HspB1, HspB5 and HspB6) to Aβ1 40 and Aβ1 42.    The 
sHsps were able to bind to both species, however they were able to modulate and inhibit 
the aggregation of the more toxic Aβ1 40 species into fibrils without affecting Aβ1 42 
aggregation.  Additionally they were also able to reduce toxicity of Aβ1 40 and Aβ1 42.  
However the degree of protection was correlated with binding affinity for each peptide 
(Wilhelmus et al., 2006a).  In an earlier study, inhibition of Aβ1 40 fibril formation by 
HspB5 was associated with increased toxicity in cultured neurons (Stege et al., 1999).  
HspB5/ Aβ complexes were suggested to maintain Aβ as a toxic non fibrillar protein.  In 
this case the sHsps intrinsic chaperone activity could potentially increase rather than 
alleviate Alzheimer’s symptoms (Stege et al., 1999).   
  HspB5 modulation of protein aggregation was also demonstrated in a study where mice 
expressing a mutation in the intermediate filament protein desmin were crossed with 
HspB5 R120G tg mice.  These mice had significantly higher levels of desmin aggregates 
than mice expressing the desmin mutant protein alone.  Additionally in the same study in 
vitro expression of a desmin mutant protein and over expression of wild type (wt) HspB5 
protein resulted in reduction of desmin aggregation (Wang et al., 2003). 
  HspB8 has also been shown to block the formation of IBs formed by the polyQ protein, 
and has been shown to inhibit accumulation of SDS insoluble htt with 43 glutamines 
(htt43Q) as efficiently as Hsp40 (Carra et al., 2005, Carra et al., 2008).  
1.6.3.b.  Modulation of the cytoskeleton 
  As described in section 1.6.1 mutations in the sHsps result in perturbations of the 
cytoskeleton.  Disruption and dysregulation of the cytoskeleton is one of the key features 
observed in disease processes.  For example, Alexander’s disease (AxD) is a primary 
disorder of astrocytes occurring as a consequence of mutations in GFAP.  The resultant 
aggregates that form are termed Rosenthal fibers or astrocytic inclusions containing 
cytoskeletal proteins in addition to molecular chaperones (HspB1 and HspB5) (Der Perng 
and Quinlan, 2004).  HspB5 regulates GFAP assembly (Nicholl and Quinlan, 1994, Ghosh 
et al., 2007) and modulation of the levels of HspB5 were found to either increase mortality 
(loss of HspB5) in an AxD mouse model or reduce disease symptoms such as seizures 
(increased HspB5) (Hagemann et al., 2009).   53 
1.6.3.c.   Modulation of inflammation 
  Inflammation is often associated with disease processes and induction of the sHsps may 
regulate this pathway.  HspB5 is a major target of T cells immunity to the myelin sheath in 
MS and is thus directly linked with inflammatory disease.  HspB5 was shown to be 
protective in a model of demyelination, experimental autoimmune encephalomyelitis 
(EAE).  HspB5 knockout mice showed worse EAE with a heightened T cell and immune 
response compared to controls.  Administration of recombinant HspB5 was able to 
alleviate the symptoms of EAE, demonstrating its protective role as a negative regulator of 
the inflammatory response (Ousman et al., 2007).   
1.6.3.d.  Modulation of oxidative stress and apoptosis 
  HspB1 has been reported to modulate oxidative stress and toxicity in a cell model of HD.  
It was able to suppress polyQ induced toxicity and cell death by reducing the levels of 
ROS.  This process was independent of changes in aggregation, as polyQ aggregation was 
not affected (Wyttenbach et al., 2002).  
  Mice expressing mutant superoxide dismutase (SOD1
G93A) as a model of amyotrophic 
lateral sclerosis (ALS) have severe motor phenotype and motor neuron cell loss.  When 
SOD1
G93A mice were crossed with mice over expressing mice HspB1, the resultant double 
tg mice showed an improved phenotype with increased survival of motor neurons at early 
stage of disease (Sharp et al., 2008), suggesting modulation of apoptotic pathway and 
stabilization of the cytoskeleton (Perng et al., 1999). However this protection was not 
sustained as HspB1 protein was down regulated in double tg animals although the mRNA 
levels remained unchanged (Sharp et al., 2008).   
  Both HspB1 and HspB5 are also able to reduce α synuclein induced toxicity (by ~80% 
and 20% respectively) in a cell culture model (Outeiro et al., 2006).  The sHsps have also 
been shown to prevent cataract formation and protect against ischemia and reperfusion 
injury during heart attack and stroke (Sun and MacRae, 2005a).   
  The sHsps likely play a critical role in tempering disease pathology particularly in protein 
misfolding diseases or proteinopathies.  Thus it would be useful to study the roles of the 
sHsps in the context of intra  and extracellular misfolding diseases.  An example of a 
chronic neurodegenerative disease characterised by either intracellular misfolded   54 
aggregates (HD, section 1.7) or extracellular misfolded aggregates (prion, section 1.8) will 
be described in detail below. 
1.7.  Huntington’s disease (intracellular proteinopathy) 
  HD is an inherited autosomal dominant neurodegenerative disorder that was first 
described by Charles Oscar Walters in 1841 and then classically defined by George 
Huntington in 1872 (Imarisio et al., 2008).  In Western countries it is estimated that about 
five to seven people per 100,000 are affected by HD (Walker, 2007).  Symptoms of HD 
include chorea (involuntary movements), weight loss as well as psychiatric and cognitive 
dysfunction.  HD is a progressive disorder resulting in death within 15 20 years after 
disease onset, and even more rapidly in young patients (7 9 years after disease onset) 
(Estrada Sanchez et al., 2008).  HD occurs due to an expansion of a polyQ tract (CAG) in 
the first exon of the gene IT15, which is located on the short arm of chromosome 4 
(Walling et al., 1998, Imarisio et al., 2008).  Generally, fewer than 36 CAG repeats results 
in the production of the cytoplasmic htt.  However, a sequence of 36 or more polyQ 
repeats results in the manifestation of the disease during adulthood (Walker, 2007).  36–40 
repeats result in a reduced penetrance form of the disease, with a much later onset and 
slower progression of symptoms.  When the number of repeats exceeds ca. 60, HD has full 
penetrance and disease symptoms are seen in young adolescents (15 20 years old) and this 
juvenile form of HD shows a different more aggressive pathology (Nance and Myers, 
2001).  Thus there is a strong inverse relationship between the age of onset of HD and the 
number of CAG repeats (Farrer et al., 1992).  
1.7.1.  HD pathogenesis 
  Expanded polyQ repeats have been suggested to confer toxic gain of function properties 
on the mutant protein, but also result in a loss of function (reviewed in(Cattaneo et al., 
2001).  Over expression of polyQ expansions (full length htt or exon 1 of htt (httEx1)) in 
monkeys, sheep, mice, Drosophila, C.elegans and zebrafish have been shown to be 
associated with neurodegenerative phenotypes (Rubinsztein, 2002, Yang et al., 2008, 
Jacobsen et al., 2010).  In human subjects, this expansion in the htt protein leads to a 
severe loss of medium spiny neurons (MSN) in the striatum.  The MSN constitute 95% of 
the total neuronal population of the striatum and receive cortical inputs releasing   55 
glutamate, the main excitatory neurotransmitter in the brain.  Glutamate can cause cell 
death by excitotoxicity and this has been suggested to be one of the mechanisms involved 
in the pathogenesis of HD (Estrada Sanchez et al., 2008).     
  Although HD pathology is predominantly associated with degeneration of the striatum, it 
also involves cortical areas.  Atrophy of the brain is initially observed in the basal ganglia 
(up to 60% loss of mass), with the caudate nucleus affected progressively and more 
severely than the putamen or global pallidus (Walling et al., 1998).  Atrophy is less severe 
(20% loss of mass) and non progressive in other areas of the brain such as the cortex  
(Walling et al., 1998).  In late stage HD other brain regions such as the hippocampus, 
hypothalamus and the cerebellum are also affected (Li and Li, 2004).   
  Although early research on HD focused on changes in the gray matter, changes in the 
white matter do occur (Fennema Notestine et al., 2004, Kassubek et al., 2004).  MRI 
imaging of HD subjects with pre symptomatic to advanced HD revealed decreased brain 
white matter volume many years before the onset of clinical HD and even before evidence 
of gray matter atrophy over time.  Additionally a correlation between white matter atrophy 
and time to onset in pre symptomatic subjects was observed (Ciarmiello et al., 2006).  
Such white matter changes are suggested to contribute to the compromised function of 
cortical circuits potentially contributing to the early clinical symptoms, such as early 
cognitive and subtle motor impairment that occur in HD (Rosas et al., 2006).   
  The (efferent) MSNs of the striatum send projections to the globus pallidus and are 
associated with the inhibitory neurotransmitter gamma aminobutyric acid (GABA).  
Decrease in inhibition of the globus pallidus externa as a consequence of MSN cell death, 
results in excessive inhibition of the subthalamic nucleus, leading to increased thalamic 
excitation and choreic movements (Albin et al., 1990, Aron et al., 2003).  Large 
cholinergic aspiny neurons in the striatum are generally spared in disease.  The basal 
ganglia often show depletion of GABA, substance P and enkephalins (Storey and Beal, 
1993).  Dendritic abnormalities are observed in transgenic mouse models of HD, with a 
significant decrease in the number of dendritic spines and a thickening of proximal 
dendrites before cell death (Li et al., 2003).     56 
1.7.2.  Functions of htt and its associated cellular mechanisms implicated in HD 
  A number of roles and functions have been proposed for the htt protein such as protein 
trafficking, vesicle transport, anchoring to the cytoskeleton, clathrin mediated endocytosis, 
postsynaptic signalling, transcriptional regulation and anti apoptotic functions (Gil and 
Rego, 2008, Imarisio et al., 2008).  Only a few potential functions that relate to pathology 
and a potential modulatory role of the sHsps as described in section 1.6.3 will be discussed 
below.  These will include protein aggregation and degradation, axonal transport and the 
cytoskeleton, oxidative stress, and transcriptional dysregulation. 
1.7.2.a.  Intracellular aggregation and alterations in the protein degradation 
systems 
  MtHtt IBs are found in the nucleus and the cytoplasmic compartments of neurons and are 
often immunoreactive for ubiquitin and chaperone proteins (Waelter et al., 2001).  
Although mtHtt is expressed in glial cells, it is the neuronal population that contains the 
majority of htt aggregates (DiFiglia et al., 1997).  Neurons are post mitotic cells and their 
ability to cope with misfolded proteins is likely to be different to glial cells, which can 
proliferate and regenerate (Barres and Barde, 2000).  MtHtt IBs sequester transcription 
factors, cytoskeletal proteins, protein kinases, ubiquitin and proteasomal subunits (Kopito, 
2000, Taylor et al., 2002).  Sequestration of these proteins into IBs could be detrimental to 
normal cellular functions and induce cellular toxicity (Perutz et al., 1994).  Indeed, cellular 
studies support the findings that there is a correlation between aggregate formation and 
cellular toxicity (Wyttenbach et al., 2000, Wyttenbach et al., 2002).  Furthermore, in HD 
mice expressing mutant httEx1, intra nuclear IBs were detected close or well before the 
appearance of behavioural changes (Bates et al., 1997, Morton et al., 2009), implicating 
polyQ aggregation as a contributor to toxicity.   
  Over expression of molecular chaperones, including Hsp40 and 70 reduced both 
aggregation and cell death induced by httEx1 in vitro (Kobayashi et al., 2000, Wyttenbach 
et al., 2000).  These chaperones may be reducing large inclusion formation by preventing 
oligomer formation, and it may be the oligomeric precursors that are the most toxic species 
(Wacker et al., 2004, Takahashi and Mihara, 2008).  Indeed neurons containing IBs are 
less likely to die in vitro (Arrasate et al., 2004).         57 
  Toxicity of mtHtt aggregates has also been linked to the UPP.  Under basal conditions, 
UPP activity decreases in an age dependent manner and is lower in neurons versus glia 
(Tydlacka et al., 2008).  It is suggested that the intrinsically lower UPP activity in neurons 
contributes to the accumulation of misfolded proteins in neurons and hence this could be a 
potential mechanism driving neuronal toxicity.  PolyQ aggregation could impair the UPP 
in polyQ diseases hinted to by studies that positively labelled polyQ aggregates with 
antibodies against ubiquitin and proteasome subunits (Diaz Hernandez et al., 2006).  This 
suggested that sequestration of UPP components in aggregates might affect UPP activity.  
It is thought that proteins containing expanded polyQ tracts cannot be easily degraded by 
the eukaryotic proteasome and therefore become trapped in the proteasome and block entry 
of other substrates into the barrel of the 20S catalytic core (Bennett et al., 2005).  It has 
also been suggested that the proteasome is able to remove flanking sequences around the 
polyQ tract, resulting in production of polyQ stretches that may in fact be more toxic than 
the pre proteasomal species (Rubinsztein, 2006). Although most in vivo studies do not 
directly show impaired UPP activity due to expanded polyQ, the accumulation of 
ubiquitinated aggregates in HD implies nevertheless a disruption and inability of 
chaperones and the UPP in preventing the build up of misfolded proteins (Jana and 
Nukina, 2003).  Htt aggregates in cell and mouse models have also been suggested to 
inhibit mTOR (mammalian target for rapamycin) function thereby inducing autophagy 
(Ravikumar et al., 2004).  Aggregation prone proteins may indeed be degraded via 
autophagic mechanisms (review by (Rubinsztein, 2006).  Inhibition of mTOR by 
rapamycin reduces the levels and toxicity of soluble mtHtt and aggregated mtHtt 
(Ravikumar et al., 2004). However, mTOR also regulates protein synthesis and rapamycin 
has been suggested to reduce polyQ toxicity via both activation of autophagy and 
inhibition of translation (King et al., 2008).  
1.7.2.b.  Axonal transport and the cytoskeleton in HD 
  Htt has been implicated in vesicular transport due to its localization to endocytic/ 
endosomal vesicles in axons and synaptic terminals, as well as its interaction with 
endocytic/trafficking proteins, including clathrin and dynamin.  MtHtt binds to synaptic 
vesicles with higher affinity than htt (Li et al., 2003).  It has recently been proposed that   58 
mtHtt inhibits Rab11 activity, a GTPase involved in endosomal recycling, resulting in 
impairment of vesicle formation and recycling endosomes (Li et al., 2009).   
  Htt is known to facilitate transport along microtubules (Gunawardena et al., 2003), 
however mtHtt aggregates are able to physically inhibit the movement of vesicles and 
mitochondria along neural projections (Lee et al., 2004).  Htt interacts directly with the 
dynein/dynactin microtubule based motor complexes (retrograde transport), as well as via 
its binding partner huntingtin associated protein 1 (HAP1) (Gauthier et al., 2004). HAP1 
binds kinesin, another motor protein involved in anterograde axonal transport (Walling et 
al., 1998, Imarisio et al., 2008).  It also functions as an adaptor protein between htt and 
InsP3R1 (inositol (1, 4, 5) tri phosphate receptor) in lipid bilayers and sensitises calcium 
release by InsP3R1 in the presence of htt.  This leads to an increase in the intracellular 
calcium load, which may contribute to the increased susceptibility to death of MSNs in the 
striatum (Tang et al., 2004). 
1.7.2.c.   Oxidative stress  
  Oxidative stress and mitochondrial dysfunction have been implicated in many 
neurodegenerative diseases.  Oxidative stress is brought about by the abnormal production 
of ROS.  ROS are highly reactive oxygen molecules that have gained unpaired electrons in 
the outer shell to form superoxide anions, hydrogen peroxide or hydroxyl radicals (Cash et 
al., 2007).  These species can be generated by the mitochondria, in the cytoplasm via 
several enzymes or by lipid peroxidation.  ROS is produced by the cell as a normal by 
product of oxygen metabolism and is buffered by enzymes such as superoxide dismutase 
and peroxiredoxins (Calabrese et al., 2007).  However, increases in ROS levels can result 
in damage to cellular structures, DNA and proteins.      
  Mitochondria are a major source of ROS production (Kowaltowski et al., 2009), but are 
also the major target of ROS damage (Guidot et al., 1993).  To protect the cell against 
ROS, mitochondria contain an antioxidant system including non enzymatic proteins, such 
as coenzyme Q10 or glutathione, as well as enzymatic proteins such as MnSOD, catalase 
and glutathione peroxidase (Valko et al., 2007).  However excessive production of ROS or 
perturbations of the antioxidant mechanisms can lead to oxidative damage of 
mitochondrial proteins, lipid and DNA (Sohal, 2002).  ROS may also result in the   59 
formation of protein carbonyls.  These modified proteins are dysfunctional and may lead to 
decreased activity of key metabolic enzymes and disturbed cellular signalling systems. 
Indeed, evidence from post mortem brains of HD patients and tg mouse models suggests 
the presence of mitochondrial metabolic dysfunction (Mangiarini et al., 1996, Browne and 
Beal, 2004).  Mitochondrial impairment and oxidative stress have also been detected in 
asymptomatic HD carriers (Saft et al., 2005). 
  Interestingly in vitro studies have demonstrated that up regulation of molecular 
chaperones (HspB1) is protective against ROS induced by httEx1 (Wyttenbach et al., 
2002).  It is thought that mitochondrial metabolic dysfunction could play a key role in HD 
pathogenesis, but it is not clear if this a primary cause or a secondary consequence of 
neuronal death (Orth and Schapira, 2001).                                              
1.7.2.d.  Transcriptional and, post translational dysregulation and cleavage of 
htt  
  Altered gene expression has been reported in the human HD caudate (Hodges et al., 
2006) and is one of the earliest molecular changes to occur in the brains of HD mice (Chan 
et al., 2002).  Htt interacts with many transcription factors and other proteins involved in 
mRNA production, and is involved in their nucleo cytoplasmic shuttling thereby regulating 
transcription (Truant et al., 2007).  An example of the adverse effects of mtHtt can be 
illustrated by CREB binding protein (CBP) regulation.  MtHtt inhibits CBP, a small 
regulatory protein that is important for cell survival (Nucifora et al., 2001) and interferes 
with CRE mediated transcription (Wyttenbach et al., 2001).  CBP has 18 glutamines which 
directly interact with mtHtt.  It normally binds DNA and has histone acetyltransferase 
activity, allowing transcription factors to access DNA.  The interaction of CBP with mtHtt 
causes CBP relocalisation from the nucleus into htt aggregates, removing this protein from 
its normal cellular localisation (Steffan et al., 2000).  
  Phosphorylation is an important post translational modification of htt.  Phosphorylation at 
serine 421 in the mtHtt protein has been shown to restore its functions in axonal transport 
(Zala et al., 2008) and abolishes mtHtt induced toxicity in cell models of HD (Rangone et 
al., 2004, Zala et al., 2008).  Phosphorylation at serine 434 by cdk5 reduces its cleavage by 
caspases (Luo et al., 2005).  These post translational modifications may regulate the half   60 
life, localization and nuclear export of htt, as well as altering the toxicity of mtHtt (Steffan 
et al., 2004). 
  Both htt and mtHtt are also post translationally modified by caspases and calpains which 
cleave at the N terminal end (Gafni and Ellerby, 2002, Hermel et al., 2004).  These N 
terminal fragments are thought to form β pleated sheet structures.  The significance of 
proteolysis for the physiological function of htt is not clear, but mtHtt cleavage is known to 
result in the production of toxic mtHtt fragments (Imarisio et al., 2008). 
1.8.  Prion disease (extracellular proteinopathy) 
  Prion diseases or transmissible spongiform encephalopathies (TSE’s) are fatal 
neurodegenerative disorders which occur in both humans and animals.  TSE’s are 
clinically characterized by dementia and motor dysfunction, and neuropathologically by 
amyloid deposition, vacuolation of the neurophil which gives a ‘sponge’ like appearance to 
the brain, neuronal cell death and activation of astrocytes and microglia (Liberski and 
Ironside, 2004).  Disease may occur sporadically, be acquired by infection or may be 
hereditary.  Many strains of prion disease exist, these are defined by different incubation 
periods and neuropathologies (Prusiner, 1996).   
  CJD is the most common human prion disease with an incident rate of between 0.5 and 
1.5 per million worldwide (Johnson, 2005).  Cases of atypical CJD raised the possibility of 
transmission of bovine spongiform encephalopathies (BSE) to humans (Prusiner, 1996, 
Johnson, 2005).  The spread of human prion diseases through consumption of infected 
material as was suggested after the BSE outbreak had been implicated historically in kuru, 
a disease of the Fore people practicing ritualistic cannibalism.  The neuropathology seen in 
kuru was compared to that seen in scrapie by William Hadlow, and later kuru was likened 
to CJD by Igor Klatzo (Prusiner, 1998).     
  Initially the causative agent in TSE’s remained unidentified.  It was found to be resistant 
to inactivation by formaldehyde, ethanol, proteases, nucleases and even ultraviolet and 
ionizing radiation.  It was subsequently suggested that the infectious agent was in fact a 
single protein devoid of nucleic acid which was named ‘prion’ (PrP) to describe this small 
proteinaceous infectious particle (Prusiner et al., 1982).  A single gene was found to 
encode PrP in the host and not a nucleic acid carried within infectious particles (Oesch et   61 
al., 1985, Prusiner, 1996).  A 27 30kDa isoform of the normal membrane glycoprotein 
(prion protein) was found to co purify with infectivity, leading to the identification of the 
33 35kDa prion protein (PrP
c), a protease sensitive protein, and the smaller 27 30kDa 
protease resistant core of a 33 35kDa disease specific protein (PrP
sc) (Prusiner, 1991, 
1996).  
1.8.1.  Prion pathogenesis 
  Prion propagation in the nervous system is thought to occur as a result of axonal 
transport, passive translocation in perineural lymphatics, and conversion of PrP
c to PrP
sc 
along neural cell membranes (Figure 1.9).  The conversion of the soluble, protease 
sensitive PrP
c into PrP
sc occurs through a process whereby a portion of its α helical 
structure is refolded into a β sheet, making PrP
sc prone to aggregation and protease 
resistant (Figure 1.10).  PrP
sc acts as a template for PrP
c to refold and adopt the PrP
sc 
conformation (Hu et al., 2007).  This misfolding insult produces a selective neuronal 
degeneration in the CNS despite the proteins wide cellular expression.  Irrespective of 
whether the disease is triggered by infection or genetic mutations, it leads to extracellular 
deposition of misfolded PrP
sc.  Neuronal loss in prion diseases as observed in post mortem 
tissue from CJD sufferers was found in the cerebellum, thalamus and also the cerebral 
cortex (Liberski and Ironside, 2004).  However animal models of prion disease display 
more selective neuronal death in specific regions of the brain preceded by synaptic loss 
(Cunningham et al., 2003; Siskova et al., 2009). 
  It has been suggested that either a gain of function of the PrP
sc conformer or a loss of 
function by conversion of the native PrP
c to PrP
sc is key to pathogenesis (Unterberger et al., 
2005).  Host PrP
c expression is necessary for disease transmission, as ablation of the PrP
c 
gene prevents disease (Prusiner et al., 1993) and overexpression of PrP
c followed by PrP
sc 















Figure 1.9. Summary of PrP processing pathways.  Pathway 1 (intracellular PrP 
processing, red): The PrP
c polypeptide (yellow circles), including genetic mutants (green 
circles), is synthesized in the ER, processed in the Golgi apparatus, and then carried in its 
mature form to the cell surface where most of it is found in lipid rafts. Generation of 
PrP
TSE (PrP
sc) (blue and dark blue boxes), from PrP
c occurs after the arrival of PrP
c at the 
cell surface. Misfolded cytosolic PrP may result in the formation of aggresomes via the 





c from the plasma membrane is internalized and processed in lysosomes. PrP
TSE 
(PrP
sc), (blue and dark blue boxes), leads to a conformational change of PrP
c before or 
during internalization via endosomes. Overloading of the endosomal lysosomal system 
may lead to accumulation of indigestible material or exocytosis of PrP
TSE (PrP
sc) that 
forms extracellular aggregated deposits. This process may be accompanied by release of 
lysosomal enzymes leading to tissue damage.  Pathway 3 (spread of PrP
TSE (PrP
sc), green): 
Endosomes may transport PrP
TSE (PrP
sc)  in the axons, in addition to the domino like 
spread of PrP
























Figure 1.10. Model of the tertiary structure of PrPc and PrPsc.  (a) Proposed structure 
of PrP
c with a high alpha helical content.  (b) Proposed structure of PrP
sc, with an high beta 
sheet content (Prusiner, 1996). 
 
 
  The phenotype of PrP null mice is controversial as genetic ablation of PrP expression in 
mice has been shown to produce little phenotypic effect apart from the inability to 
propagate prions (Bueler et al., 1992).  However subtle abnormalities have been described 
in these mice (reviewed in (Steele et al., 2007).  For example PrP null mice have been 
shown to display deficits in spatial learning (Criado et al., 2005), altered long term 
potentiation (Maglio et al., 2004) and increased excitability of hippocampal neurons 
(Mallucci et al., 2002).  In vivo models of seizure activity have shown increased mortality 
in PrP null mice (Walz et al., 1999, Khosravani et al., 2008).          
  Excitability and excitotoxicity are associated with N methyl D asparatate receptor 
(NMDAR) activity.  It has recently been shown that PrP
c is able to modulate synaptic 
NMDA currents, and is neuroprotective by its ability to suppress NMDAR activity, 
thereby preventing excitotoxicity and cell death (Khosravani et al., 2008).  So, loss of 
function may promote excitotoxicity due to enhanced NMDA activity. 
1.8.2.  Functions of PrP and its associated cellular mechanisms implicated in prion 
disease 
  As for HD (see above), only a few functions that relate to prion pathology and a potential 
modulatory role of the sHsps as described in section 1.6.3 will be considered below.  These   64 
will include protein aggregation and degradation, oxidative stress, and gliosis and 
inflammation.  
1.8.2.a.   Extracellular aggregation and alterations in the protein degradation systems 
  The presence and pattern of histopathological changes in prion disease are variable 
between individuals and disease subtypes (Budka, 2003).  Originally it was thought that 
disease associated histopathological changes in the brain were correlated with PrP
sc 
deposition (Jendroska et al., 1991).  However it was later noted that the consistency 
between the amount and distribution of PrP
sc and the severity of local tissue damage did 
not always correlate.  For example in a time course study in mice with experimental CJD, 
spongiform changes preceded PrP
sc deposition in various brain regions (Kordek et al., 
1999).  Accumulation of PrP
sc in the nervous system is a gradual process occurring during 
disease progression and ultrastructural studies have shown that the process begins at the 
cell membrane of neurons and in the extracellular space (Jeffrey et al., 1994). 
  Impairment/alteration of protein degradation processes are observed in prion disease.  For 
example, autophagy is involved in processing both PrP
c and PrP
sc and changes in levels of 
lysosomal enzymes have been reported in CJD brain regions with prominent pathology 
(Kovacs et al., 2007).  Pathological PrP
sc oligomers may be released from cells to the 
extracellular environment by direct recycling and/or via exosome secretion (Fevrier et al., 
2004).  Neurons in the vicinity of tissue damage were found to contain PrP
sc in lysosomes, 
indicating that overloading endosomal/lysosomal function may correlate with regional 
pathology (Kovacs et al., 2007). 
  PrP
sc has been shown to inhibit and impair the UPP in a number of cell lines.  This has 
been attributed to oligomeric species of PrP
sc directly inhibiting the catalytic subunits of 
the 26S proteasome (Kristiansen et al., 2007).  In humans cytosolic PrP
sc aggregates 
supporting the above process have not yet been observed.  However, in sCJD nuclear 
redistribution and accumulation of UPP components have been observed in areas of tissue 
damage, suggesting involvement in DNA repair mechanisms and/or cell death machinery 
(Adori et al., 2005).    65 
1.8.2.b.  Oxidative stress  
  An antioxidative function of PrP
c has been suggested by in vitro studies.  PrP
c deficient 
mice have lower levels of Zn/Cu SOD activity compared to controls (Prusiner, 1998).  
Additionally neurons lacking PrP
c were more vulnerable to hydrogen peroxide toxicity 
than wt cells (White et al., 1999), whereas increased activity of SOD and glutathione 
peroxide is seen in neurons expressing higher levels of PrP
c.  This suggests a role of PrP
c in 
the cellular defence mechanisms.  PrP
c may protect against oxidative damage by simply 
chelating redox active copper or by acting as a quencher of ROS (Brown et al., 1999).  The 
N terminal octarepeat region is thought to be important in this function (Mitteregger et al., 
2007).  PrP
c null mice have also been shown to exhibit higher levels of oxidative damage 
to proteins and lipids in the brain compared to wt animals (Klamt et al., 2001).  Correlation 
of PrP
c expression and the copper content of the brain, cellular copper uptake, and copper 
incorporation into Zn/Cu SOD have been described (Brown et al., 1997, Brown et al., 
1998) suggesting PrP
c is involved in cellular oxidative defence mechanisms (Rachidi et al., 
2003). 
  Mitochondrial function is shown to be compromised in prion disease before symptoms 
are apparent (Ferreiro et al., 2008).  A significant reduction of mitochondrial manganese 
(Mn) SOD activity was described in animal models of prion disease (Choi et al., 1998, Lee 
et al., 1999).  Oxidative damage to DNA, proteins and lipids was also shown in late stage 
prion disease (Choi et al., 1998, Choi et al., 2000, Guentchev et al., 2000). 
  Additionally in vitro studies have reported that accumulation of PrP
sc correlated with 
reduced proteasomal activity and increased levels of ROS (Lee et al., 1999).  Increased 
ROS production has been associated with increased MAPK activation in hamster brains 
infected with scrapie (Lee et al., 2005a, Pamplona et al., 2008). 
1.8.2.c.   Gliosis and inflammation  
  GFAP up regulation and astrocytosis is a prominent feature of prion diseases.  Up 
regulation of astrocytic enzymes precedes development of lesions but follows the increase 
in PrP
sc, suggesting that the astrocytic response is induced by PrP
sc (Kordek et al., 1997).  
Microglial activation is seen in human and mouse prion disease (Sasaki et al., 1993, Giese 
et al., 1998) and is confined to areas with spongiform changes and PrP
sc deposition   66 
(Williams et al., 1994).  In vitro studies show that microglia produce inflammatory 
cytokines IL 1β (interleukin 1 beta) and IL 6 (interleukin 6) in response to the neurotoxic 
PrP106 126 peptide (Brown et al., 1996).  Microglia have also been shown to contain PrP
sc 
suggesting that it may be degraded or processed in some way in these cells consistent with 
a macrophage like role (Rezaie and Lantos, 2001).  Indeed, the immunological anti 
inflammatory phenotype of microglia in vivo has been suggested to closely resemble that 
of macrophages having ingested apoptotic cells (Perry et al., 2002).  TNF α, as well as IL 
6 deficient mice are fully susceptible to prion disease when challenged with ME7 scrapie 
(Mabbott et al., 2000) supporting a redundant role of pro inflammatory cytokines in prion 
pathogenesis.  However, it has been proposed that although microglia do not express 
significant amounts of pro inflammatory cytokines, they could be in a “primed” state, and 
if further stimulated by peripheral infections are able to alter their response and secrete 
inflammatory mediators which promote the neurodegenerative process (Perry et al., 2002). 
1.9.  Models of neurodegenerative disease 
  The importance of the numerous neurodegenerative diseases has given rise to many in 
vitro and in vivo models of chronic neurodegeneration.  The neurodegenerative process can 
be triggered in many ways and is most tractable in the face of an acute insult whereby the 
sequence of events resulting from neuronal insult, dysfunction and death can be followed 
in a short period.  In vitro models are useful in studying the toxic effects of mutant proteins 
and also allow cellular changes to be investigated in a very short time period.  However the 
nature of these models makes it difficult to resolve the full sequelae which are much better 
studied in in vivo systems.  Additionally, although the sHsps react to acute stress as 
described in the previous section and also reviewed in Wyttenbach et al. (2010 in press) 
their role during chronic conditions of stress are the main focus of this thesis, therefore 
only examples of chronic models of neurodegeneration will be described below followed 
by more detailed descriptions of a HD and prion mouse models. 
1.9.1.  Chronic models of neurodegeneration 
  In vivo models of chronic neurodegeneration are routinely used to provide a disease 
setting that much better reflect the human conditions.  These models develop 
neurodegeneration over a time course of a number of weeks and months thus taking into   67 
account the slow and progressive distinctive nature of these diseases, but still in an 
experimentally tractable timescale (Turmaine et al., 2000). 
  Tg models of PD and AD have been described, for example mice overexpressing mutant 
α synuclein A53T from the mouse prion promoter develop adult onset neurodegeneration 
and motor dysfunction leading to death (Lee et al., 2002).  These mice also show neuronal 
abnormalities including pathological accumulations of detergent insoluble α synuclein, 
ubiquitin and thioflavin S positive structures.  The α synuclein inclusions are reported to 
be similar to LBs and contain fibrils similar to those observed in PD patients (Giasson et 
al., 2002).       
  Drosophila models of tauopathies such as fronto temporal dementia with parkinsonism 
linked to chromosome 17 (FTDP 17) have also been established.  Tg flies expressing 
FTDP 17 mutant (R406W or V337M) tau show late onset disease, accumulation of mutant 
tau, progressive degeneration, shortened lifespan and selective neuronal vulnerability 
(Wittmann et al., 2001). 
  Non human primate models have also been used to study chronic neurodegeneration.  
Due to the high degree of physiological, neurological and genetic similarities with humans, 
non human primates such as rhesus macaques are considered one of the best models for 
understanding human physiology and disease (Yang et al., 2008).  Lentiviral gene transfer 
has been used to genetically modify animal genomes and was the basis of the generation of 
tg HD monkeys.  These monkeys reveal unique cellular changes and pathogenesis, 
including clinical features such as dystonia, chorea and seizure that could be compared to 
HD patients (Wang et al., 2008, Yang et al., 2008).  
  In vivo models have been particularly useful in contributing a greater understanding of 
pathogenesis and offer the possibility of using genetic screens to unravel the mechanisms 
of pathogenesis.  All of these disease models have differing pathologies, with region and 
cell type specific vulnerabilities and abnormal deposits of protein aggregates as described 
above.  The locations of these aggregates differ with some being extracellular and others 
intracellular.  Two well established models of extra/intracellular aggregation are the R6/2 
HD mouse model and the ME7 prion disease mouse models that show different disease 
pathologies that will be described below.  The analysis of these particular models in 
relation to chaperone expression would allow a comparison of the consequences of   68 
extracellular and intracellular protein deposition respectively.  Indeed, there is good 
evidence that both HD and prion diseases are modulated by chaperone pathways (Sakahira 
et al., 2002, Summers et al., 2009).  Given than many of the cellular functions that can be 
modulated by the sHsps are also altered during either disease as described above, suggests 
a potential involvement for the sHsps in both intracellular and extracellular 
proteinopathies. 
1.9.2.  Models of polyQ diseases  
  Examples of models include a variety of fly and mouse models of polyQ diseases such as 
SCA1 (Fernandez Funez et al., 2000) and SCA3 (Warrick et al., 1998).  These models vary 
in the length of the mutant protein and number of polyQ repeats.  For example SCA1 tg 
mice have been established bearing full length ataxin 1 with 82 polyQ residues and are 
characterized by Purkinje cell dysfunction as determined by loss of motor coordination 
(Clark et al., 1997).  Knock in mice expressing full length ataxin 1 SCA1 79Q produce 
only a mild, late onset phenotype (Lorenzetti et al., 2000). 
  Many transgenic model of HD are currently utilized to investigate the pathological 
mechanisms associated with the expression of mtHtt.  These models consist of either full 
length htt or exon 1 fragments of the mtHtt protein in which there is an expanded poly Q 
repeat.  For example, the yeast artificial chromosome (YAC) mouse model expresses a 
full length human mtHtt gene with 46 or 72 polyQ repeats (Hodgson et al., 1999).  These 
mice show selective degeneration of the MSNs and present with intranuclear inclusions.  
The R6/1 and R6/2 transgenic lines on the contrary only express the first exon of the 
human mtHtt gene with an expanded polyQ tract and were the first mouse models 
developed to study HD (Mangiarini et al., 1996).  R6/2 transgenic mice also show 
phenotypic features of HD such as motor alterations, cognitive impairment and loss of 
body weight (Carter et al., 1999, Lione et al., 1999, Stack et al., 2005).  Several knock in 
mice have also been generated by the insertion of CAG repeats into the endogenous htt 
gene (Menalled, 2005).  The R6/1 (approximately 115 polyQ repeats) and R6/2 
(approximately 150 polyQ repeats) transgenic lines differ in CAG repeat length and 
disease onset.  R6/1 animals develop a progressive neurological phenotype at   69 
approximately 4 5 months of age, whereas for the R6/2 line this occurs at around 2 months 
(Mangiarini et al., 1996). 
1.9.2.a.  The R6/2 HD mouse model 
  The R6/2 mouse model of HD is routinely used to investigate the progression of HD, as it 
serves as a valuable model of chronic neurodegeneration with region and cell specific 
vulnerabilities.  R6/2 mice show initial signs of motor symptoms at 5 6 weeks and 
difficulties in a number of tasks such as swimming and rotarod performance are observed 
(Carter et al., 1999).  MtHtt intranuclear and extranuclear ubiquitinated inclusions appear 
intracellularly in the striatum and the cortex at 3 4 weeks of age (Morton et al., 2009).  
Neurological abnormalities are seen by 8 weeks, particularly stereotypical hind limb 
grooming movements.  Between 8 12 weeks, balance and coordination become 
increasingly impaired (Carter et al., 1999).  Impairments in learning and memory are seen 
in the Morris water maze test, which worsen up to the age of 7 weeks after which this 
cognitive task cannot be used due to severe motor deficits.  Typically R6/2 mice are 
severely impaired by 7 12 weeks of age and show progressive loss of body weight after 12 
weeks (Mangiarini et al., 1996, Carter et al., 1999).  The R6/2 mice in most colonies die at 
around 13 16 weeks of age, but this may vary by a few weeks.   
  Although no gross or microscopic abnormalities in the brain structures of R6/2 mice are 
observed (Mangiarini et al., 1996), motor dysfunction involving resting tremor in all limbs 
in R6/2 animals strongly suggests a basal ganglia lesion.  Additionally, epileptic seizures 
have a cerebral focus and are observed in these animals.  These mice do not develop a 
pronounced ataxia, wide based gait or fall when moving; neither do they lose their righting 
reflex.  This suggests that there is no major cerebellar lesion in the R6/2 mice (Mangiarini 
et al., 1996).  Thus the striatum and the cortex could be considered to be regions 
particularly vulnerable in this disease model and the cerebellum as a relatively spared area 
of the brain.  In the R6/2 striatum, the cell bodies of the MSNs shrink by about 20% and 
the size of their dendritic fields are also reduced (Klapstein et al., 2001).  However, there 
are also a number of peripheral pathologies and inclusion bodies have been detected in 
several other non CNS tissues (Sathasivam et al., 1999).  The pathological events 
















Figure 1.11. Summary of pathological events in the R6/2 mouse model of HD.  Arrows 
indicate the time at which pathological events have been described (Carter et al., 1999, 
Morton et al., 2009). 
 
 
1.9.3.  Models of prion disease 
  Infection of mice with sheep scrapie and subsequent mouse to mouse passages has led to 
the identification of different scrapie strains which differ in the neuropathological changes 
they induce.  These strains are used as models of prion disease and are distinguished by 
their incubation times and patterns of vacuolation (Bruce, 2003).  Additionally the same 
strains are able to produce different disease outcomes, such as severity, location, and 
duration of disease, as a consequence of interactions with the host genotype (Gonzalez et 
al., 2002).  Examples of some scrapie strains used in many studies are shown in Table 1.5.  
The ME7 strain displays distinct hippocampal pathology with selective neuronal loss 
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Strain  Pathology 
ME7  Deposition of PrP mainly in the hippocampus.  Synaptic and cell loss in 
CA1 (Gray et al., 2009) 
22L  PrP
sc deposition and vacuolation in the cerebellar cortex (Skinner et al., 
2006) 
RML  PrP
sc deposition and vacuolation mainly in the pons, midbrain and 
thalamus (Siso et al., 2002) 
87V  PrP
sc deposition and selective CA2 cell loss (Jamieson et al., 2001)  
Table 1.5. Examples of scrapie stains with specific neuropathology. 
 
1.9.3.a.  ME7 mouse model of prion disease 
  The ME7 mouse model of prion disease in C57BL/6J mice is routinely used to investigate 
the progression of prion disease in mammals and serves as a model of chronic 
neurodegeneration with cell specific vulnerabilities (Gray et al., 2009).  Disease is 
transmitted by injecting prion infected brain homogenate (ME7) into the dorsal 
hippocampus of C57/BL mice.  Control animals are injected with non infected brain 
homogenate (NBH).  Prion infected mice develop progressive neurodegeneration with 
hippocampal pathology over a number of weeks post injection (pi).  The selective 
hippocampal deficits observed in this model has been shown to be independent of the site 
of injection in the brain (Bruce et al., 1991).  The distinct pattern of degeneration in the 
hippocampus and the defined anatomical pathways and neuronal circuitry allows the 
investigator to specifically study hippocampal pathology in a tractable way.  It is also 
important to note that ME7 infected mice show pathological changes in other brain regions 
at end stage of disease, for example neuronal loss, vacuolation and astrocytosis are 
observed in the thalamus (Bruce et al., 1991, Cunningham et al., 2005).  
  One of the early events to occur in ME7 animals is the extracellular deposition of 
abnormal misfolded PrP
sc (Jeffrey et al., 2000).  This is first observed in the hilus of the 
dentate gyrus (DG) at 8 weeks post inoculation followed by the CA3 and CA1 regions.  
Increasing burden and deposition of misfolded PrP
sc occurs in a time dependent, 
anterograde fashion (Cunningham et al., 2003).  At late stage of disease deposits are 
present throughout the hippocampus in the extracellular space surrounding neurons and   72 
their processes.  This is similar to the deposition seen in human brains (Armstrong et al., 
2001b).  PrP
sc accumulation does not correlate with neuronal/synaptic loss, as 
neurodegeneration is first seen in the stratum radiatum of the CA1 at which point PrP
sc is 
sparsely distributed in this region (Siso et al., 2002, Cunningham et al., 2003).   
  Prior to the onset of clinical symptoms and neuronal death, degeneration within the CA1 
region of the hippocampus is seen.   Synaptophysin staining was found to be significantly 
reduced at 12 weeks with increasing disorganization of the CA1 region (Cunningham et 
al., 2003, Gray et al., 2009).  This was associated with a loss of synapses in the stratum 
radiatum of the hippocampus.  By 19 weeks 40% neuronal loss was observed in the CA1 
region (Jeffrey et al., 2000, Cunningham et al., 2003, Siskova et al., 2009). 
  ME7 infected animals produce an inflammatory response with activation of microglia and 
astrocytes as early as 8 weeks, coinciding with PrP
sc deposition (Betmouni et al., 1996).  
The inflammatory response seen during ME7 induced prion disease is atypical in nature 
(Perry et al., 2002).  Pro inflammatory cytokines interleukin 1β (IL 1β), tumor necrosis 
factor α (TNF α) and interleukin 6 (IL 6) are modestly induced, however the anti 
inflammatory molecule TGFβ1 is induced and an ensuing anti inflammatory response is 
observed (Betmouni et al., 1996, Walsh et al., 2001, Cunningham et al., 2002).  Activated 
microglial morphology along with an anti inflammatory profile is rather indicative of a 
macrophage like response associated with phagocytosis and digestion of apoptotic cells 
(Fadok et al., 2001).  This activation correlates with synapse loss leading to the speculation 
that activated microglia are involved in removal of these synapses.  However, recent data 
suggests that this may not be the case and microglia may not be involved in ‘synaptic 
stripping’, but that this could be a neuron autonomous event (Siskova et al., 2009). 
  Synaptic loss and dysfunction are thought to underlie the early behavioural deficits seen 
in this mouse model of neurodegeneration.  Mice display impairment of burrowing 
behaviour, nesting, glucose consumption, and increased open field activity at 13 weeks.  
Impairments in other behavioural readouts such as rotarod and horizontal bar tasks become 
apparent later in disease (Deacon et al., 2001).  By 21 weeks clinical signs are visible. The 
pathological events that occur in the ME7 model are summarized in Figure 1.12. 
 

















Figure 1.12. Summary of pathological events in the ME7 mouse model of prion 
disease.  Arrows indicate the time post infections (pi) at which pathological events have 
been described (Betmouni et al., 1996, Cunningham et al., 2003, Gray et al., 2009). 
 
 
   The hallmarks and tractability of the ME7 model is useful to study chronic 
neurodegenerative changes in a relatively short time window.  While this model allows 
investigation into the neurodegenerative processes associated with extracellular protein 
aggregation, the R6/2 model of HD (described in section 1.9.2 a) allows examination of 
chronic neurodegeneration in the context of intracellular aggregation.  Due to the tractable 
neuropathology and the similarly short lifespan of these two animal models, they offer an 
excellent opportunity to investigate the involvement of molecular chaperones at specific 
time points during disease progression. 
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1.10.  Aims 
  The importance of the sHsps is evident by the key cellular processes in which they 
participate and hence dysregulation of sHsp function could participate in proteinopathies of 
the CNS.  Little is known about the physiological role of the sHsps under normal 
conditions in the CNS or their contribution to CNS disease progression.  Therefore, the 
aims of this project are (i) to investigate and establish a baseline of mRNA and protein 
expression for the sHsp family in the mouse CNS under physiological conditions, (ii) with 
a focus on the sHsps found to be constitutively expressed as established in (i), investigate 
their expression under pathological conditions by using two mouse models of protein 
misfolding disease (ME7 and R6/2).  The use of these two models would allow analysis in 



























Chapter 2 – Materials and Methods 
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2.1.  Animal husbandry 
  C57BL/6J inbred mouse strain resulting from the crossing of consecutive generations of 
brother/sister matings, allowing offspring to posses genetic and phenotypic uniformity 
were housed in groups of 5 or 10 and maintained at a room temperature of 21 23°C and the 
relative humidity was controlled (55 ± 10%) on a standard 12 hour light: 12 hour dark 
cycle.  Mice had ad libitum access to food (standard laboratory chow [RM 1, Special Diet 
Services, UK]) and water.  Mice were purchased from Harlan Laboratories (UK) or 
Charles River Laboratories (UK) and were permitted to acclimatise for at least seven days 
prior to undergoing any surgical procedures.  C57BL/6J mice from either Harlan or 
Charles River do not differ in pathology (Asuni et al., 2010).   
  R6/2 tg mice were genotyped and maintained in the Department of Pharmacology, 
University of Cambridge through a collaboration (courtesy of Dr. A. Jennifer Morton).  
Husbandry was performed as above; in addition, mice were given a supplementary feed 
each morning of a mash prepared by soaking 100g dry food in 230ml of tap water until the 
pellets were soft and fully expanded.  Genotyping was carried out as previously described 
(Mangiarini et al., 1996, Morton and Leavens, 2000).  Briefly genotyping was performed 
by PCR from tail snips taken at 3 weeks of age and CAG repeat lengths measured by 
sequencing (Laragen, USA).  Mice with CAG repeat lengths of 227 236 and age matched 
wt littermates were used for all experiments.  All procedures were carried out in 
accordance with the Animals (Scientific Procedures) Act, 1986. 
2.2.  Animal Surgery 
2.2.1.  Surgery (NBH and ME7 models of prion disease) 
  Surgery was performed on C57BL/6J mice between 8 and 10 weeks old.  Mice were 
anaesthetised with a cocktail of Ketamine/Xylazine given at a dose of 0.1ml/10g intra 
peritoneally (1ml Ketaset, 0.5ml Rompun and 8.5ml sterile saline were mixed via inversion 
and stored at 4°C).  The anaesthetic was kept on ice on the day of use, and was 
administered at 0.1ml per 10g of mouse.  Lacrilube was used to prevent the eyes of the 
mice drying out during surgery, and Lidocaine ointment (BioRex Laboratories) was 
applied in both ears for local anaesthesia.  Once fully anaesthetised, mice were mounted in   77 
a stereotaxic frame (David Kopf instruments, CA).  The scalp was cut and the skull 
exposed.  The stereotaxic coordinates relative to Bregma were  0.2mm (anterior to 
posterior) and ± 0.17mm (medial   lateral), for the dorsal hippocampus.  Holes were made 
at these coordinates and 1 l of normal (NBH) or ME7 infected (ME7) brain homogenate 
was injected bilaterally over a period of 1 minute, at a depth of  0.16mm.  The incision was 
sutured using Mersilk (0.2mm).  Animals were placed in a heated chamber (37°C) and 
allowed to recover as Ketamine/Xylazine may result in hypothermia.  Once full righting 
reflex was restored, animals were re housed in groups of 5 or 10.  Experiments were 
conducted under project licence no: 30/2543 with personal licence: 30/8604.  All 
procedures were carried out in accordance with the Animals (Scientific Procedures) Act, 
1986. 
2.2.2.  Perfusion and tissue fixation 
  Animals were terminally anaesthetised with Pentobarbital and the thoracic cavity opened 
to expose the heart.  A butterfly needle (27 gauge, Venisystems, Eire) was inserted into the 
left ventricle, and the right atrium was cut.  Animals were perfused with heparin saline 
(0.9% saline containing 5000U/L heparin) until the perfusate ran clear.  Where tissue was 
required for immunohistochemical analysis, animals were perfusion fixed with 10% 
neutral buffered formalin.  R6/2 animals were perfusion fixed with 4% paraformaldehyde 
(PFA) at the University of Cambridge (courtesy of Dr. A. Jennifer Morton).  ME7 and 
NBH animals were sacrificed at 8, 13 and 20 weeks post surgery.  R6/2 tg and wt 
littermates were sacrificed at 4, 9 and 17 weeks of age. 
2.3.  Tissue extraction 
2.3.1.  Immunohistochemistry 
  Animals were terminally anaesthetised and perfusion fixed (section 2.2.2) before 
decapitation.  The skull was removed and the exposed brain was carefully isolated, post 
fixed in formalin or 4% PFA (R6/2) and stored at 4°C.  The brain tissue was dehydrated 
through an increasing alcohol series and immersed in Histoclear in a Leica TP 1020 tissue 
processor: 
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70% ethanol      2 hours 
70% ethanol      2 hours   
80% ethanol      1 hour 
90% ethanol      1 hour 
Absolute ethanol I    1 hour 
Absolute ethanol II    1 hour 
Absolute ethanol III    overnight 
Histoclear 2 I      4 hours 
Histoclear 2 II     2 hours 
Histoclear 2 III    overnight 
 
The brains were submerged in paraffin wax (Polywax, UK) at 40°C, embedded in fresh 
wax and allowed to cool.  The wax blocks were stored at room temperature.  10 m 
sections were cut on a Leica RM2255 rotary microtome and floated on dH2O at 40°C 
(tissue floatation bath, LAMB).  Sections were mounted on SuperFrost Plus (Fischer) 
microscope slides and dried overnight at 37°C.  Slides were stored at room temperature. 
2.3.2.  NBH and ME7 tissue extraction 
  Animals were terminally anaesthetised and perfused with heparin saline (section 2.2.2).  
Animals were decapitated and the skull removed before the brain was lifted out.  The 
forebrain and the cerebellum were removed.  The brain was opened out from the midline, 
and the midbrain removed to reveal the hippocampi.  The hippocampi were rolled away 
from the cortex, detached and the white matter removed from the two lobes of the 
hippocampus.  The hippocampus was further microdissected into CA1, CA3 and DG 
regions.  Tissue was weighed and kept on ice before homogenisation (10% w/v) in buffer 
(20mM Hepes/100mM KCl, pH 7.4, with Complete
TM protease inhibitors).  100 l 
equivalent to 20mgs (weight) of tissue was used immediately for RNA extraction using the 
RNeasy kit (section 2.5.1) and the remaining homogenates were stored at  20°C.  Aliquots 
of all samples were taken to determine protein concentrations (section 2.8.2).  40 g of 
protein from each region was resolved by SDS PAGE unless otherwise stated (section 
2.8). 
2.3.3.  R6/2 transgenic and wild type (and human) mouse tissue extraction 
  R6/2 tg and wt littermates were sacrificed by cervical dislocation and decapitated.  The 
brains were carefully removed, snap frozen in liquid nitrogen and stored at  80°C until   79 
required.  This allowed the subsequent extraction of both protein and mRNA from the 
same tissue.  Specific brain regions such as frontal cortex, striatum and cerebellum from 9 
and 17 week R6/2 tg and wt animal were dissected on ice from frozen mice brains under a 
dissection microscope.  Samples were processed for protein and mRNA extraction as 
described in section 2.5.1 and 2.8.1. 
  Frontal cortex, striatum and cerebellum from 4 and 9 week old R6/2 tg and wt animals 
and human samples were extracted at the University of Cardiff by Dr. Andreas 
Wyttenbach as follows.  Pre cut or microdissected brain tissue was added to pre cooled 
0.5ml tubes ( 20C) containing half of the amount of beads from “Lysing D tubes” 
(obtained from Q biogene). 400 l of ice cold lysis buffer was then added on ice, 
containing: 
 
        40mM beta glycerolphosphate 
       1mM EDTA 
       1mM Na orthovanadate 
       25mM NaF 
       50mM Tris HCl, pH 7.5 
       1% NP 40 
       120mM NaCl 
       1mM Benzamidine 
       Roche Protease inhibitor Coctail 
       Antifoam (1:1000, Sigma) 
 
This lysis buffer was chosen as it inhibits proteases and phosphatases for analysis of 
phospho proteins.  Groups of 12 tubes were then processed in a fast preparation machine 
(using a bead extraction approach) for 30 seconds (speed rotation: 4), left to cool down and 
extracted for 5 minutes on ice after which the tubes were spun for 3 minutes at 6000rpm in 
a microfuge.  This ensured that tissue chunks and beads were not used for analysis.  Then 
3 4 x 100  l aliquots of supernatant from each extraction tube was aliquoted into 
eppendorf tubes and frozen on dry ice with subsequent storage at minus 80°C. 
  Subsequently, human brain tissue was re extracted by adding the supernatants back to the 
tubes containing the beads and remaining tissue chunks with addition of 2% SDS after 
which the tubes were transferred to a heating block and left for 4 minutes at 95C, after 
which the tubes were spun for 3 minutes at 6000rpm to remove any remaining SDS 
insoluble materials and the beads.   80 
  Human tissue was provided by Drs. Richard Faull (University of Auckland, NZ) and  
Lesley Jones (University of Cardiff, UK) and all human samples were processed and 
analysed by A. Wyttenbach and  M. U. Sajjad.  Protein concentrations were estimated by 
BioRad protein assay (section 2.8.2).  40 g of protein from each brain region were 
resolved by SDS PAGE for all experiments unless otherwise indicated (section 2.8). 
2.3.4.  C57BL/6J tissue extraction 
  For characterization of the sHsps under physiological conditions, (Chapter 3) adult (p60, 
C57BL/6J) mice were sacrificed by cervical dislocation and decapitated.  Each was pinned 
dorsal side up and a laminectomy performed to extract the spinal cord.  The mice were 
then pinned ventral side up, the skin was cut and pulled back to expose internal organs and 
skeletal muscle.  Skeletal muscle from upper fore and hind limbs were removed.  Testis, 
heart and eyes were also removed.  Brains were carefully removed with olfactory bulbs 
intact.  Brain and spinal cord tissue to be used for in situ hybridization was immediately 
placed in Tissue Tek OCT (Bayer Diagnostics) on dry ice (section 2.7).  All samples were 
wrapped in foil and placed immediately in liquid nitrogen.  The frozen tissues were stored 
at  80˚C until required. 
2.3.5.  C57BL/6J whole brain tissue extraction 
  Whole brain from p60 adult mice (C57BL/6J) were removed and dissected in half.  Each 
half was either homogenised in 10 volumes Hepes/KCl buffer (20mM Hepes/100mM KCl, 
pH 7.4, with Complete
TM protease inhibitors) or lysis buffer as described in section 2.3.3 
using a PowerGen 125 homogenizer (Fisher Scientific).  Brain tissue homogenised in 
detergent (NP 40) was subsequently extracted on ice for 10min before spinning at 4ºC for 
10min at 3,000rpm.  The resultant pellet (P1) was re suspended in 5% SDS.  An aliquot of 
the supernatant (S1) was kept for analysis and the remaining S1 sample was extracted on 
ice for 15min prior to spinning at 4ºC for 6min at 6,000rpm.  The pellet (P2) and 
supernatant (S2) were retained for analysis.  This protocol was designed to investigate the 
differential distribution of the sHsps. 
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2.4.  Reverse transcription Polymerase Chain Reaction (RT PCR) 
2.4.1.  RNA extraction  
  Brain, muscle, testis, heart and eye tissues (section 2.3.4) were weighed and homogenized 
in 1ml of TRIzol Reagent (Invitrogen) per 50 100mg of tissue using a PowerGen 125 
homogenizer (Fisher Scientific).  Muscle homogenates were first centrifuged at 4˚C for 
10mins at 12,000 x g.  This additional isolation step was performed to remove 
polysaccharides and high molecular weight DNA into the pellet, and retain RNA in the 
supernatant.  The supernatant was transferred to a clean eppendorf tube and treated in the 
same way as other samples.  Homogenized samples were incubated at 15 30˚C for 5min to 
allow the complete dissociation of nucleoprotein complexes.  0.2ml of chloroform was 
added per 1ml of TRIzol Reagent in a fume hood.  Samples were shaken vigorously by 
hand for 15sec and incubated at 15 30˚C for 3min.  Samples were then centrifuged at 4˚C 
for 15mins at 12,000 x g.  Following centrifugation, the colourless mRNA containing 
upper aqueous phase was removed carefully to prevent disruption of the lower phenol 
phase and mRNA was precipitated by adding propan 2 ol.  The samples were incubated at 
15 30˚C for 10min, and centrifuged at 4˚C for 10mins at 12,000 x g.  The supernatant was 
removed and the RNA pellet washed once with 75% ethanol (at least 1ml) by vortexing 
prior to centrifuging at 4˚C for 5min at 7,500 x g.  The supernatant was removed and the 
mRNA pellets air dried for 10min.   Pellets were dissolved in diethylpyrocarbonate 
(DEPC)  H2O by passing the solution a few times through a pipette tip, giving an 
approximate concentration of 2mg/ml; samples were then incubated at 55˚C for 10min to 
promote dissolution of the mRNA pellet. 
2.4.2.  cDNA synthesis 
  The concentration and quality of mRNA was determined using a spectrophotometer and 
the Agilent 2100 Bioanalyser.  First strand cDNA synthesis was set up as follows using 
SuperScript
TM II RT (Invitrogen): 
 
  Oligo (dT)12 18 (500 g/ml)  1 l 
  Total RNA  (1ng 5 g)  4 l 
  dNTP Mix  (10mM each)  1 l 
  DEPC H2O      6 l   82 
The above reaction was heated to 65˚C for 5min and quick chilled on ice.  Tubes were 
briefly centrifuged and the following reagents added: 
 
  5X First Strand Buffer  4 l 
  0.1M DTT      2 l 
  ddH2O       1 l 
 
Tubes were mixed gently and incubated at 42˚C for 2min.  1 l of SuperScript
TM II RT was 
added, and mixed by pipetting.  Reaction tubes were incubated at 42˚C for 50min and the 
reaction was inactivated by heating at 70˚C for 15min.  cDNA was stored at  20˚C. 
2.4.3.  Polymerase Chain reaction (PCR)  
  Oligonucleotide primers designed against mRNA were supplied by Invitrogen (Table 2.1) 
and were used to amplify cDNA specific targets.  A master mix (x7) was set up as follows 
for each primer pair:   
10x PCR Buffer    5 l 
      dNTP mix (10mM each)  1 l 
      Forward Primer (10 M)  1 l 
      Rev Primer (10 M)    1 l    50 l 
Taq DNA polymerase   0.5 l 
ddH2O       39.5 l 
TEMPLATE       1 l 
   
  A thermal cycler (Gene AMP PCR System 9700 – Applied Biosystems) with a heated lid 
was used to set up cycling conditions for PCR.  The cycling parameters highlighted in 
boxes were adjusted in order to optimize conditions for each primer pair, details are listed 
in Table 2.1: 
Initial denaturation:  2min  94˚C 
                          Denaturation:  40sec  94˚C 
                 Annealing:  30sec  57˚C    35 cycles 
            Extension:  2min  72˚C 
            Final Extension:  10min 72˚C 
   
Re amplified cDNA products were stored at  20˚C.   83 
2.4.3.1.  Oligonucleotide primer design 
All sequences were subjected to an NCBI nucleotide to nucleotide blast search to check 
for specificity.  Self annealing and hairpin formation was checked using the 
Oligonucleotide Properties Calculator.  All oligonucleotides are listed in pairs. 









HspB1 A   Forward  CGC CTC TTC GAT CAA GCT TTC  549  58  1 
HspB1 B   Reverse  CTA CTT GGC TCC AGA CTG TTC       
HspB2 A  Forward  CTG CCG AGT ACG AAT TTG CC  501  57  1 
HspB2 B  Reverse  CTC TGG CTA TCT CTT CCT CTT       
HspB3 A  Forward  TGC GTT ATC AGG AGG AGT TTG  392  57  1 
HspB3 B  Reverse  CCA CCA AGA TTC CAT CAT GAC       
HspB4 A  Forward  TCA GCA TCC TTG GTT CAA GCG  427  58  1 
HspB4 B  Reverse  CAC ATT GGA AGG CAG ACG GTA       
HspB5 A  Forward  TTC TTC GGA GAG CAC CTG TTG  417  58  1 
HspB5 B  Reverse  CTC TTC ACG GGT GAT GGG AAT       
HspB6 A  Forward  TGC TTC AGS TCC TTT ACC AG  305  57  1 
HspB6 B  Reverse  CTC GAG CAA TGA ATC CGT GT       
HspB7 A  Forward  TTC AGA GCG GAG AGA AGC TTC  466  59  1 
HspB7 B  Reverse  GGA AGG TCT GCT GGA CAT GTT       
HspB8 A  Forward  CTT TTC CAG ACG ACT TGA CAG  466  57  1 
HspB8 B  Reverse  GTG ACT TCC TGG TTG TCT TGA       
HspB9 A  Forward  AAC GGA ATC AAG TGG CCA CTC  360  58  1 
HspB9 B  Reverse  TTT CTG GGA CTG GCC TGT TTG       
HspB10 A  Forward  TTG GAC AGT GTT AGG AGG GAC  699  58  1 
HspB10 B  Reverse  GAA TCG GCT TCC ACA GGG ATA       
Hsc70 A  Forward  CCT GCA GTT GGC ATT GAT CTC  1903  57  2 
Hsc70 B  Reverse  CTG AAG AAG CAC CAC CAG ATG       
18S A  Forward  CTC CTC TCC TAC TTG GAT AAC  1663  57  2 
18S B  Reverse  CTC ACT AAA CCA TCC AAT CGG       
HspB1 A  Forward  ATG AGT GGT CGC AGT GGT T  275  56  1 
HspB1 B  Reverse  CCG AGA GAT GTA GCC ATG TT       
HspB8 A  Forward  AGG TTT GGA GTG CCC GCT  349  56  1 
HspB8 B  Reverse  GTG ACT TCC TGG TTG TCT TGA       
ATP5b A  Forward  CAC GGT CAG AAC TAT TGC TAT G  1152  58  1.5 
ATP5b B  Reverse  TCC TTT AAT GGT CTC CTT CAA       
Table 2.1.  Oligonucleotide list used for PCR amplification  
 
2.5.  Quantitative PCR (QT PCR) 
2.5.1.  RNA extraction 
  Tissue was extracted as detailed sections 2.3.2 and 2.3.3.  20mg of tissue was used to 
extract total RNA using a Qiagen RNeasy Mini kit, according to the manufacturer’s 
instructions (QIAGEN).  Briefly, tissues were homogenised using a hand held Pellet Pestle   84 
Motor (Kontes) in RLT buffer containing 1% β mercaptoethanol.  Samples were 
centrifuged for 5min at 14,000 rpm; the supernatant was removed and mixed with 1 
volume 70% ethanol.  Samples were loaded onto RNeasy mini columns.  Columns were 
washed with RW1 buffer, followed by RPE buffer.  RNA collected onto RNeasy mini 
columns was eluted in 50 l of RNase free water.   
2.5.2.  Reverse transcription (RT) 
  The concentration of RNA was measured on a NanoDrop spectrophotometer; all samples 
had an absorbance A260/A280 ratio close to 2 or above, denoting an acceptably pure nucleic 
acid sample.  Using OligodT primers, 800ng of RNA from each sample was converted to 
cDNA using iScript cDNA synthesis Kit BIO RAD.   Briefly, first strand cDNA synthesis 
was set up as follows: 
   
Oligo (dT)12 18 (500 g/ml)  2 l 
      Total RNA  (800ng)    l 
      5x iScript reaction mix  8 l 
      iScript Reverse transcriptase  2 l 
      Nuclease free H2O    up to 40 l 
   
  Samples were incubated for 5min at 25˚C, 30min at 42˚C, 5mins at 85˚C and the reaction 
was terminated at 4˚C.  cDNA was stored at  20˚C. 
2.5.3.  Polymerase Chain reaction (QT PCR)  
  HspB1, B5, B6 and B8 primers used for non quantitative PCR (section 2.4.3) were tested 
for use by QT PCR.  HspB5 and HspB6 primers showed good amplification efficiency and 
melting curves showed a single peak.  However HspB1 and HspB8 primers produced 
additional peaks in the melting curves, suggesting non specific amplification and potential 
primer dimer formation.  For optimal PCR efficiency amplicon length should ideally be 
between 50 250bp, therefore additional primers were designed for HspB1 and HspB8 with 
the shortest possible amplicon size (Table 2.1 in bold).  Additionally primers were 
designed against the housekeeping genes GAPDH (Applied Biosystems  TaqMan Rodent 
GAPDH Control Reagents) and ATP5b (Table 2.1).  For HspB8, the reverse primer used   85 
for non quantitative PCR and the forward primer specifically designed for QT PCR (in 
bold Table 2.1) provided the most optimal combination for QT PCR analysis. 
  Reactions for QT PCR were conducted in 96 well Microseal PCR plates (BIORAD) in a 
total volume of 25 l per well, using 1 l of cDNA, 10 M each of forward and reverse 
primers and 12.5 l of iQ SYBR Green supermix (BIO RAD).  Each sample was processed 
in duplicates.  Cycling conditions were as described in section 2.4.3; additionally HspB1, 
HspB6 and HspB8 were run for 40 cycles.  Cycle threshold levels (Ct) were automatically 
set at x1 standard deviation over the cycle range using Opticon Monitor 3 software.  
Melting curves of primer/template were checked to confirm the presence of a single peak 
indicating selective amplification of target cDNA (see Appendix 1). 
  QT PCR and data collection were conducted using a Chromo4 real time PCR machine.  
A “no template control” in which cDNA was omitted was included for each gene.  cDNA 
(starting material = 800ng of RNA) from physiological tissue was used to generate a 
standard curve.  This was constructed from 5 fold serial dilutions, starting with undiluted 
cDNA up to a 1:625 dilution.  These samples were processed by QT PCR with each of the 
mRNA specific primers so that a standard curve could be constructed from the resulting Ct 
values for each gene.  The standard curve for each target gene was then used to calculate 
the relative concentrations of the target gene in all samples (as relative expression (arbitary 
units)).  The relative expression of the target genes (sHsps) were normalised to the relative 
expression of the reference genes (GAPDH or ATP5b).  Student’s paired t test was used to 
compare normalised data between ME7 and NBH; and R6/2 wt and tg animals.  All brain 
regions were analysed separately.  All statistical analyses were made using Graph Pad 
Prism 4.0 (section 2.15). 
2.6.  Agarose gel electrophoresis 
  Agarose gels containing ethidium bromide were used to separate DNA (PCR products) 
according to size.  1% gels were made by dissolving 0.5g of agarose in 50ml Tris acetate 
(TAE 1X) (mini gel), or 1.5g agarose in 150ml  TAE (maxi gel).  The TAE was prepared 
from a 50X stock (100ml/L 0.5M EDTA pH 8.0, 2M TrisBase, 57.1ml/L Glacial Acetic 
Acid, made up to 1L with ddH20).  The agarose was dissolved by heating the mixture in a 
microwave.  The molten agarose was allowed to cool slightly before pouring into a casting   86 
mould.  10mg/ml of ethidium bromide was added; the gel was allowed to set and then 
placed into an electrophoresis chamber containing 1X TAE.  Samples were mixed with gel 
loading buffer (6X, Invitrogen; 30% (v/v) glycerol, 60mM Tris HCl (pH 7.5), 60mM 
EDTA, 0.36% (w/v) XCFF, and 3.6% (w/v) Tartrazine) to achieve a 1X final 
concentration.  A molecular weight marker (1Kb Plus DNA Ladder, Invitrogen) was 
included in an adjacent lane to asses the size of the separated DNA.  Mini gels were run at 
75mV and large gels at 120mV.   
2.7.  In situ Hybridization 
2.7.1.  Sectioning of Mouse Brains and Spinal Cords 
  Adult p60 mice (C57BL/6J) were sacrificed by cervical dislocation.  Brains and spinal 
cords were carefully removed to keep all structures intact and immediately immersed in 
Tissue Tek OCT (Bayer Diagnostics), on 2 methylbutane over dry ice.  The Frozen tissues 
were stored at  80˚C until required. 
  Brain and spinal cord tissue were placed in a cryostat (Leica, CM3050S) set at a chamber 
temperature of  16˚C to  18˚C for a minimum of 1 hour prior to cutting sections.  12 M 
sections were cut and thaw mounted onto slides (SuperFrost Plus, Fischer), air dried for 
10mins, and desiccated at  80˚C until required.  
  Mouse brains were cut in three orientations: longitudinal, sagittal, and coronal.  Coronal 
sections were cut approximately 1.10mm to  2.70mm (dorsal ventral), sagittal sections 
were cut ± 2.76mm (medial lateral), and horizontal sections were cut 0mm to 4mm 
(anterior posterior) relative to Bregma.  Spinal cords were cut longitudinally and coronally.  
Cell bodies were visualized with Nissl stain to determine the position of the sections 
relative to Bregma, every 10
th slide was stained. 
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2.7.2.  Nissl staining 
   Cresyl Violet was used to stain every 10
th slide using the following protocol: 
 
      4% PFA (Chilled, on ice)  5min     
      dH2O (X2)      3min 
      dH2O/acetic acid    3min 
0.25% Cresyl Violet    10min 
dH2O/acetic acid    5 10sec 
70% ethanol      5 10sec 
80% ethanol       5 10sec 
95% ethanol      5 10sec 
100% ethanol I    5 10sec 
100% ethanol II    1min 
Xylene       3min 
 
Coverslips were then placed over the sections using DPX (Dibutyl phthalate   Xylene) 
Mounting medium.  
2.7.3.  Probe selection for In situ Hybridization 
  Oligonucleotide probes were designed against sense and anti sense mRNA sequences for 
each target gene.  The probes were 45 bases long and supplied by Eurogentec (Table 2.2).  
Self annealing and hairpin formation was checked to determine specificity of primers.  
Primers with potential self annealing and hairpin formation were excluded and alternative 
primers designed (Oligonucleotide Properties Calculator).  Sequence specificity for the 
desired target mRNA was determined using NCBI nucleotide to nucleotide BLAST 
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Position 
in gene 
Name  5’ 3’ sequence 
669 713  HspB1 antisense  GAG ATA GGC AGC AGG CTG ATG GCT TCT ACT TGG CTC 
CAG ACT GTT 
  HspB1 sense  AAC AGT CTG GAG CCA AGT AGA AGC CAT CAG CCT GCT 
GCC TAT CTC 
491 535  HspB3 antisense  TTG TAC TGT CTG GTG AAA CTC CGC GAT ATA AAC CCG 
TGT TCG TCC 
  HspB3 sense  GGA CGA ACA CGG CTT TAT ATC GCG GAG TTT CAC CAG 
ACA GTA CAA 
1025 1069  HspB5 antisense  AAA CTC AAT GAG GAA AGG GGA TCT ACT TCT TAG GGG 
CTG CGG CGA 
  HspB5 sense  TCG CCG CAG CCC CTA AGA AGT AGA TCC CCT TTC CTC 
ATT GAG TTT 
361 495  HspB6 antisense  GGC AGG CGG TAT CGG CGG TGG AAC TCT CGA GCA ATG 
AAT CCG TGT 
  HspB6 sense  ACA CGG ATT CAT TGC TCG AGA GTT CCA CCG CCG ATA 
CCG CCT GCC 
1271 1315  HspB6 antisense  TGC ATT TAT TGG GGA CTG ATG GTA GGA AGG CCT GCG GAG 
ATG GGA 
  HspB6 sense  TCC CAT CTC CGC AGG CCT TCC TAC CAT CAG TCC CCA ATA 
AAT GCA 
1519 1563  HspB7 antisense  GCC AGT GGG GGA GGA GAT AAG GGG GAG GCC AGG GGT 
GGA GAG ACC 
  HspB7 sense  GGT CTC TCC ACC CCT GGC CTC CCC CTT ATC TCC TCC 
CCC ACT GGC 
1083 1127  HspB7 antisense  CAT GGG TGG GTC CTG GGC TGG AAG GGC ACG GGA GGC 
CGA AGA AGA 
  HspB7 sense  TCT TCT TCG GCC TCC CGT GCC CTT CCA GCC CAG GAC CCA 
CCC ATG 
976 1020  HspB8 antisense  CCT GGG GCT GGG GAT GGG AGC GAA GGA CCA AGG CTG 
ACG TCT 
  HspB8 sense  AGA CGT CAG CCT TGG TCC TTC TTC GCT CCC ATC CCC 
AGC CCC AGG 
303 347  HspB9 antisense  GGA TCT AAG GTC GGC GGG AGC TGC ATT TGT CGG TGA 
ACA CTC TGC 
  HspB9 sense  GCA GAG TGT TCA CCG ACA AAT GCA GCT CCC GCC GAC 
CTT AGA TCC 
916 960  HspB10 
antisense 
CCT ACA GGA GAA TCG GCT TCC ACA GGG ATA GCA GGG 
GTT GCA AGG 
  HspB10 sense  CCT TGC AAC CCC TGC TAT CCC TGT GGA AGC CGA TTC 
TCC TGT AGG 
Table 2.2.  Oligonucleotide primer sequences used for In situ hybridization 
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2.7.4.  Radioactive labeling of probes for In situ Hybridization 
  A typical labelling reaction consisted of: 
 
Oligonucleotide probe (20ng)         4 l   
5X TdT Reaction buffer (Roche)        2 l   
[alpha 
35S] dATP (Amersham, 9.25MBq, 250Ci (25 l))  1.3 l 
CoCl2                0.4 l   
Terminal Transferase (Roche @ 10U/  l)      1 l   
ddH2O               1.3  l   
 
The reaction was placed in a 33˚C water bath for 2hrs and the reaction volume was 
adjusted to 50 l by adding 40 l of ddH2O. Labelled oligonucleotides were purified using 
ProbQuant G 50 Micro Columns (Amersham) according to manufacturer’s instructions.  
To assess the quality of the labelling reaction the counts/min (cpm) were measured before 
(total count) and after (column count) purification of the oligonucleotide.  These values 
were used to calculate specific activity of the probe as described below. 
 
% incorporation     = (Column count / Total count) × 100 
Total cpm incorporated   = (Column count × reaction volume) / volume counted 
Average number of bases  = (% incorporation / 100) × molar ratio of nucleotide to  
    added to each oligo                                               oligo in reaction 
 
Amount of DNA synthesized = Average base added × 330 (average MW of base) 
          × pmol of oligo present in the reaction 
Specific activity    =                  Total cpm incorporate 
           g DNA template +  g of DNA synthesized 
 
HspB1 is used as example below: 
The Total count for the HspB1 anti sense probe was 766,139 cpm and the Column count 
was 373,338 cpm.  A 50 l reaction was set up containing 1.3pmol of 
35S dATP and 20ng 
(13pmol) of oligonucleotide: 
% incorporation     = (373338cpm / 766139cpm) × 100  =  48% 
Total cpm incorporated   = (373338cpm × 50 l) / 2 l    =  9.3 × 10
6     90 
Average number of bases  = (48% / 100) × (13/1.3)    =  4.8/oligo 
Amount of DNA synthesized = 4.8 × 330 × 1.3pmol     =  2ng 
Specific activity                     =          9.3 × 10
6    =  4.2 ×10
8cpm/ g                                        
nnnnnnnnnnnnnnnnnnnnnnnnnnnnnn0.02 g + 0.0019 g 
Typically the specific activity should be in the range of 1×10
8 – 1×10
9 cpm/ g. 
2.7.5.  Prehybridization 
  To preserve the tissue, and prepare it for the hybridisation protocol, the section were 
fixed, delipidated, acetylated, and dehydrated. All solutions were made using DEPC 
treated ddH2O and all reagents used were ‘molecular biology grade’ (i.e. RNAase free) 
  Sections were removed from the  80˚C freezer, and allowed to thaw for 10min.  Sections 
were fixed in chilled 4% PFA made in phosphate buffered saline (PBS) pH 7.0 for 5min 
and rinsed twice with PBS.  The slides were then rinsed twice with PBS. For each coplin 
jar, 50ml of TEA/AA solution was made immediately prior to use: 
 
0.7ml Triethanolamine, TEA 
0.125ml Acetic anhydride, AA 
49.75ml DEPC treated ddH20 
 
The slides were immersed in the TEA/AA solution for 10min to allow positively charged 
amine acid groups within the section to become acetylated, which will subsequently reduce 
non specific  binding.  The TEA/AA solution  was  removed  and  the  sections dehydrated 
with graded ethanol solutions, delipidated in chloroform, and dehydrated again: 
 
70% ethanol  1min 
80% ethanol  1min 
95% ethanol  2min 
100% ethanol  1min 
  Chloroform  5min 
100% ethanol  1min 
95% ethanol  1min 
 
The sections were then placed upright in a slide holder and allowed to air dry.   91 
2.7.6.  Hybridization 
  Hybridization buffer containing the following reagents was made a day prior to use and 
stored at 4˚C: 
50% Formamide (molecular biology grade) 
4X SSC (20X stock: 175.3g NaCl, 88.2g Sodium Citrate, up to 1L with 
DEPC ddH20) 
200 g/ml sheared salmon sperm DNA 
100 g/ml long chain polyadenylic acid 
25mM Sodium phosphate (pH7) 
1mM Sodium pyrophosphate 
10% Dextran Sulphate 
5X Denhardt’s solution (100X Stock: 20g Ficoll, 20g Polyvinylpyrolidone, 
and 20ng) 
Bovine Serum Albumin, up to 1L with DEPC ddH20 
20 l/ml of 1M DTT (added just before use)  
 
  The labelled probes were added at 200,000cpm/100 l of hybridization buffer, and mixed 
by vortexing.  A 500 fold xs of unlabelled anti sense probe was added to the remainder of 
hybridization buffer containing labelled anti sense probe as an addition control.  100 l of 
hybridization buffer containing the specific probe was pipetted onto each slide (~50 l per 
section).  Parafilm coverslips were carefully placed over the sections using forceps, whilst 
ensuring that there were no air bubble and the buffer was evenly spread.  The slides were 
placed into chambers containing tissue paper saturated in 50% formamide and 4X SSC.  
The containers were sealed with parafilm and placed in an incubator at 42˚C overnight. 
2.7.7.  Post hybridization 
  1X SSC was preheated in a water bath at 55˚C.  The slides were placed in a rack after 
overnight hybridization and transferred to a wash chamber containing 1X SSC at room 
temperature for 10 minutes.  The parafilm coverslips were gently removed from the slides.  
The slides were then transferred to wash chambers containing 55˚C 1X SSC for 30min.  
The slides were subsequently washed with 1X SSC (room temp) for 1 min, followed by a 
5min wash in 0.1X SSC.  The sections were dehydrated with 70% ethanol for 1 min and 
95% for 5min.  Finally, the slides were left to dry for 30min.   92 
2.7.8.  Signal detection – Film autoradiography 
  Dried slides were placed into an x ray cassette and secured using ‘magic tape’. BioMax 
‘Maximum Resolution’ (Amersham) film which contains a single dull emulsion side was 
placed (emulsion face down) onto the slides.  The cassette was closed, wrapped in plastic 
bags, and left at room temperature.  Exposure times were set at 2 and 6 weeks for all 
probes. 
2.7.9.  In situ hybridization – Emulsion radiography 
  Slides used for film autoradiography were subsequently subjected to emulsion 
radiography.  A light box fitted with a Kodak Safelight No.1 filter was used throughout the 
procedure.  The light box was kept as far from the work bench as possible to minimize 
light exposure.   
  25ml of distilled water, plus one drop of glycerol was pre warmed to 42ºC in a Coplin jar.  
Shreds of emulsion (Ilford K5 emulsion) were added to bring the solution up to 45ml and 
the solution was warmed to 42ºC to melt the emulsion.  The solution was stirred carefully 
to avoid production of bubbles.  Each slide was dipped in the emulsion and the back wiped 
clean before placing onto a metal sheet, which had been covered with ice.  The slides were 
left to dry for 10min before being placed into slide holders and air dried for 2 hours in the 
dark.  Slides were placed into racks and stored in a light proof box at 4ºC until ready for 
developing (3 5 fold exposure time for film autoradiography). 
2.7.10. Signal detection – Emulsion radiography 
  Slides were removed from the fridge and allowed to equilibrate at room temperature.  
Kodak D19 developer was diluted 1:1 with distilled water and Ilford Hypam fixer was 
diluted 1:5 with distilled water.  Under the same safelight conditions, the slides were 
placed into developer for 6min.  The slides were then rinsed in distilled water and placed 
into fixer for 4min.  The slides were then rinsed twice in distilled water and left to air dry. 
Sections were counterstained with cresyl violet by the following protocol: 
 
ddH2O + acetic acid     3min 
Cresyl violet (0.25%)   2min 
ddH2O + acetic acid     10 seconds 
70% ethanol      10 seconds   93 
80% ethanol      10 seconds 
95% ethanol      10 seconds 
100% ethanol 1    30 seconds 
100% ethanol 2    1min 
 
Coverslips were then placed over the sections using DPX Mounting medium.  Slides were 
left to dry at room temperature overnight. 
2.8.  Western Blotting 
2.8.1.  Protein extraction 
  Tissues were extracted as described in section 2.3.  Where tissue was not immediately 
homogenized after extraction, it was thawed on ice and homogenized in 10%w/v buffer 
(20mM Hepes/100mM KCl, pH 7.4, with Complete
TM protease inhibitors).  Samples were 
stored at  20ºC until required. 
2.8.2.  BioRad protein assay 
  Serial dilutions of the tissue homogenates were used to assay protein concentration using 
the BioRad Dc protein assay method.  Quantification was determined against a bovine 
serum albumin (BSA) standard curve (2mg/ml   0.062mg/ml).  All samples were tested in 
triplicates on a 96 well microtitre plate.  Samples were incubated for 15min at room 
temperature before taking absorbance readings at 630nm. 
2.8.3.  SDS Polyacrylamide Gel electrophoresis (SDS PAGE) 
  The BioRad mini Protean II gel system was used for casting and running SDS PAGE 
gels.  The amounts of each reagent used to make the resolving and stacking gels is 
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% Resolving 
gel 








H2O  TEMED 
15     5ml  1.25ml  50 l  100 l  Up  10 l 
12.5     4.2ml  1.25ml  50 l  100 l  To  10 l 
10     3.3ml  1.25ml  50 l  100 l  10  10 l 
7.5     2.5ml  1.25ml  50 l  100 l  Mls  10 l 
Stacking Gel  5ml        50 l        10 l 
Table 2.3. Amounts of reagents used to make SDS PAGE gels. APS = ammonium 
persulphate, TEMED = N, N, N’, N’ tetramethyl ethylenediamine. Stacker solution (15ml 




  TEMED was added to the resolving and stacking gels immediately prior to pouring.  The 
resolving gel (pH 8.8) was poured and carefully overlaid with water until the gel 
polymerized.  The water was removed and the stacking gel (pH 6.8) was poured onto the 
resolving gel.  A 10 well comb was carefully inserted into the stacking gel avoiding 
formation of bubbles, until the gel was set. 
  Gels were placed in a gel tank containing 1X Laemlli buffer (5mM Tris pH8.3, 192mM 
Glycine, 0.1% SDS) and gel combs removed.  5X Sample buffer (10% SDS, 50% 
Glycerin, 25% β mercaptoethanol, 312.5mM TRIS (pH 6.8), 0.005% Bromophenol Blue 
dye) was added to samples to get a 1X concentration.  The samples were boiled at 95˚C for 
4mins and centrifuged for 1min at 14,000rpm.  Samples and 5 l of molecular weight 
markers (BioRad, Precision Plus Protein Standards) were loaded into the wells.  The gels 
were run at 30mA through the stacking gel, and 50mA through the resolving gel.   
2.8.4.  Colloidal coomassie staining 
  To quantify the relative protein load of individual samples in each lane, fluorescence 
intensity derived from Colloidal Coomassie stained gels was used.  After electrophoresis, 
protein gels were fixed for 1hr in 7% glacial acetic acid/40% methanol.  Gels were soaked 
in colloidal stain (4 parts 1X working solution to 1 part methanol (Sigma)) overnight.  Gels 
were placed in destain (45% ddH20, 45%Methanol, 10% Glacial acetic acid) for 60secs 
with shaking before rinsing in 25% methanol.  Gels were further destained in 25% 
methanol for 4 6 hours before scanning at 700nm to visualize and quantify total protein 
content in each lane using an Odyssey Infrared Imaging Scanner and software (Licor).    95 
Intensity values from boxed areas around single lanes were calculated by measuring the 
pixel intensity of the lane and subtracting the background pixel intensity value.  Lanes 
were normalized to one another based on intensity values.  The ratios were then used to 
normalize the calculated intensity for each antibody labelled protein band (Gray et al., 
2009).  Student’s paired t test was used to compare data.  All statistical analyses were 
made using Graph Pad Prism 4.0 (section 2.15). 
2.8.5.  Semi dry/overnight protein transfer 
  After electrophoresis gels were processed by semi dry or overnight wet transfer. Blotting 
paper (Whatmans) and nitrocellulose membrane were immersed in transfer buffer (1X 
Laemmli buffer containing 20% (v/v) methanol).  Gels were layered between sponge, 
blotting paper, and a nitrocellulose membrane.  The nitrocellulose membrane was placed 
facing the positive electrode.  For semi dry transfer, the blotting paper, nitrocellulose, gel 
sandwich was placed in a semi dry blotter, moistened with transfer buffer and run at 90mA 
for 90min.  Overnight transfer involved placing the sandwich in an electrophoresis transfer 
chamber overnight at 4ºC at a voltage of 30V.  Protein transfer was checked by washing 
the nitrocellulose membrane in dH2O, staining for 10min in Ponceau Red (BDH, UK), and 
rinsing in dH2O to visualize the protein bands. 
2.8.6.  Antibody labeling 
  The nitrocellulose membranes were blocked with TBS (Trizma buffered saline (TBS, 
25mM Tris, 0.15M NaCl, pH7.2) + 4% (w/v) milk powder + 0.5% (v/v) Tween 20)) for 
1hr at room temperature and then incubated with primary antibody as indicated (Table 2.4) 
for 90min or overnight with shaking.  Following overnight incubation membranes were 
washed in TBS Tween (TBS + 0.5% (v/v) Tween 20) and incubated in 2.5% milk powder 
with the appropriate Alexa fluorophore coupled secondary antibody (Alexa Fluor 680; 
Alexa Fluor 800, Molecular Probes), or one conjugated with horse radish peroxidase 
(HRP) (1:10,000 dilution), for 45min in the dark.  The membranes were washed in TBS 
Tween.  Fluorescence was visualized and quantified with an Odyssey Infrared Imaging 
Scanner (Licor) at 700nm and 800nm to give intensity values in pixels/mm
2.  The 
enhanced chemiluminescence (ECL) detection method was used according to   96 
manufacturer’s instructions, when detecting a signal with HRP conjugated secondary 
antibody.  BioMax chemiluminescence film was used to develop the signal. 
   
Antibody  Supplier   Dilution  Species 
αA crystallin  



















Huntingtin (full length) 
Stressgen (SPA 221) 
Stressgen (SPA 222) 
Sigma, UK (C2206) 
Stressgen (SPA 816) 
Abcam (ab15896) 
Dr. Ch. Mohan Rao 
Abcam (ab66063) 
Stressgen (SPA 801) 
Dr. W. Boelens 
Dr. W. Boelens 
Stressgen (SPA 796) 
Dr. W. Boelens 
Dr. W. Boelens 
Dr. W. Boelens 
Chemicon (Sy38) 
Upstate signalling 
DAKO (Z 0334) 
Upstate signalling 
Dr. Gill Bates (S830) 












































Table 2.4. List of primary antibodies used for western blotting.   
Dr W. Boelens (Radboud University, The Netherlands); Dr. M. Rao (Centre for cellular 
and molecular biology, India); Prof G. Bates (University of London, UK). 
  
2.9.  Dot Blot analysis  
  Brain homogenate samples were extracted from R6/2 and wild type mice and subjected to 
dot blot analysis.  Samples were treated with 100 l of DNase I (0.5mg/ml) for 1hr at 37ºC, 
triturated and left for 30min at 37ºC. Samples were quenched by adjusting the mixture to 
20mM EDTA, 2% (w/v) SDS and 50mM DTT before boiling for 5min.  200 l (40 g) of 
the samples and a 2 fold dilution were loaded onto BioRad 96 well dot blot apparatus 
containing nitrocellulose acetate membrane (Whatman  200nm pore size).  The 
nitrocellulose membrane was soaked in 2% SDS prior to use.  Samples were extracted 
through the membrane by suction, and each well washed through twice with 0.1% SDS.    97 
The membrane was then subjected to antibody labelling as described in section 2.8.6. Dot 
blots were developed by ECL. 
2.10.  Brain fractionation and synaptosome sub fractionation  
  This method was adapted from (Cohen et al., 1977, Phillips et al., 2001).  Whole brains 
(~0.5g) or hippocampi were homogenised in buffer A (0.32M sucrose, 1mM MgCl2, 
0.1mM CaCl2, 0.1mM PMSF) using a glass Teflon homogeniser (12 strokes), at 4˚C.  The 
homogenate was split into ultracentrifuge tubes and brought to a final sucrose 
concentration of 1.25M, by the addition of 2M sucrose and 0.1M CaCl2.  An aliquot of the 
homogenate was taken to assay protein content and to be used in western blotting.  The 
homogenate was overlaid with 10mls of 1M sucrose, containing 0.1mM CaCl2 and 5mls 
buffer A.  This was centrifuged at 24,000rpm for 3hrs at 4ºC (Beckman L7 ultracentrifuge 
– SW28 Rotor).  A band representing the synaptosome layer was collected at the 
1.25M/1M sucrose interface; the myelin band was collected at the 1M sucrose/0.1M CaCl2 
buffer interface.  The pellet (P1) was also collected and resuspended in buffer A.  The 
synaptosome fraction was diluted in 1:10 ice cold CaCl2, and brought to a final 
concentration of 1% Triton X100 and 20mM Tris (buffered to pH6 or pH8).  The samples 
were incubated on ice for 30 minutes and the insoluble material was pelleted by 
centrifugation at 20,000rpm for 30mins at 4ºC (Beckman L7 ultracentrifuge – Ti 70 Rotor.  
The insoluble pellets were resuspended in 5% SDS.  Proteins in the soluble fractions were 
precipitated in 4 volumes acetone at  20ºC overnight, and recovered by centrifugation at 
11,200rpm for 30min at 4ºC (Beckman – JA 20 Rotor).  Resultant pellets were 
resuspended in 5% SDS.  12 18 g of protein from each fraction were separated by SDS 
PAGE, electroblotted onto nitrocellulose membranes and probed with antibodies. 
2.11.  Immunohistochemistry 
  Coronal sections (10 m) were slide mounted as described in section 2.3.1.  Sections were 
heated for 30min at 60°C before being de waxed in xylene I and II for 10min and re 
hydrated through a series of decreasing ethanol concentrations (100%   70%) at room 
temperature. 
 Slides were washed in PBS for 5min and incubated in 1% hydrogen peroxide/PBS for 
15mins before washing in PBS Tween (0.05%).  Slides were microwaved for 3min in   98 
citrate buffer (pH6), cooled and washed again in PBS Tween (0.05%).  Non specific 
immunolabelling was blocked by incubation with 5% BSA for 1hr in a covered chamber.  
Sections were incubated with primary antibodies overnight in a covered chamber at 4°C 
using appropriate dilutions (Table 2.5), while the negative control sections were covered in 
0.25%BSA/PBS.  Slides were washed in PBS Tween (0.05%) and incubating in 
appropriate biotinylated secondary antibody, diluted 1:200 (Vector Laboratories, UK).  
Sections were incubated in ABC complex (Vector Laboratories) for 45min and washed 
further in PBS Tween (0.05%).  Location of antibody binding was determined by 
immersing the sections in a diaminibenzidine (DAB) solution.  The reaction was halted by 
transferring the slides to PBS.  Sections were routinely developed for 1 3mins for optimal 
immunoreactivity.  After washing further in PBS, sections were counterstained with Harris 
haematoxylin (BDH) for approximately 10 seconds.  Once developed, sections were 
rehydrated through an increasing alcohol series (70%   100%) and placed in xylene (Fisher 
Scientific) before coverslips were applied with DPX (VWR).  Treatment with 1% 
hydrogen peroxide/PBS was omitted in sections used for fluorescent labelling. 
  Alexa fluorophore coupled secondary antibodies (Alexa Fluor 488; Alexa Fluor 546, 
Molecular Probes) were diluted to 1:250 and used in place of biotinylated secondary 
antibodies.  Slides were washed in PBS Tween (0.05%); sections were counterstained with 
DAPI (Vector Shield) and coverslips were placed on top of sections and stored at 4°C prior 
to imaging. 
  Some minor changes to the protocol above were necessary for certain primary antibodies.  
For ubiquitin staining, the antigen retrieval step (citrate buffer treatment) was omitted and 
the sections were incubated in primary antibody for 1 week at 4°C with the addition of 
0.1% sodium azide (personal communication, Dr J Morton).  Lectin staining required the 
use of a manganese buffer (Na Tris 25mM, 0.1mM MgCl2, 0.1mM CaCl2, 0.1 mM MnCl2, 
1% Triton X 100) which was used to incubate both primary and secondary antibodies.                
All control and disease tissue were treated in parallel.  All images were taken using a Leica 
CM5000 microscope with settings as shown in Table 2.6.  LAS AF software was used for 
fluorescence microscopy and Q Win image analysis for brightfield images.   99 
2.12.  Luxol fast blue staining 
  Slide mounted coronal (10 m) sections from R6/2 tg and wt littermates (section 2.3.1) 
were warmed for 30min at 37ºC.  Sections were de waxed in xylene I and II for 5min and 
hydrated up to 95% alcohol (100% I, 100% II and 95%) for 3mins.  Sections were stained 
with Luxol fast blue (0.1% luxol fast blue powder, 95% alcohol, 0.5% acetic acid) for 2 
hours at 60ºC.  Slides were washed in distilled water and differentiated in 0.01% lithium 
carbonate till grey/ white matter was clearly distinguishable.  Slides were further washed in 
distilled water and dehydrated in 95%, 100% II and 100% I alcohol, before clearing in 
xylene.  Coverslips were placed on sections using DPX. 
2.13.  Tissue culture 
  HeLa cells were seeded on coverslips at a cell density of 20,000 cells per/well in a 24 
well plate.  Cells were supplemented with high glucose DMEM containing L Glutamine 
(2mM), 10% fetal bovine serum (FBS) and penicillin/streptomycin (all from Sigma, UK). 
After 24 hours a 50 80% cells confluency was achieved and cells were transfected with 
constructs for EGFP Q25 as a transfection efficiency control, HspB1 (Hsp25), HspB5 (αB 
crystallin), HspB6 (Hsp20) and HspB8 (Hsp22).  0.6 g of DNA (constructs) and 1.2 l of 
lipofectamine (Invitrogen, UK) were diluted in 50 l of OPTI MEM and incubated for 
15min.  DMEM was removed and replaced with pre warmed OPTI MEM (37ºC).  50 l of 
lipofectamine/DNA was added to wells and mixed gently.  Cells were incubated at 37ºC 
with 95% humidity and 10% CO2 for 5 hours. 1ml of DMEM with 20% FBS, L glutamine, 
penicillin and streptomycin was then added per well to obtain a final FBS concentration of 
10%.  24 hours after transfection, media was replaced with fresh supplemented DMEM.   
  Cells were either extracted (section 2.13.1) or processed for immunocytochemistry 
(section 2.13.2).  Tissue culture and cell lyses were conducted by Dr. Andreas Wyttenbach 
and Ben Samson. 
2.13.1. Collection of sHsp transfected cell lysates 
  Transfected cells were trypsinised and spun for 5min at 1,500rpm.  Supernatant was 
removed and the pellet was overlaid with PBS.  Pellets were spun for 1min at 3,000rpm.  
Supernatant was removed and pellets were resuspended in 30 l cell lyses buffer containing 
protease inhibitor (Roche) (1mM Tris HCL (pH 7.5)  , NP 40, 0.2M NaCl, 0.2M EDTA,   100 
0.5M NaF, 1M β glycerol phosphate, 1M benzamidine).  Samples were incubated on ice 
for 30min and the cell lysates stored at  20°C.  Lysates were subjected to western blot 
analysis (section 2.8). 
2.13.2. Immunocytochemistry of cell culture 
  Transfected cells were fixed onto the coverslips with 4% PFA for 15min.  Coverslips 
were washed 3 times for 5min in PBS and placed in fresh PBS before storing in 24 well 
plates at 4ºC.  Coverslips containing cells were incubated in PBS containing 0.2% Triton 
X100/1%BSA for 30mins before washing in PBS and incubating with monoclonal Hsp22 
(a kind gift from Dr Mohan Roa) for 1hour.  Coverslips were washed in PBS, and 
incubated in secondary antibody, diluted 1:500 (mouse Alexa 488) for 1 hour at antibody 
dilution of 1:50.  Coverslips were washed in PBS, counterstained with Hoechst for 5min 
(1:1000) and washed further in PBS before being mounted with flouromount G.  
Coverslips were allowed to dry and stored in the dark at 4ºC.  Images were taken using a 
Leica CM5000 microscope.  LAS AF software was used for fluorescence microscopy. 
 
 
Table 2.5.  Antibodies and conditions for use in immunohistochemistry and 
immunocytochemistry 
Antibody  Supplier  Dilution  Species 
6H4 (PrP
sc)  Prionics  1:4000  Mouse 
GFAP  Dako (Z0334)  1:1000  Rabbit 
GFAP  Sigma (G3893)  1:1000  Mouse 
Tomato Lectin  Sigma (L0651)  1:100  Biotinylated glycoprotein 
Synaptophysin  Chemicon (sy38)  1:1000  Mouse 
HspB1  Stressgen (SPA801)  1:1000  Rabbit 
HspB5  Stressgen (SPA223)  1:400  Rabbit 
HspB5  Stressgen (SPA222)  1:200  Mouse  
MBP  Upstate signalling  1:1000  Mouse 
CNPASE  Abcam (AB6319)  1:400  Mouse 
HspB8  Dr. Ch. Mohan. Roa  1:50  Mouse 
Hsp22  DAKO (Z0458)  1:50  Mouse 
Ubiquitin  Sigma (U5379)  1:1000  Rabbit   101 
2.14.  Microscopy 
2.14.1. Fluorescence 
Tissue sections were imaged with a Leica DCF 300 FX microscope.  Leica Application 
Suite Advanced Fluorescence imaging software was used to process images.  Tissue 
sections were processed simultaneously from age matched NBH and ME7 animals (13 and 
20 weeks) or R6/2 wt and tg (17 weeks) animals.  Microscope settings were kept constant 
within age matched tissue; however it was necessary to adjust microscope settings for 
different objectives and between antibodies (Table 2.6). 
Objective  10X  20X  40X  63X 
13wks (ME7/NBH)  E  G  I  E  G  I  E  G  I  E  G  I 
HspB1  1  2  5  1  2  5  1  1  5  0.5  1  4 
GFAP  1  2  5  2  3  5  1  3  5  1  3  4 
DAPI  1  2  5  1  1  5  0.7  1  5  0.3  1  4 
20wks (ME7/NBH)                         
HspB1  4  1  5  0.7  3  5  1  1.5  5  0.7  1  5 
GFAP  6  1  5  3  3  5  1.5  5  5  2  2  5 
DAPI  4  1  5  1.5  2  5  1  2  5  0.2  1  5 
20wks (ME7/NBH)                         
HspB5  4  2  5  2  2  5  1  2  5          
GFAP  3  2  5  2  4  5  2  4  5          
DAPI  2  1.5  5  1.5  1  5  1  2  5          
20wks (ME7/NBH)                         
HspB8  2  4  5  1  4  5  1  4  5          
GFAP  3  5  5  3  4  5  1  5  5          
DAPI  1  3.1  5  1.6  4  4  1  3.5  4          
17wks (R6/2 tg/wt)                         
HspB5  2.4  4.1  5  1  7  5  1  5  5          
CNP  5  3  3  5  3  4  2  4  5          
DAPI  2  4  4  2  4  4  1  2  5          
17wks (R6/2 tg/wt)                         
MBP  4  5  5  2  2  5  2  4  5          
DAPI  2  2  5  3  5  5  1  2  5          
Table 2.6.  Microscope fluorescence imaging settings.  E = exposure; G = Gain; I = 
intensity. Unless otherwise stated in the results chapters, all settings were as shown in 
Table 2.6.   102 
2.14.2. Visualising DAB staining 
  Tissue sections were imaged with a Leica DCF 300 FX microscope.  Leica QWin V3 
software was used to process images.  Microscope settings were kept constant for all tissue 
analysed (Brightness = 77%; Gain = 1.0; Intensity = 1.5).  It was not necessary to adjust 
these settings for different objectives.  Shading corrections were set to none and where 
necessary white balance was automatically adjusted. 
2.14.3. HspB5 cell count (R6/2 animals) 
Images taken from the CA1, CA3 and DG (20X objective) of R6/2 wt and tg animals that 
had been processed for HspB5 and CNP (2’ 3’ cyclic nucleotide 3’phosphodiesterase) 
double immunofluorescence were used to analyze the number of HspB5 and CNP positive 
oligodendrocyte cell bodies.  Leica Application Suite Advanced Fluorescence software 
was used to identify positive cells.  20X magnification allowed analysis of the entire CA1, 
CA3 and DG field.  Identifiable CNP positive cells (i.e. cell bodies that were 
immunopositive) were highlighted with a circle using software tools; this was 
automatically transferred to the equivalent image showing HspB5 immunofluorescence.  
The number of cell bodies stained for both proteins were manually counted.  All cells that 
were CNP positive were also HspB5 positive therefore the total numbers of CNP/HspB5 
positive cells from each hippocampal region in NBH animals were directly compared to 
the number of positive cells in ME7 animals. Student’s paired t test was used to compare 
data (section 2.15).   
2.14.4. Confocal microscopy 
13 week ME7 brain sections were imaged with a Zeiss LSM 510 Meta microscope and 
confocal images for excitations at 385 470 and 505 were scanned sequentially.  DAPI 
(4',6 diamidino 2 phenylindole) was visualised using excitation at 558 719. Images were 
taken with a 63X objective.  The gain, offset and pin hole were setup for each wavelength 
as shown in Table 2.7. 
 
 
   103 
Wavelength (nm)  385 470  505  558 719 
Gain  854  682  719 
Offset  0.1%  0.1%  0.1% 
Pin hole  M  88  86  80 
Table 2.7. Confocal imaging settings.  GFAP fluorescence was analysed at 385 470nm 
and HspB1 fluorescence was analysed at 505nm. 
 
2.15.  Statistics 
  Western blot and QT PCR data was analysed in Graph Pad prism (version 4.0).  Student’s 
paired t test (two tailed) was used to compare ME7 microdissected hippocampal tissue to 
age matched NBH tissue at all time points analysed, at a significance level of P<0.05.  
Unless otherwise stated, one way analysis of variance (ANOVA) was used to compare 
expression of R6/2 tg tissue from each region to age matched wt littermates from the same 
region and between brain regions at each time point.  This was followed by Newman 







Chapter 3 – Expression of the small 
heat shock protein family in the mouse 
CNS under physiological conditions   105 
3.1.  Introduction 
  The importance of molecular chaperones is evident by the physiological and pathological 
processes in which they participate (see general introduction).  “Physiological” will be 
used to refer to a non pathological state from this point forward.  Some members of the 
sHsp family have been characterized and studied extensively; in particular HspB1 and 
HspB5.  Many of these studies have focused on the role of the sHsps under stress and 
disease conditions (for review see (Sun and MacRae, 2005a, Ackerley et al., 2006) with 
few studies addressing their roles under physiological conditions (Plumier et al., 1997, 
Armstrong et al., 2001a).  The sHsps are believed to have a unique expression profile in 
different tissues and some, like HspB9, are reported to be exclusively expressed in the 
testis (de Wit et al., 2004).  Others, such as HspB1 have been shown to be ubiquitously 
expressed (Sugiyama et al., 2000, Kappe et al., 2001).   
  Little is known about the physiological roles of the sHsps in the CNS.  However they are 
known to be involved in the regulation of cytoskeleton dynamics, redox homeostasis and 
apoptosis, (see general introduction).  Table 3.1 summarises what is known from the 
literature about the expression of the sHsps under physiological conditions prior to this 
study.  The data consists of studies using rat, rabbit, pig and human tissue and reflects 
mRNA expression and/or protein expression.  Currently the tissue expression profile of all 
10 members of the sHsp family has not been systematically and comparatively 
characterized within a distinct tissue (e.g. the brain) from the same organism under 
physiological conditions in a single study.   
 3.2.  Aims 
  The aims of this chapter are 1) to characterize the mRNA expression profile of the sHsps 
by RT PCR in the mouse CNS and in control tissue (were they have been well 
documented); 2) to investigate the anatomical/spatial distribution of the sHsps in the CNS 
by in situ hybridization; 3) to investigate the protein expression of the sHsps in the CNS 
relative to control tissue;   4) to investigate the potential compartmentalization of the sHsps 
using brain and synaptosome fractions.  This will allow a baseline for sHsp expression in 
the mouse brain to be established under physiological conditions.      106 
 3.3.  Experimental design 
  We have used a number of techniques to measure transcript and protein in different 
tissues from adult mice.  The choice of tissue used to characterise expression was 
determined by tissues previously reported to show expression.  Brain and spinal cord tissue 
were used to represent the CNS.  Non CNS tissue such as muscle was used as control 
tissue, as up to 7 of the sHsps are known to be expressed in this tissue (Table 3.1).  Eye 
was used as a control for HspB4 as this sHsp is abundantly expressed in this tissue.  The 
testes were used as a control tissue for HspB9 and HspB10 expression, due to their 
selective expression in this tissue. 
  mRNA expression was investigated by two complementary techniques; RT PCR and in 
situ hybridization  (section 2.4 and 2.7).  Protein expression of the sHsps was investigated 
by western blotting.  In order to expand the characterization of the sHsp family, brain 
fractions and synaptosome sub fractions (section 2.10) were used to investigate potential 
compartmentalization of the sHsps in the CNS. 
 
  Brain  Lens  Heart  Liver  Kidney  Lung  Muscle  Testis 
HspB1  √ (a)  √ (a)  √ (a)  √ (a)  √ (a)  √ (a)  √ (a)  √ (d) 
HspB2      √ (b)        √ (e)   
HspB3      √ (h)        √ (h)   
HspB4    √ (i)             
HspB5  √ (a), (c)  √ (a)  √ (a)  √ (a)  √ (a)  √ (a)  √ (a)   
HspB6  √ (b), (c)  √ (b)  √ (b)  √ (b)  √ (b)  √ (b)  √ (b)   
HspB7      √ (g)  √ (b)      √ (g)   
HspB8  √ (b), (c)    √ (b)  √ (b)  √ (d)  √ (b)  √ (b)  √ (d) 
HspB9                √ (d) 
HspB10                √ (f) 
Table 3.1.  Literature based expression profile of the sHsps in various tissues.  
Combining data from a number of studies shows the different expression profiles of the 
sHsps.  HspB1, HspB5, HspB6 and HspB8 show expression in most of the tissue analyzed.  
The heart and muscle are two tissues in which up to 7 of the sHsps are expressed.  HspB4, 
HspB8 and HspB10 show selective expression in one tissue only.  This table represents 
data from a number of species and techniques, so the expression profile of the sHsps are 
not directly comparable to one another.  (a) (Tallot et al., 2003), (b) (Verschuure et al., 
2003), (c) (Lein et al., 2007), (d) (Kappe et al., 2001), (e) (Golenhofen et al., 2004), (f) 
(Petersen et al., 1999), (g) (Krief et al., 1999), (h) (Sugiyama et al., 2000), (i) (Yang and 
Cvekl, 2005). 
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3.3.1.  10 members of the sHsp family in the mouse genome (sequence alignment) 
  The α crystallin domain defines the sHsps, and is characteristic of this family of 
molecular chaperones.  The 10 members were originally identified using databases 
provided by the public International human Genome Sequencing Consortium (IHGSC) and 
the private Celera human genome project.  The human Hsp27 (HspB1) protein sequence 
was initially used as the query protein sequence to search the databases; this resulted in the 
identification of the 10 sHsps in humans (Kappe et al., 2003). 
  To determine whether the 10 sHsps present in the human genome, were also present in 
the mouse genome and to confirm they all contained the homologous and characteristic α 
crystallin domain the NCBI (National Centre for Biotechnology Information) database 
(www.ncbi.nlm.nih.gov) was used to search for the sHsp. 
  BlastN and BlastP were used to search the NCBI database.  The NCBI nucleotide search 
was used to search for proteins by name.  In order to confirm that each sHsp contained the 
α crystallin domain, the blast program rpsblast was used to search the conserved domain 
database (data not shown).  The sequences obtained were used to perform a protein 
sequence alignment of all 10 members of the sHsp mouse family using ClustaW 
(www.ebi.ac.uk), a multiple sequence alignment program (Figure 3.1). 
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3.3.2.  mRNA expression of the sHsps family 
3.3.2.1.  RT PCR 
  mRNA was extracted from brain, spinal cord, eye, testis and muscle tissue (see section 
2.4).  The quality of the mRNA was monitored by the use of a spectrophotometer, agarose 
gel (data not shown) and Agilent bioanalyser.  The spectrophotometer was used to 
determine the concentration and quality of the mRNA samples.  10 l of each RNA sample 
were run on agarose gels containing ethidium bromide, so that the two bands 
corresponding to 18S and 28S ribosomal subunits could be visualized (data not shown).  In 
addition to this, the Agilent bioanalyser was used to determine mRNA concentration, 
quality and DNA contamination if present with the use of just 1 l of sample (Figure 3.2). 
  The mRNA samples were reverse transcribed with equal amounts of template to produce 
cDNA.  The cDNA was used to amplify target mRNA transcripts by PCR using gene 
specific primers designed  to amplify across introns with the exception of the intronless 
genes HspB3 and HspB9 (Table 2.1).  5 l of PCR product were run on agarose gels 
(Figure 3.3), amplicons were of the predicted size for cDNA amplification (Table 2.1).  
Control reactions lacking reverse transcriptase were set up to exclude genomic 
amplification of the sHsps.  All family members showed mRNA specific amplification in 
control tissue; HspB1, B2, B3, B5, B6, B7 and B8 displayed amplification in muscle 
homogenate, HspB4 expression was restricted to the eyes, and HspB9 and HspB10 showed 
expression in the testis (Figure 3.3).  Five of the sHsps (HspB1, HspB5, HspB6, HspB7 
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Figure 3.2 a. Computer generated gel of mouse tissue RNA.  
Virtual gel image produced by Agilent 2100 bioanalyser, showing 
28S and 18S ribosomal bands.  Intactness of these bands and lack 
of smearing is indicative of good quality mRNA.  1 l of each 
sample was loaded onto a microchip and analyzed by the Agilent 




         marker         18S      28S 




1: EYE            rRNA ratio: 1.3    2: BRAIN                        rRNA ratio: 1.4 









5. MUSCLE                     rRNA ratio: 1.3 
Figure 3.2 b. Electropherograms of RNA samples from mouse tissue. 
Electropherograms produced by the Agilent bioanalyser for each mRNA sample are 
shown.  Peaks correspond to 18S and 28S ribosomal RNA that are also visualized as bands 
in Figure.3.1a.  Ribosomal RNA (rRNA) ratios (28S/18S) for each tissue are shown, these 
ratios provides information regarding quality of the mRNA sample (ratios greater that 1 
represent good quality RNA).  This mRNA was used to make cDNA for subsequent PCR 
reactions. 

































Figure 3.3. mRNA expression profile of the sHsp family in various mouse tissues by 
RT PCR.  All 10 family members of the sHsp family are expressed in control tissues.  For 
HspB1, B2, B3, B5, B6, B7 and B8 this is the muscle; for HspB4 this is the eye; and for 
HspB9 and HspB10 it is the testis.  5 of the sHsps (HspB1, HspB5, HspB6, HspB7 and 
HspB8) show mRNA expression in the CNS.  35 PCR cycles were performed for all the 
sHsps and 25 cycles for Hsc70 and 18S.  All cDNA amplifications were of the expected 
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3.3.2.2.  In situ hybridization 
  The anatomical/spatial expression of the sHsp family in brain and spinal cord tissue was 
investigated by in situ hybridization.  Mice brains were cut in three orientations: coronal, 
sagittal and horizontal.  Spinal cords were cut in both longitudinal and coronal orientations 
(see section 2.7.1).  A high throughput in situ hybridisation study of a vast number of 
genes has been established (Lein et al., 2007).  The data has been compiled into a database 
called the Allen Brain Atlas (http://brain map.org).  This database is useful in that it 
provides a point of comparison for the characterisation of the sHsps by in situ 
hybridisation, which previously was not possible. 
3.3.2.2.a.  Film autoradiography 
  In situ hybridization was performed as described in section 2.7.  Films were developed 
after 2 and 6 week exposure times.  In all cases signals not detected at 2 weeks, did not 
become detectable if left for another 6 weeks.  Figure 3.4   3.8 show in situ hybridization 
images of the sHsps for which a signal was detectable at 2 and 6 weeks.  Images are shown 
after a 2 week exposure as there was no difference at 6 weeks.   
  HspB1, HspB5 and HspB8 showed specific patterns of expression.  HspB1 is expressed 
in the lateral (lv) and dorsal (d3v) ventricles of the brain (Figure 3.4 a).  HspB5 shows a 
pattern suggestive of white matter specific expression (Figure 3.5 a).  White matter 
structures such as the corpus callosum (cc), external capsule (ec) and fimbria (f) are 
labelled.   Other white matter containing structures labelled by the HspB5 probe are listed 
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Structure  Function 
Alveus of the hippocampus (alv)  Thin layer of myelinated fibers that cover 
the lateral ventricles  




Connects cingulate gyrus to the entorhinal 
cortex 
Internal capsule (ic)  White matter that connects the thalamus 
and the cortex 
Lateral/Medial habenular nucleus 
(LHb/MHb) 
Input pathway of stria medullaris thalami 
Fimbria (fi)  Major output pathway of the hippocampus 
(myelinated axons –mostly efferent) 
Stria terminalis (st)  Subcortical fiber system of the amygdala 
Paraventricular thalamic nucleus (PV)  Sends projections to the nucleus 
accumbens 
Submedius thalamic nucleus (Sub)  Receives spinal and medullary input 
Forceps minor of the corpus callosum 
(fmi) 
Links both hemispheres 
Forceps major of the corpus callosum 
(fmj) 
Links both hemispheres 
 
Table 3.2. White matter containing brain structures labelled by HspB5 probe.  
This table lists some of the white matter structures that are shown to express HspB5 by In situ 
hybridization.  A brief description of the function of these structures is given.   
 
 
  The expression pattern of HspB8 (Figure 3.7) overlaps with that seen for HspB1.  The 
signal detected in the cerebellum and hippocampi are non specific as they are also seen 
with the sense probe (Figure 3.7 c), but expression in the lateral and dorsal ventricles is 
specific to the antisense probe.  HspB1, B5 and B8 also show expression in the spinal 
cord by in situ hybridization (Figure 3.4 d, 3.5 d and 3.7 d).  Coronal section reveal 
distinct puncta for HspB1 and HspB8 (Figure 3.4 d and 3.7 d) in the ventral horn of the 
spinal cord.  HspB5 shows diffuse expression throughout the coronal and transverse 
spinal cord sections (Figure 3.5 d).  The strength of the signal masks the specificity of 
the expression at this level of analysis, but emulsion radiography was able to resolve 
this (see below and Figure 3.8) 
  Neither HspB6 (data not shown) nor HspB7 produced a signal with the antisense 
probe, but a specific signal with a pattern similar to that seen in Nissl stained sections 
was observed with the HspB7 sense probe (Figure 3.6).  A second set of 
oligonucleotides for both these sHsps were used for in situ hybridization (Table 2.2  
italics), but again a similar pattern was seen for both HspB6 and HspB7 (data not   118 
shown).  The remaining 5 sHsps did not produce a signal by in situ hybridization (data 
not shown).   
3.3.2.2.b.  Emulsion autoradiography 
  Emulsion autoradioagraphy allows visualization of the cellular basis of the in situ 
hybridization signals.  The slides require an exposure of 3 5 times of that needed to see 
a strong signal by film autoradiography.  Radiolabelled sections for HspB1, B5 and B8 
were coated with emulsion and left for 12 weeks at 4ºC, in the dark.  Sections were 
developed and counterstained with cresyl violet to visualize cell bodies (section 2.7.9 
and 2.7.10). 
  Expression of HspB1 and HspB8 in spinal cord sections was confirmed to be specific 
to the large motor neurons in the ventral horn (Figure 3.8).  The distinct white matter 
specific expression of HspB5 in brain sections as seen by in situ hybridization (Figure 
3.5) was confirmed to be specific to oligodendrocytes.  The diffuse staining in the 
spinal cord sections revealed a specific and selective expression in cells typical of 
oligodendrocytes (Figure 3.8 c, d).  Oligodendrocytes characteristically form tandem 
array structures in white matter regions and labelling of HspB5 can be seen to follow 





















































Figure 3.8. Cellular mRNA expression of the sHsps by emulsion in situ hybridization.  
Spinal cords were cut in transverse and coronal orientations and mouse brain sections were cut 
coronally.  Emulsion audioradiography was used to visualise the expression of the sHsps at a 
cellular level.  (a) HspB1 labelling of coronal spinal cord section shows expression in the large 
motor neurons in the ventral horn, (b) HspB1 labelling of transverse spinal cord sections, also 
showing labelling of large motor neurons.  (c) HspB5 labelling of coronal spinal cord section 
shows labelling over populations of cells characteristic of oligodendrocytes (see inset), (d) 
horizontal brain sections also show labelling of oligodendrocytes in the white matter tracts.  (e) 
HspB8 labelling of coronal spinal cord section shows expression in the large motor neurons in 
the ventral horn, (f) HspB8 labelling of transverse spinal cord sections, also showing labelling 
of large motor neurons.  Magnifications: a, x20; b, x10; c, x10; d, x10; e, x20; f, x40).  Sections 
were counterstained with cresyl violet. 
 
a. HspB1     b. HspB1   
c.HspB5   
e.HspB8   
d.HspB5   
f.HspB8   
Oligodendrocytes 
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3.3.3.  Protein expression of the sHsp family 
3.3.3.1.  Characterization of sHsp expression in various mouse tissue 
  Total tissue homogenates from heart, testis, eye, muscle and brain were extracted and 
homogenised in Hepes/KCl buffer (section 2.8.1).  Samples were used to analyse the 
protein expression of the sHsp family by western blotting (section 2.8).  Expression of 
HspB3 and HspB10 could not be determined due to lack of antibodies.  As these two 
sHsps did not show mRNA expression in the CNS by RT PCR and in situ 
hybridization, antibody production was not pursued.  Three antibodies for HspB8 were 
tested on homogenate samples (data not shown).  The non commercial antibody 
provided by Dr. Boelens (Radboud University, The Netherlands) showed the strongest 
immunoreactivity and was therefore the preferred antibody.  The other two antibodies 
(ab66063 and HspB8 gifted by Dr. Mohan Rao (Centre for cellular and molecular 
biology, India)) showed very faint or no immunoreactivity using 50 g of homogenate 
(data not shown).   
  Many of the polyclonal non commercial antibodies produced background 
immunoreactivity, mainly high molecular weight bands, but specific bands of the 
correct size where clearly distinguishable.  Due to the sequence similarity and 
conserved α crystallin domain of the sHsps, the potential for cross reactivity was 
addressed.  Firstly there were clear differences in the size of some of the sHsps (Figure 
3.9).  Where there was not a size difference, for example HspB2 and HspB5 both 
showed immunoreactivity at ~20kDa, specificity was determined by expression in 
control tissue versus non control.  So, HspB2 only showed immunoreactivity in the 
heart and muscle, whereas HspB5 showed ubiquitous expression.  Where more than 
one band was present close to the predicted molecular weight of the target protein, as 
was the case for HspB6, specificity was determined by pre absorption of the antibody 
(Figure 3.9 B).   
  Secondly, the antigen used to produce the antibodies was considered.  The antigen 
sequences were subjected to BlastP analysis to determine any homology or sequence 
similarity to other mouse protein.  Proteins showing highest homology with the antigen 
apart from that specific sHsp are shown in Table 3.3.  Although antigens used to raise 
commercial antibodies show some sequence homology with other sHsps, these 
antibodies do not cross react with other sHsps as stated on the data sheet 








HspB1 HspB5 HspB6 HspB8 Ladder Ladder Ladder Ladder
specificity (Figure 3.9 and Figure 3.10).  Moreover, the specificity of the non 
commercial antibodies had previously been described (Verschuure et al., 2003, de Wit 

















Figure 3.9. Specificity of antibodies against sHsps expressed in the mouse CNS.  50 g of brain 
homogenate were loaded onto polyacrylamide gels and transferred to nitrocellulose membrane.  
Antibodies against the sHsps were tested and the 4 sHsps that showed immunoreactivity in the CNS are 
shown.  All show bands of differing sizes.  HspB1 (SPA 801) antibody recognises a band at ~25kDa, 
HspB5 (SPA 222) antibody recognises a band at ~20kDa, HspB6 (non commercial) antibody recognises 
3 isoforms of the protein, bands are at ~21, 18 and 16kDa and the HspB8 (non commercial) antibody 












44% H to HspB4  25  25 
HspB2 
(Boelens) 
Rat full length 
recombinant protein 




peptide (164 173) 
52% H to HspB5  20  20 
HspB5  
(SPA 222) 
Purified HspB5 from 
bovine lens 
49% H to HspB4  20  20 
HspB6 
(Boelens) 
Rat Full length 
recombinant protein 




peptide (156 170) 




peptide (179 193) 




peptide (137 151) 
58% H to guanylate  
cyclase 
~16  18 
Table 3.3.  Sequence homology of antigens recognised by antibodies against the sHsps.  This table 
shows the antigens used to produce antibodies against the sHsps.  BlastP was used to determine if the 
antigen sequences had any sequence similarity with other proteins in the mouse genome.  The protein 
with the highest homology is listed.  (SWI/SNF, related, matrix associated, actin dependent regulator of 
chromatin, subfamily e, member 1).       122 
  Antibodies against four of the sHsps (HspB1, B5, B6 and B8) showed 
immunoreactivity in control tissue and showed ubiquitous expression in other mouse 
tissues including the brain (Figure 3.9).  HspB2 and HspB7 showed expression in heart 
and muscle tissue and HspB4 expression was restricted to the eye.  The HspB6 
antibody detected 3 distinct bands (Figure 3.10 a).  To confirm specificity a 
competition experiment was set up where the HspB6 antibody was pre absorbed with 
the antigen (recombinant Hsp20, provided by Dr. Boelens (Radboud University, The 
Netherlands)).  All bands seen in the brain, heart, testis and muscle disappeared 
supporting the specificity of the antibody for the target protein.  The large band/s seen 
in the eye in the original blot also decreased to some extent but two bands still 
remained visible (Figure 3.10 b).  This is probably due to cross reactivity of the 
antibody with the αA /αB crystallins which constitute about one third of the total 
protein in the lens and present 50% homology to HspB6.   
 










     
                                                             
 
Figure 3.10. Protein expression of the sHsp family in various mouse tissues and 
brain.  (A) All of the sHsps show immunoreactivity in control tissues. A total of 50 g 
of total protein was loaded for each tissue.  However the protein concentration was 
increased to 100 g to detect immunoreactivity in control tissue for HspB2, HspB7 and 
HspB9.  HspB1, HspB5, HspB6, HspB8 show expression in the brain (n=3).  (B) The 
HspB6 antibody was pre absorbed with antigen confirming the specificity of the signal.  
All three bands seen in the brain tissue (asterisks) disappeared.  Immunoreactivity 
decreased in the eye tissue, leaving two fainter bands, suggesting cross reactivity of the 
antibody with the crystallin proteins in the eye.  Molecular weights (HspB1 = 25kDa, 
HspB2 = 20kDa, HspB4 = 20kDa, HspB5 = 20kDa, HspB6 = 18 (middle band), HspB7 
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3.3.3.2.  Protein expression of the sHsps in brain and synaptosomal fractions 
  To extend the protein analysis of the sHsps and to address the cellular and sub cellular 
expression and possible enrichment in specific compartments we analysed expression 
of the sHsps in brain and synaptosome sub fractions (section 2.10).   
  Fractions consisted of total brain homogenate, cell body/nuclear (P1), myelin and 
synaptosomes.  The synaptosome fraction was treated with Triton X100 at pH6 and 
pH8.  The soluble fraction at pH6 consists of plasma membrane proteins and the 
insoluble fraction contains paired pre  and post synaptic structures.  At pH8 the 
presynaptic specialization disintegrates leaving the postsynaptic density (PSD) as the 
insoluble fraction and the presynaptic components in the soluble fraction (Phillips et 
al., 2001).   
  The fractions were tested with the use of four control antibodies with known distinct 
patterns of compartmentalization (Figure 3.11 a).  Beta catenin was found in all 
fractions with a slight enrichment in the P1 (cell body) fraction, synaptosome, and pH6 
insoluble compartment.  Beta catenin is part of the synaptic adhesion junction where it 
actively regulates cadherin function.  The vesicular protein synaptophysin is enriched 
in the synaptosome fraction and is completely solubilised at pH6 and pH8 (Figure 3.10 
a).  PSD 95 is a post synaptic protein and as expected is enriched in the insoluble 
fractions particularly at pH8.  Myelin basic protein (MBP) was found to be highly 
enriched in the myelin light membrane fraction, and de enriched in the non myelin 
fractions apart from the insoluble pH8 synaptosome fraction (Figure 3.12 a).   This is 
indicative of some myelin contamination of the synaptosome insoluble fractions. 
  HspB2, HspB7 and HspB9 did not show immunoreactivity in homogenate fractions, 
or appear enriched in other brain fraction (data not shown).   The four sHsps for which 
robust protein expression was found in the brain (Figure 3.10) showed differential 
distributions and solubilities in the brain and synaptosome sub fractions.  HspB1 and 
HspB8 were both present in the synaptosomal fraction, but with differential detergent 
extractability (Figure 3.11 b).  HspB1 was present mainly in the soluble fractions at 
both pH6 and pH8, whereas HspB8 displayed most reactivity in the insoluble fraction 
at pH6, but solubility increased at pH8.  HspB5 and HspB6 were both enriched in the 
myelin fraction (10 fold and 5 fold respectively as measured in two independent 
experiments).  This was derived by measuring fluorescence intensities and normalizing 
to protein loading.  Enrichment of HspB5 in the white matter was consistent with the   124 
white matter specific expression profile seen by in situ hybridization (Figure 3.5) and 
confirmed both presence of the transcript and proteins in this compartment.  HspB5 and 
HspB6 are also found in the synaptosomal fraction, but their biochemical properties are 
quite distinct upon treatment with detergent.  HspB6 was completely insoluble at pH6 






























Figure 3.11. sHsp expression in brain fractions and synaptosomal subfractions. 
(A) Fractions extracted from whole brain homogenate were tested with β catenin, 
synaptophysin, PSD 95 and MBP antibodies. Beta catenin showed expression in all fractions, 
with enrichment in the P1 and synaptosome insoluble fractions; synaptophysin showed 
enrichment in the synaptosomes and localization to the soluble fractions (pre synaptic 
compartment); PSD 95 showed enrichment in the insoluble fractions of the synaptosome, 
particularly at pH8 which consists of the PSD specialization. MBP shows enrichment in the 
myelin fraction, de enrichment in the synaptosome fraction, but enrichment in the pH8 
insoluble fraction (this is indicative of a minor myelin contamination). (B) HspB1 and HspB8 
are found in all fractions with HspB1 being moderately enriched in the cell body/nucleus (P1) 
compartment and present mainly in the soluble synaptosomal fractions. HspB5 and B6 show 
enrichment in the myelin fraction to varying degrees. HspB6 is also enriched in the PSD 
synaptosome fraction.  18 g of protein were loaded for each fraction, n=2 (also see Appendix 
2).   125 
3.4.  Discussion 
  The aim of this chapter was to systematically characterize the expression profile of all 
10 members of the sHsp family in naïve mouse tissue in order to establish a baseline 
for sHsp expression in the CNS under physiological conditions.   
3.4.1.  Summary of sHsp expression in the mouse CNS 
  The mRNA and protein data obtained for sHsp expression in the mouse CNS is 
summarized in Table 3.4.  All of the sHsps were expressed in reference/control tissue; 
additionally 4 were expressed in the brain.  RT PCR highlighted expression of 5 of the 
sHsp in the brain; however, in situ hybridization was only able to confirm mRNA 
expression of 3 sHsps.  In situ hybridization allowed the identification of cell types 
expressing the mRNA, with HspB1 and HspB8 expressed in motor neurons and HspB5 
in oligodendrocytes.  This data highlights the constitutive expression of four sHsps, 
HspB1, HspB5, HspB6 and HspB8 in the naïve mouse CNS.   
  The sHsps were given a new classification scheme by Taylor and Benjamin, (2005).  
They proposed a simple scheme to reflect their specialized roles (apoptosis, protein 
trafficking, redox control and cytoskeletal interactions).  In this classification HspB1, 
HspB5, HspB6 and HspB8 were grouped as Class I proteins, that are ubiquitously 
expressed, have similar properties and form multimeric complexes with one another 
(Taylor and Benjamin, 2005).  Identification of this subset of sHsps that show specific 
and selective expression in the CNS is consistent with this classification and may 
reflect a common/overlapping function in different cells.  These sHsps share between 
28 and 45 percent sequence homology (Taylor and Benjamin, 2005) and are able to 























Expressed in brain? 
      Protein  RT 
PCR 
In situ  Cell type  Cell type (literature) 




HspB2  Muscle  Yes  No  No  No       
HspB3  Muscle  Yes     No  No       
HspB4  Eye  Yes  No  No  No       
HspB5  Muscle/
Eye 




HspB6  Muscle  Yes  Yes  Yes  No       
HspB7  Muscle  Yes  No  Yes  No       
HspB8  Muscle  Yes  Yes  Yes  Yes  Motor neurons/ 
endothelial 
Motor neurons (e) 
HspB9  Testis  Yes  No  No  No       
HspB10  Testis  Yes     No  No       
Table 3.4. Summary of sHsp expression data in the mouse CNS.  This table summarises 
expression of the sHsp in the CNS, as shown by the three techniques employed in this study.  
mRNA expression data has confirmed tissue specific expression of the sHsps in the various tissues 
of the mouse by RT PCR, highlighting 5 of the sHsps to be expressed in the brain.  Expression of 
only 3 of these sHsp was confirmed by in situ hybridization.  HspB6 and HspB7 did not show 
expression using 2 distinct oligonucleotides.  HspB1 and HspB8 showed expression in motor 
neurons and HspB5 was expressed in oligodendrocytes.  4 of the sHsps were detected in the CNS 
using antibody staining by western blotting.  Although HspB7 showed immunoreactivity in control 
tissue, protein expression was not confirmed in the brain.  It may be likely that this protein is below 
the limit of detection or that better reagents are required.  Combining this information has 
highlighted HspB1, HspB5, HspB6 and HspB8 as members of the sHsp family that are 
constitutively expressed at detectable levels, in the CNS under physiological conditions.  
(a)(Armstrong et al., 2001a), (b) (Plumier et al., 1997), (c) (Klemenz et al., 1993), (d) (Iwaki et al., 
1992), (e) (Irobi et al., 2004).  
  
3.4.2.  mRNA expression 
  RT PCR data identified expression of five of the sHsps (HspB1, B5, B6, B7 and B8) in 
the brain (Figure 3.3).  HspB7 expression was thought to be confined to heart and muscle 
tissue, but RT PCR revealed expression in the brain and all other tissues tested.  The 
mRNA expression of HspB1, HspB5 and HspB8 was confirmed by in situ hybridization, 
but expression of HspB6 and HspB7 could not be detected in the brain and spinal cord 
sections despite using two sets of oligonucleotide probes.  In the case of HspB6 the Allen 
Atlas also fails to detect a signal hence a lack of sensitivity may explain this finding 
(Figure 3.12 C).  However we detect protein expression of this sHsp by western blotting in   127 
the brain.  Although in situ hybridization of HspB7 did not show expression using two 
different antisense probes, a signal was seen using the sense probes (Figure 3.6 c).  The 
signal detected was very similar to that seen on Nissl stained sections.  This suggests that 
the signal may reflect the biochemical properties of the probe, allowing it to hybridize to 
mRNA rich regions (Nissl bodies) contained within cell bodies.  The lack of specific signal 
using antisense probe and the specific signal seen by the sense probe additionally suggests 
the possibility that the sense oligonucleotide probe is reacting with genomic DNA.   The 
Allen brain Atlas shows an abundant expression of the HspB7 transcript in the adult mouse 
brain (Figure 3.12 D) (Lein et al., 2007).  This signal is also very similar to that seen with 
the sense probe.  However the Allen Atlas used gene specific ribo nucleotide probes 
labelled with non isotopic digoxigenin (DIG) (Lein et al., 2007), thus the inconsistencies 
could arise from the differences in probes used.  Protein expression of HspB7 in the brain 
was undetectable with the available antibody, and a good signal in control tissues (heart 
and muscle) required loading of 100 g of total protein in a lane (Figure 3.10).  Thus the 
expression and specificity of HspB7 remains to be defined.  HspB7 does not appear to 
share the same phylogenetic class as the other 4 sHsps expressed in the CNS (Figure 3.13) 
(Taylor and Benjamin, 2005).  The divergence suggests HspB7 does not fall into the same 
functional group as HspB1, B5, B6 and B8, and may reflect the lack of protein expression 
in the CNS. 
  In situ hybridization has shown HspB1 and HspB8 expression to be localized to the 
lateral and dorsal ventricles of the brain.  These ventricles are lined with ependymal cells 
that make the cerebrospinal fluid (csf) (Brown et al., 2004) and these could be the cells that 
show high levels of HspB1 and HspB8.  Expression was also observed in discrete 
populations of cells in the spinal cord as is evident by the distinct puncta seen in the ventral 
horn (Figure 3.4 d and Figure 3.7 d).  Emulsion radiography can be used to reveal the 
cellular localization of the signal seen and showed HspB1 and HspB8 expression to 
localise to the large motor neurons in the spinal cord, as previously described (Armstrong 
et al., 2001a).  Expression of HspB1 has previously been studied in rat, mouse and human 
brain and spinal cord tissue, showing association with blood vessels (Armstrong et al., 
2001a, Wilhelmus et al., 2006c), cells of the choroid plexus (Plumier et al., 1997) and 
motor neurons in the spinal cord (Armstrong et al., 2001a, Irobi et al., 2004).  The   128 
anatomical expression seen by in situ hybridization is therefore in keeping with previous 
studies.  HspB1 mRNA expression in the brain as documented in the Allen Brain Atlas 
shows a very weak signal in regions localized to the lateral and dorsal ventricles (Figure 
3.12 A) (Lein et al., 2007).  HspB8 also shows expression in the ventricles (Figure 3.7 a) 
that is very similar to the staining observed for HspB1 (Figure 3.4 a).  Staining of the 
ventricles was not seen with the HspB8 sense probe suggesting specificity of this signal.  
Indeed similar staining of the lateral and dorsal ventricles was also documented in the 
Allen Brain Atlas (Figure 3.12 E).  Expression of these two sHsps in the ventricles and 
choroid plexus in the normal mouse brain may reflect the very high metabolic activity of 
these tissues.  The choroid plexus contains a high number of mitochondria to support its 
function potentially leading to higher levels of oxidative stress (Cornford et al., 1997).  It is 
known that HspB1 can protect against oxidative stress (Wyttenbach et al., 2002), indeed 
HspB8 may serve a similar function, and hence this tissue may be able to use the sHsps to 
counteract possible oxidative stress due to leakage of free radicals from the mitochondria 
(Preville et al., 1999, Wyttenbach et al., 2002).  The similarity in expression of HspB1 and 
HspB8 is also suggested by their potential structural similarity as shown in Figure 3.13.  
Both HspB1 and HspB8 originate from the same main branch point.  
  HspB5 is known to be expressed in the CNS, particularly in glial cells (Iwaki et al., 1992, 
Klemenz et al., 1993).  Analysis by RT PCR and in situ hybridization shows HspB5 
expression in the brain and spinal cord (Figure 3.5 and 3.8).  A clear and distinct white 
matter expression pattern is seen by in situ hybridization and emulsion radiography (Figure 
3.8), which is also confirmed in the Allen Brain Atlas (Figure 3.12 B) (Lein et al., 2007).  
The expression profile is consistent with localization to oligodendrocytes.  
The mRNA expression pattern of HspB5 in the brain and the spinal cord is distinct from 
that of HspB1 and HspB8, implying cell specific transcriptional regulation of these sHsps.  
The selective expression of HspB5 in the white matter may reflect the intrinsic 
vulnerabilities of oligodendrocytes (Husain and Juurlink, 1995), thus supporting the need 
of a molecular chaperone that can regulate/modulate many cellular processes such as redox 
homeostasis, apoptosis and cytoskeleton regulation (Kappe et al., 2003, Verschuure et al., 
2003, van Noort, 2008).  The expression and potential contribution to the white matter 






























Figure 3.12. In situ hybridization images of the sHsps as determined by the Allen Brain Atlas.  Nissl 
stained images are shown in the left panel and corresponding in situ hybridization images are shown in the 
right panel.  Levels of gene expression are depicted by colour, ranging from blue (low expression) to red 
(high expression). (A) HspB1, (B) HspB5, (C) HspB6, (D) HspB7, (E) HspB8 (Images taken from Lein et 
al., 2007; http://mouse.brain map.org).   130 
 
















Figure 3.13. sHsp phylogenetic tree (Cladogram).  Representative Cladogram of 
translated sHsps proteins.  Cladogram was created using TreeView and diagrams the 
evolutionary divergence of the sHsps within and between species.  sHsps expressed in the 
CNS are highlighted by ovals.  HspB1 and HspB8 (green) appear to be more closely 
related to one another compared to HspB5, B6 and B7.  HspB5 and HspB6 also extend 
from a common branch point (blue); HspB7 extends from the main root node suggesting 
greater divergence in sequence compared to other sHsps.  m (mouse), r (rat), and h 
(human) (Adapted from Taylor and Benjamin, 2005).   131 
3.4.3.  Protein expression 
  Western blot analysis of the sHsps has highlighted protein expression of HspB1, HspB5, 
HspB6 and HspB8 in the brain (Figure 3.10).  These four sHsps are constitutively 
expressed but to varying degrees in the tissues analyzed.  HspB6 is known to be present as 
four phospho isoforms in bovine heart, consisting of 3 phosphorylated species and one un 
phosphorylated (Beall et al., 1999).  The three distinct bands seen in Figure 3.11 are likely 
three of these phospho isoforms.  The human protein atlas (http://www.proteinatlas.org/) 
provides limited information on the protein expression of HspB1, B5 and B6 by 
immunohistochemistry.   HspB1 was shown to have moderate expression in neuronal cells 
of the cerebral cortex, cerebellum and lateral ventricle, while HspB5 showed moderate to 
strong staining in non neuronal cells in these regions.  To some extent this is consistent 
with the in situ hybridization data, where HspB1 expression is seen in the lateral ventricles 
and HspB5 shows non neuronal expression (oligodendrocytes).  The human protein atlas 
detects weak expression of HspB6 in the cerebral cortex and moderate expression in the 
lateral ventricles. 
3.4.3.1.  Protein expression in brain and synaptosome subfractions 
  Protein expression and potential compartmentalisation of the sHsps in brain and 
synaptosome fractions was also investigated.  HspB1 showed presence in all the fractions 
which is consistent with its ubiquitous expression and broad role in various cellular 
processes such as regulation of the cytoskeleton and redox homeostasis (Figure 3.12 b).  Its 
presence in the synaptosomal fractions and its differential distribution across detergent 
(Triton X 100) soluble and insoluble fractions follows the trends shown by a number of 
synaptic proteins including those associated with the cytomatrix (Figure 3.11) (Phillips et 
al., 2001).  It is well established that HspB1 is able to regulate cytoskeletal homeostasis 
(Richter Landsberg and Goldbaum, 2003), suggesting this role could be extended to the 
synaptic compartment.  Indeed, other molecular chaperones are known to play significant 
roles in this compartment such as Hsc70, cystein string protein and small glutamine rich 
tetratricopeptide repeat containing proteins (Tobaben et al., 2001).   
   HspB8 also showed immunoreactivity in all fractions but with a different distribution 
across detergent treated fractions.  HspB8 was preferentially present in the pH6 insoluble   132 
fraction suggesting localization to the paired pre  and post synaptic structure.  The lack of 
enrichment in pH8 soluble and insoluble fractions suggests that this protein is not 
preferentially associated with either the pre  or post synaptic structures and may 
potentially be associated with synaptic scaffolding proteins.   
  HspB5 and HspB6 show a similar expression pattern in brain fractions, however with 
differential Triton X 100 solubility in the synaptosomal fractions.  This may support a role 
for these sHsps in a sub cellular organization that is involved in synaptic regulation.  The 
presence of MBP in synaptosomal fractions suggests expression of these otherwise white 
matter enriched sHsps may occur as a result of myelin contamination in these fractions, 
therefore suggesting alternative functions in non neuronal cells.  Accordingly, the apparent 
PSD association of HspB6 may arise through genuine synaptic compartmentalization or be 
indicative of biochemical specializations within the myelin membrane.  For HspB5, 
enrichment in the white matter is expected as it is expressed specifically in 
oligodendrocytes (also see Chapter 4).  But evidence would support that HspB6 is 
similarly highly expressed in the white matter.  Indeed phylogenetic data (Figure 3.12) also 
suggest structural similarity of these two sHsps and lends weight to similar expression 
profiles.  One concern would be cross reactivity of the HspB6 antibody with the conserved 
alpha crystallin domain of HspB5, but size and preabsorption suggest bono fide distinct 
reactivity in the brain (Figure.3.10).  The data indicates that both HspB5 and HspB6 can be 
organized around the biochemical assemblies defined by differential Triton X 100 
extraction (Phillips et al., 2001). 
  The overlapping but distinct compartmentalization of these four sHsps reflects their 
known cooperativity and interactions (Sun et al., 2004, Fontaine et al., 2005) and illustrates 
the potential for distinct functional outcomes in different cellular compartments.  
3.5.  Summary 
  This chapter has described the expression profile of the sHsp family in the naïve mouse 
CNS by a number of techniques providing a baseline for sHsp expression and distribution.  
The results suggest the presence of different cellular pools of sHsps distributed in a cellular 
and sub cellular specific fashion.  Some of this work has been published (Quraishe et al., 
2008) and has complemented other published work and public databases.  This   133 
characterisation of the sHsps can now be extended to investigate changes under disease 
conditions during which a region and cell specific pathology occurs in the brain.  The 
schematic shown in Figure 3.14 summarizes what is presently known about the sHsps in 
the CNS under “physiological” conditions.  The major sites of expression with known 




















Figure 3.14. Schematic illustrating the major sites and functions of the 4 sHsps 
constitutively expressed in the CNS.  HspB5 and HspB6 are expressed in the white 
matter as depicted by the myelin sheath.  HspB5 is enriched (5 fold) in this compartment).  
HspB1 and HspB8 are localized to neuronal cells.  The sHsps are involved in modulating 
many cellular processes as shown.  These include: regulation of protein folding and 
degradation by their chaperone capacity and interaction with other proteins such as Bag 3, 
a stimulator of autophagy; modulation of the inflammatory pathway, by interacting with 
receptors on antigen presenting cells; preventing oxidative stress by sequestering ions such 
as Cu2+ or Zn2+ as well as maintaining antioxidants in a reduced state; and modulation of 
the cytoskeleton.                 indicate potential stimulation of pathways, and                  
indicate potential block of pathways.   134 
 









Chapter 4:  White matter expression of 
HspB5   135 
4.1.   Introduction 
  As shown in the previous chapter, four out of the 10 sHsps were found to be 
unequivocally expressed in the mouse CNS under physiological conditions by a number of 
techniques.  Expression of a fifth Hsp (HspB7) remained unclear.  Of these, HspB5 was 
shown to have a selective expression in non neuronal cells, displaying the characteristic 
profile associated with the oligodendroglial cell populations which typically align in 
tandem arrays in tissue.  The expression pattern for HspB5 is also consistent with the 
literature, where HspB5 has been shown to be expressed in oligodendrocytes and Schwann 
cells under physiological conditions (Iwaki et al., 1992, Klemenz et al., 1993).  HspB5 
expression is highly induced in Schwann cells during peripheral nerve development and 
myelination.  Sciatic nerve axotomy was shown to downregulate HspB5 levels suggesting 
that HspB5 expression depends on axonal signals (D'Antonio et al., 2006). 
   Oligodendrocytes perform an essential function by providing insulation to axons which 
contributes to rapid conduction of nerve impulses.  The counterparts of oligodendrocytes in 
the peripheral nervous system (PNS) are Schwann cells.  Both oligodendrocytes and 
Schwann cells encapsulate nerve fibres with a specialised plasma membrane structure, the 
myelin sheath.  Schwann cells encapsulate a single axon, however, oligodendrocytes are 
able to send out many projections (up to 40) each of which is able to wrap extensively 
around a single axon (Fanarraga et al., 1998).  The CNS myelin may lie a significant 
distance from the cell body, being connected to it by a slender cellular process (Figure 4.1 
A) (Ludwin and Bakker, 1988).   The myelin sheath is tightly packed by extrusion of the 
cytoplasm that provides insulation to the ensheathed axon and minimises loss of electrical 
signal caused by transverse diffusion (Waxman and Ritchie, 1993).   
  The myelin membrane is divided into sub domains (compact and non compact myelin) 
with distinct protein and lipid compositions (Simons et al., 2000).  Compact myelin 
contains virtually no cytoplasm whereas the non compact regions (abaxonal, periaxonal 
and adaxonal) contain cytoplasm (Figure 4.1 B) (Scherer and Arroyo, 2002).  At the lateral 
ends of the myelin sheath, where opposing internodes form the nodes of Ranvier, the 
membrane splits to form cytoplasmic paranodal loops that attach to the axons.  The 
innermost membrane in contact with the axon also contains cytoplasmic channels such as   136 
the potassium channels that may be involved in signal transduction between axon and 
oligodendrocyte (Scherer and Arroyo, 2002) (Figure 4.1 C).  The molecular organization 
of the paranode contains heterodimers of the adhesion proteins contactin and Caspr 
(contactin associated protein) that are localized to the paranodal axolemma in myelinated 
fibers of the PNS and CNS (Einheber et al., 1997, Rios et al., 2000). 
 





























Figure 4.1. Myelinating schwann cells and oligodendrocytes.  The myelin sheath is 
segregated in different sub domains with unequal protein and lipid distribution. (A) 
Oligodendrocytes cell bodies and processes are labelled yellow, extending to myelinating 
axons labelled green.  A single oligodendrocyte can send out many projections to 
myelinate many axons.  (B) The circumferential organization of a myelinated axon is 
shown.  (C) A complex set of adhesion molecules, cytoskeleton elements and membrane 
receptors are important for nodal integrity and correct localization of ion channels 




4.1.1.  Molecular composition of myelin 
   The myelin membrane consists of distinct sub sets of proteins associated with either 
compact or non compact compartments.  In compact myelin, the myelin membrane forms 
axon 
C  A 
B   137 
tightly packed structures implying that the specific set of proteins in this compartment have 
intimate interaction with the myelin membrane.  In non compact myelin the intracellular 
space hold significant amounts of cytoplasm and cytoskeleton assemblies.  In addition to 
specific proteins associated with this compartment, ubiquitous cytoplasmic proteins are 
present in high concentration (Kursula, 2008).     
Table 4.1 shows the localization and function of major myelin proteins in the compact and 



















Table 4.1. Localisation and function of major myelin proteins in compact and non 
compact myelin. (a) (Griffiths et al., 1998), (b) (Fitzner et al., 2006), (c) (Yamamoto et 
al., 1994, Yamamoto et al., 1999), (d) (Schaeren Wiemers et al., 1995, Frank et al., 1998), 
(e) (Brunner et al., 1989, Rasband et al., 2005), (f) (Bartsch et al., 1989, Schachner and 
Bartsch, 2000), (g) (Brunner et al., 1989), (h) (Tait et al., 2000), (i) (Ishibashi et al., 2004), 
(j) (Gow et al., 1999). (Taken from (Maier et al., 2008). 
 
 
  Compact myelin proteins include; proteolipid protein (PLP) and myelin basic protein 
(MBP) which are required for compaction of the myelin sheath, myelin associated 
oligodendrocytic basic protein (MOBP) and myelin and lymphocyte protein (MAL). 
Proteins specific to the non compact myelin compartment include 2’ 3’ cyclic nucleotide 
3’phosphodiesterase (CNP), myelin associated glycoprotein (MAG), 
myelin/oligodendrocyte glycoprotein (MOG), neurofascin155 (NF155), the tetraspanin 
protein CD9, and the oligodendrocyte specific protein (OSP)/claudin11 (Maier et al., 
2008).    138 
  The relative abundance of myelin proteins in the CNS has previously been hugely over 
estimated with PLP accounting for 30 45% of total myelin protein, two of the four MBP 
splice isoforms account for 22 53%, CNP account for 4 15 % and the remaining proteins 
account for 5 25% (Morell et al., 1972, Norton and Poduslo, 1973, Banik and Smith, 1977, 
Deber and Reynolds, 1991).  However, a recent systematic proteomics study has revealed 
342 proteins associated with CNS myelin and consequently lower levels of the proteins 














Table 4.2. Comparison of myelin protein abundance.  Myelin protein abundance was 
quantified by liquid chromatography mass spectrophotometry (LC MSE) with previous 
estimates based on band intensity after 1D PAGE and various protein staining techniques. 
The abundance of PLP and MBP was previously overestimated because low abundant 
proteins did not constitute significant bands due to limitations in the resolving power of the 
1D gels and in the dynamic range of protein staining (Taken from (Jahn et al., 2009). 
 
 
Interestingly, and in keeping with the white matter specific expression, this study also 
highlighted the presence of Cryab (an alternative nomenclature for HspB5), as part of the 
CNS myelin proteome (Jahn et al., 2009). 
  CNP is one of the myelin proteins found throughout the non compact myelin 
compartment and is absent from the compact myelin, it is an enzymatic protein that 
catalyses the hydrolysis of 2’,3’ cyclic nucleotides into their corresponding  2’ nucleotides 
(Sprinkle, 1989).  CNP associates with the cytoskeleton and is involved in the biogenesis 
and differentiation of myelin (De Angelis and Braun, 1996).  It is among the first proteins 
detected in developing oligodendrocytes and it is enriched in the periaxonal membrane 
during axonal ensheathment prior to the formation of compact myelin membranes (Trapp   139 
et al., 1988).  The importance of CNP in myelination arises from studies involving 
transgenic (tg) mice overexpressing CNP or CNP null mice.  Mice overexpressing CNP via 
a potential gain of function, produce abberant myelin membranes, lacking the distinct 
major dense lines (MDL) in compact myelin (Yin et al., 1997).  The characteristic structure 
of the myelin sheath as determined by electron microscopy shows the presence of MDL 
that alternate with thinner intraperiod lines to form repeating units. The MDL results from 
the fusion of the thicker, inner leaflet of the oligodendrocytic plasma membrane, whereas 
the intraperiod line is formed by the apposition of the thinner, outer leaflet of this 
membrane (Figure 4.2) (Baumann and Pham Dinh, 2001). 
 













Figure 4.2.  Electron microscope image showing structure of the myelin sheath.  The 
myelin sheath is appears in a regular organization of major dense lines (arrows) and the 
double stranded intraperiod lines (arrowheads) (see inset). Double arrows indicate the 
cytoplasmic Schwann cell collar around the myelinated axon, double arrowheads the 
axolemma (Adapted form (Martini et al., 1995). 
 
 
Myelin membranes without MDLs were found to be deficient in MBP and enriched in 
CNP.  CNP is thought to inhibit the accumulation of MBP by preventing its binding to 
membranes and targetting to the correct compartment (Yin et al., 1997).  mRNA levels of   140 
MBP were unaltered in CNP overexpressing mice, however protein levels were reduced by 
30% suggesting reduced MBP translation and/or increased turover.  CNP is likely to 
modulate these effects by participating in the dynamic regulation of submembranous actin 
microfilaments (Gravel et al., 1996).  The mechanism by which this occurs could resemble 
those involving the the Rho family of GTP binding proteins (Zigmond, 1996) as CNP 
share several structural features with these molecules (Gravel et al., 1996).  Additionally, 
CNP knockout mice have disrupted axoglial interactions.  These mice contain mislocalised 
proteins such as the paranodal adhesion proteins (Caspr) and ion channels.  These mice 
develop axonal degeneration, suggesting the importance of CNP in maintaining the 
integrity of paranodes and axoglial signalling (Rasband et al., 2005). 
4.1.2.   Transport and cytoskeletal elements 
  Both oligodendrocytes and Schwann cells synthesize a vast amount of myelin membrane 
with the appropriate proteins and lipids that are all targeted, transported and integrated into 
the emerging myelin sheath by an orchestrated interplay of cytoskeletal elements including 
vesicular transport.  The myelin sheath; the sub domains and compartments initially laid 
out have to be maintained throughout life (Poliak and Peles, 2003).  Myelin sheath 
production and maintenance occurs as a result of polarized transport in oligodendrocytes 
involving: (1) the sorting of proteins and lipids destined for the different plasma membrane 
domains, (2) the directed transport towards the different plasma membrane domains along 
the cytoskeleton and finally (3) the specific targeting to and incorporation in the correct 
membrane domains.  Most of the major myelin proteins are transmembrane proteins and 
are synthesized at the endoplasmic reticulum (ER).  They are transported by vesicular 
transport to the golgi apparatus and further to the plasma membrane (Maier et al., 2008).  
However compact myelin proteins MBP and MOBP are transported towards the myelin in 
the form of their mRNA and subjected to local synthesis. As both proteins are extremely 
adhesive this may be the reason why their synthesis is restricted to their final location 
(Barbarese et al., 1995).  In contrast, several other myelin proteins such as PLP (compact) 
and MAG (non compact) are localized in endosomal compartments (Trapp et al., 1989, 
Kramer et al., 2001, Trajkovic et al., 2006), suggesting that transport through the 
endosomal system is also important for myelin proteins.  PLP has been localized in late   141 
endosomes/lysosomes however does not co localise with other myelin proteins such as 
MOG and MAG, indicating that PLP is transported separately of other myelin proteins and 
implies that myelin proteins are sorted into distinct trafficking pathways (Kramer et al., 
2001).   
   The cytoskeleton is essential for the coordinated process outgrowth during 
oligodendrocyte differentiation (Richter Landsberg, 2000). In addition, the polarized 
trafficking of mRNA granules and transport vesicles towards the myelin membrane 
depends on an intact cytoskeleton.  Microtubules are thought to provide the tracks for 
directed vesicular and organelle transport in oligodendrocyte processes allowing 
production and maintenance of the myelin sheath (Lunn et al., 1997).  The MT network is 
abundant in the cell body and all processes, but does not extend into the most distal ends 
whereas actin filaments are localised to the fine processes and myelin like membranes of 
oligodendrocytes (Kachar et al., 1986, Larocca and Rodriguez Gabin, 2002). 
  The motor protein kinesin is important in directing transport towards the plus end of 
microtubules and thus towards the myelin sheath (Carson et al., 1997).  Actin has been 
predominantly implicated in the formation of the lamellipodium, which initiates the 
myelination of the axon.  In addition, a number of studies have directly linked the 
modulation of the actin cytoskeleton to myelin directed transport (Siskova et al., 2006, 
Kippert et al., 2007). 
  Disruption of genes, e.g., CNP and MAL that are likely to affect the transport of myelin 
components does not impair the initial formation of the myelin sheath, whereas later in life 
a defect in myelination, in particular in the paranodes becomes apparent (Maier et al., 
2008).  MAL may be required for the targeting of myelin proteins through the myelin 
sheath, whereas CNP may be important for the integration of actin and microtubule 
cytoskeleton thus facilitating the transport towards the paranodal loops (Maier et al., 2008). 
4.1.2.  White matter diseases 
4.1.2.1.  Multiple Sclerosis 
  The importance of functional oligodendrocytes and appropriate myelination becomes 
clear when considering diseases such as multiple sclerosis (MS), an inflammatory 
demyelinating disease, where abnormalities in development, maintenance and damage to   142 
the myelin sheath results in a devastating and incapacitating disease with severe 
neurological symptoms (Lassmann and Lucchinetti, 2008).  Additionally there are a 
number of genetically inherited disorders that affect CNS myelin, collectively termed 
leukodystrophies (Boespflug Tanguy et al., 2008).  This heterogeneous group of diseases 
is characterized by the loss of motor, sensory, and mental capabilities and the susceptibility 
to seizures (reviewed in (Kaye, 2001). 
  MS occurs as a result of damage to the myelin sheath leading to demyelination and glial 
scarring (Holley et al., 2003).  This affects neuronal function, as axons are no longer able 
to effectively conduct signals (Compston and Coles, 2002).  Approximately two thirds of 
MS patients have phases of relapse and remission.  Relapse phases are characterised by 
inflammatory lesions, particularly in the white matter, consisting of B cells, T cells and 
macrophages.  Inflammation in MS generally occurs in specific regions, including the 
optic nerve, the brainstem, the cerebellum and the long motor and sensory spinal cord 
fibers (Steinman, 2009).  Relapses involve rapid onset of neurological defects over a short 
period of hours or days, including problems with vision, sensation and motor function.  
These periods are generally followed by remission, where there is recovery of some or 
most of the lost neurological functions (Steinman, 2009). 
  The continuous cycle of relapse and remittance can lead to a chronic and progressive 
disease.  It is postulated that three key players are involved in the relapse  remitting 
disease; osteopontin, which acts as a ligand for adhesion molecules which are involved in 
modulating disease in mice with experimental autoimmune encephalomyelitis (EAE) 
(Ashkar et al., 2000), α4β1 integrin the main adhesion molecule involved (Brocke et al., 
1999) and HspB5 that is essential for the recovery from neurological relapse by its anti 
inflammatory properties (Ousman et al., 2007).   
  Relapse during MS is induced by osteopontin binding to α4β1 integrin on T cells; this in 
turn increases the phosphorylation of IkB kinase β (IKKβ).  Subsequent phosphorylation of 
the NF kB (nuclear factor kB) alpha subunit releases the p50 and p65 subunits of NF kB, 
which translocates to the nucleus promoting the production of pro survival genes (Chabas 
et al., 2001, Jansson et al., 2002) and blocking apoptosis by inhibition of forkhead box 
O3A (FOXO3A) (Hur et al., 2007).  Thus, reactive T cell survival is promoted and   143 
subsequent release of cytokines, osteopontin and other molecules by T cells and antigen 
presenting cells (APC) damage oligodendrocytes and the myelin sheath (Hur et al., 2007). 
  HspB5 is the most abundant transcript that is unique to MS lesions (Chabas et al., 2001).  
HspB5 expression is associated with remission of the effects mediated by osteopontin  
α4β1.  It specifically decreases the activation of NF kB and p38MAPK in T cells, 
macrophages, dendritic cells and glial cells (Ousman et al., 2007).  Additionally HspB5 
knockout mice with EAE showed increased T cell responses to myelin (Ousman et al., 
2007).  Administration of recombinant HspB5 to mice with EAE showed a lower number 
of apoptotic glial cells, and decreased T cell cytokine production, indicating a protective 
effect of HspB5 (Ousman et al., 2007).  However, HspB5 is reported to produce one of the 
strongest T cell responses in MS patients (van Noort et al., 1995), thus potentially 
exacerbating inflammation and demyelination in MS (Ousman et al., 2007) 
4.1.2.2.  White matter changes in protein misfolding diseases 
  Alexander’s disease (AxD) is a fatal neurodegenerative disease that also belongs to the 
leukodystrophies.  It occurs as a result of mutations in the GFAP gene resulting in 
abnormal folding of GFAP and accumulation into protein aggregates called Rosenthal 
fibers.  The association of misfolding events, (accumulation of Rosenthal fibers) and 
perturbations of astrocytic function with a failure in myelination are poorly understood 
(Sawaishi, 2009).  However, AxD patients have extensive white matter abnormalities (van 
der Knaap et al., 2001), suggesting a cell autonomous effect. 
  Many neurodegenerative diseases characterised by misfolded proteins are also reported to 
have white matter abnormalities.  For example, HD patients have been shown to have pre 
symptomatic changes in the white matter prior to neuronal dysfunction and cell death 
(Ciarmiello et al., 2006).  Additionally changes in the white matter have been observed in 
AD.  Fibrillar Aβ pathology in the grey matter of the neocortex was associated with focal 
demyelination and loss of oligodendrocytes in sporadic and preclinical AD cases (Mitew et 
al., 2010). 
  Charcot Marie Tooth disease type 1A, is a hereditary demyelinating neuropathy, usually 
caused by overexpression of peripheral myelin protein 22 (PMP22) due to genomic 
duplication (Patel et al., 1992, Nelis et al., 1996) or point mutations in one copy of the   144 
PMP22 gene (Gabreels Festen et al., 1995).  PMP22 is a minor white matter protein (Suter 
and Snipes, 1995) and the mechanism for demyelination is unclear.  Tg mice in which 
PMP22 expression is regulated by a tetracycline promoter were shown to develop normally 
when overexpression was switched off by feeding the mice tetracycline.  However, up 
regulation of the gene was shown to rapidly induce active demyelination within 1 week 
(Perea et al., 2001). Radioactive labelling of myelin proteins suggests they are extremely 
stable (Sabri et al., 1974) thus the rapid demyelination in PMP22 overexpressing mice 
suggests PMP22 causes active demyelination
 either by affecting the differentiation state of 
the Schwann
 cells or by the production of abnormal myelin which then affects
 the whole 
myelin sheath (Perea et al., 2001). 
   Furthermore, it is increasingly apparent that it is not only the neuronal cell population 
that are adversely affected during various age related neurodegenerative diseases, but 
associated structures (myelin sheaths) and glial cells are also affected.  Hence it is possible 
that abnormalities in the glial cell compartment (e.g. within oligodendrocytes) either 
directly contribute to disease progression or modulate disease outcomes through secondary 
responses, for example via altered cross talk between affected glial cells and neighbouring 
neurons. Proteins such as HspB5 are therefore interesting candidates potentially involved 
in neurodegeneration (also see chapter 5 and 6).  
4.2.  Aims 
In view of the rather selective expression of HspB5 based on the in situ hybridisation data 
and enrichment in the myelin fraction, we wanted to better define the expression of HspB5 
in oligodendrocytes by immunohistochemistry and to analyse the mRNA expression 
observed in Chapter 3 in greater detail. 
4.3.  Results 
4.3.1.  HspB5 mRNA localization in the white matter 
  In the previous chapter (Chapter 3) HspB5 mRNA was shown to localise to 
oligodendroglial cells, with intense staining over and diffuse staining around the cell 
bodies (Figure 3.8).  To further investigate mRNA distribution of HspB5 by emulsion 
radiography, higher magnification images of HspB5 in the corpus callosum and spinal cord   145 
were analysed.  HspB5 mRNA showed localisation over cell bodies as previously 
observed; additionally extra somatic staining was seen to extend away from the cell bodies 
and potentially order over cellular processes (Figure 4.3).  This phenomenon was observed 
in many areas of the corpus callosum as well as the spinal cord, showing the presence of 
discrete particles along these processes (Figure 4.4).  The signal was competed in controls 
(using sense and xs anti sense oligonucleotides) (data not shown).   
  The staining pattern was very similar to that observed for myelin basic protein (MBP) 
mRNA (Figure 4.5).  MBP mRNA is known to be targeted to the oligodendrocyte 
processes allowing it to be available for local synthesis at it desired location.  Small 
clumps as indicated by arrows in Figure 4.5 are observed along the processes and are 
termed ‘RNA granules’. 
Figure 4.3. mRNA expression of HspB5 by emulsion in situ hybridisation in the corpus 
callosum.  Emulsion radiography was used to visualise the expression of HspB5 in coronal mouse 
brain sections.  Along with labelling of oligodendrocytic cell bodies, positive labelling also 
appeared to occur in processes emanating from the cell bodies (asterisk). Enlarged images of a, b 
and c are shown in the insets.  Magnification: x20.  Sections were counterstained with cresyl violet. 
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Figure 4.4. mRNA expression of HspB5 by emulsion in situ hybridisation in the spinal 
cord.  Emulsion radiography was used to visualise the expression of HspB5 in spinal cord 
sections.  Distinct staining in the form of small clumps (asterisk) that were very similar to 
MBP RNA granules were observed emanating from the oligodendrocytic cell bodies.  
Enlarged images of a, and b are shown in the insets.  Magnification: x63.  Sections were 

















Figure 4.5. High resolution non radioactive in situ hybridisation image of myelin 
basic protein.  The nucleus has no staining (asterisk) but the surrounding cytoplasm is 
intensely stained.  MBP mRNA extends along processes arising from the cell body 
(arrows). (Taken from (Bessert and Skoff, 1999). 
* 
* 
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4.3.2.  Sequence analysis of transport elements in HspB5 mRNA 
  Conserved elements have previously been identified for a number of RNA species that 
are specifically targeted to distinct cellular regions in different cell types (Ainger et al, 
1997).  These mRNAs contain a 21 nucleotide sequence, termed the RNA transport signal 
(RTS).  The RTS consensus sequence (GCCAAGGAGCCAGAGAGCAUG) contains two 
partially overlapping, homologous decanucleotide sequences: GCCAAGGAGC (rts1) and 
GCCAGAGAGC (rts2) (Ainger et al., 1997).  A perfect or almost perfect match to either 
of these sequences is observed in many transported mRNA.   
  The complete HspB5 mRNA sequence obtained from the NCBI database (accession no: 
NM_009964) (Figure 4.6) was used to determine homology with either rts1 or rts2 
decanucleotide sequences.  This was done by processing the sequences in the alignment 
tool clustaw2 (www.ebi.ac.uk) which revealed an almost perfect match to the first of the 
decanucleotide sequences (9/10) (Figure 4.7). 
 





















Figure 4.6. HspB5 mRNA sequence (NM_009964).  The complete mRNA sequence for 
HspB5 was used to determine homology with rts decanucleotide sequences.  The region of 
rts homology within the entire sequence is highlighted in red.  5’ untranslated region (5’ 
UTR) is shown in black.  Start and stop codons are highlighted in light blue.  3’ UTR is 
highlighted in dark green and the poly A tail is highlighted in light green. 
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                      247                     
    HspB5          TGGACAGAGAGCTAGTGAAACAAGACCATGACA  
    rts1                    GCCAGAGAGC    
    rts2                    GCCAAGGAGC    
                                                               
Figure 4.7. RTS homology in HspB5 mRNA.  HspB5 mRNA shows an almost perfect 
match to one of the RTS consensus decanucleotide sequences using clustalw2 software.  
No other regions in the HspB5 mRNA sequence produced overlapping sequence similarity.  
Residues 247 – 279 are shown as this was the region were sequence homology was 
present.  The region of homology is located in the 5’ untranslated region (UTR).  
 
4.3.3.  HspB5 expression in oligodendrocyte processes (immunohistochemistry) 
  HspB5 expression was visualised by DAB immunohistochemistry and displayed a similar 
pattern of staining to that observed by in situ hybridisation.  The hippocampus showed less 
HspB5 immunoreactivity in comparison to the corpus callosum and fimbria (Figure 4.8 A).  
The corpus callosum showed intense staining in cell bodies and fibre tracts (Figure 4.8 
B/C) and the striatum oriens showed little immunoreactivity for HspB5 in comparison 
(Figure 4.8 C).  The CA3 hippocampal region displayed an intricate pattern of staining 
(Figure 4.8 D).  This pattern was also observed in other hippocampal regions.  Cell bodies 
were intensely staining with delicate processes extending away into the CA3 pyramidal 
cell layer and surrounding area.  Immunoreactivity in the CA1 displayed a similar pattern 
to that observed in the CA3, with intense staining of the perikaryon and a meshwork of 
processes extending into the stratum pyramidal.  A fewer number of cell and processes 
were immunopositive in the CA1 in comparison to the CA3 (Figure 4.8 E).  Staining of the 
lacunosum molecular region of the CA1 demonstrates the elaborate nature of HspB5 
expression.  Strong immunoreactivity in cells bodies was observed, as well as delicate 
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Figure 4.8. Immunohistochemical analysis of HspB5.  Coronal brain sections of the dorsal hippocampus 
including the overlying corpus callosum were subjected to immunohistochemistry for detection of HspB5 
immunoreactivity.  (A) The hippocampal regions, CA1, CA3 and DG show some immunoreactivity which is 
sparse in comparison to the myelin rich cc and fimbria.  (B) Immunoreactivity is observed in the fibre tracts 
of the cc as well as staining in cell bodies in and around this region.  The SOr is de enriched for HspB5 in 
comparison.  (C) Higher magnification image of the cc showing distinctive staining of the cell bodies as well 
as fibre tract.  (D) The CA3 hippocampal region shows an intricate pattern of staining also observed in other 
hippocampal regions.  Cell bodies are intensely stained with delicate processes extending away into the CA3 
pyramidal cell layer and surrounding area.  (E) Immunoreactivity in the CA1 displays a similar pattern to that 
observed in the CA3, with intense staining of the perikaryon and a meshwork of processes extending into the 
Spy.  (F) Staining of the LMol demonstrates the elaborate nature of HspB5 expression.  Cells bodies are 
clearly and intensely stained.  A number of processes extend away from the cell bodies, which line up in 
register with one another.  Images are representative of staining from 4 animals.  Corpus Callosum (cc), 
stratum oriens (SOr), stratum pyramidal (Spy), stratum radiatum (SRad), CA3 pyramidal cell layer (CA3Py) 
and lacunosum molecular (LMol).  (Magnifications: A, x10; B, x20; C, x40; D, x63; E, x63; F, x100). 
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4.3.4.  HspB5 expression in oligodendrocytes (immunofluorescence) 
  HspB5 expression in oligodendrocytes was investigated by fluorescence 
immunohistochemistry.  Tissue was prepared and processed as detailed in section 2.11.   
HspB5 staining was consistent with expression in white matter tracts such as the corpus 
callosum, cingulate gyrus (Figure 4.9) and the fimbria (data not shown).  The anatomical 
protein expression was consistent with mRNA expression (Figure 3.5 and 3.8 d) indicating 
white matter specific expression.  Co localisation of HspB5 was observed with CNP 
double immunofluorescence (Figure 4.9).  Immunostaining of HspB5 was more 
pronounced in oligodendroglial cell bodies than CNP in comparison to staining of the fiber 
tracts in the corpus callosum and fiber bundles in the cingulate gyrus.  CNP staining was 
more pronounced in the fiber tracts/bundles and although cell body staining was observed 
it was predominately masked by the intensity of the staining in the fiber tracts. 
  To confirm co localisation of HspB5 and CNP in oligodendrocyte cell bodies, brain tissue 
from the dorsal hippocampus was analysed as the hippocampus is sparsely myelinated in 

















Figure 4.9. Double immunofluorescence staining of HspB5 and CNP.  HspB5 shows 
co localisation with CNP staining in the fibre tracts/bundles of the corpus callosum and 
cingulate gyrus.  Circles show cell body staining of both proteins.  Images are 
representative of staining from 4 animals. Corpus callosum (cc), cingulate gyrus (cg).  
Scale bar, 50 m. 










































Figure 4.10. Double immunofluorescence staining of HspB5 and CNP in the hippocampus.  HspB5 
shows co localisation with CNP staining in cell bodies of oligodendrocytes in all hippocampal regions.  The 
sparse myelination of this brain region in comparison to other highly myelinated regions (cc) allows cell 
body staining to be observed.  (A) The CA1 region LMol shows a number of HspB5 positive cells that are 
also CNP positive (see arrow and inset).  (B) The CA3 region shows many HspB5 positive cells that are also 
CNP positive (see arrow).  Insets show higher magnification images of the boxed cell.  (C) Higher 
magnification images of HspB5 and CNP staining, showing co localisation in cell body of an 
oligodendrocyte.  Images are representative of staining from 4 animals. Stratum Radiatum (SRad), Stratum 
Lacunosum Molecular (LMol).  (Magnifications: A, x40; B, x20 (inset = x63); C, x63).   152 
4.4.  Discussion   
4.4.1.  Potential targeting of HspB5 mRNA in oligodendrocytes  
  Emulsion radiography showed intense labelling of HspB5 mRNA over oligodendrocyte 
cell bodies along with expression in cellular processes extending away from the cell body.  
This was observed in all myelinated regions analysed (Figure 4.3 and Figure 4.4).  The 
non somatic expression suggested the possibility that HspB5 mRNA is transported or 
indeed targeted to specific compartments in the myelin as shown for a number of myelin 
specific proteins such MBP (Ainger et al., 1997).  Selective targeting of mRNA to distinct 
cellular compartments has also previous been described in neuronal dendrites (Kuhl and 
Skehel, 1998) suggesting similar mechanisms occur in different systems.  HspB5 also 
displayed a very similar expression pattern by in situ hybridization to that observed for 
MBP.  Distinct globular staining was observed for both HspB5 (Figure 4.4) and MBP 
(Figure 4.5).  MBP mRNA is specifically targeted to oligodendrocyte processes in ‘RNA 
granules’ that are observed as globular round clumps along the processes as shown Figure 
4.5.  The transport of MBP protein makes it available for local synthesis on free polysomes 
primarly in cell processes in close proximity to the myelin forming plasma membrane 
(Trapp et al., 1987).  MBP is synthesised locally to prevent this highly basic protein from 
interacting non specifically with membranes.  The sequence of events involved in MBP 
mRNA targetting is depicted in Figure 4.11 illustrating the sub compartment specific, 
multistep mechanisms involved.  As HspB5 displays a similar pattern of mRNA expression 
extending into the oligodendrocyte processes, suggests it is specifically targetted, possibly 
by a similar mechanism as employed for MBP.  This would allow localised and rapid 
synthesis of a chaperone protein, involved in cytoskeletal regulation, redox homeostasis 























Figure 4.11. Multi step model for intracellular trafficking of MBP mRNA in 
oligodendrocytes. A schematic diagram of an oligodendrocyte is shown (not drawn to 
scale). The following cellular components are labelled above the diagram: nucleus, 
perikaryon, RNA granules, microtubules, kinesin motors, microfilaments, and myelin 
membrane.  The major steps in translocation of MBP mRNA are indicated in boxes below 
the diagram (Carson et al., 1997). 
 
   
  Local synthesis of  HspB5 has previously been reported in injury conditioned dorsal root 
ganglion (DRG) neuronal cultures (Willis et al., 2005).  The dual localisation of HspB5 in 
both the perinuclear cytoplasm and also cellular processes, suggest an overlapping function 
with proteins such as MBP and CNP.  CNP mRNA is concentrated around oligodendrocyte 
perinuclear regions and is sythesised by free ribosomes and MBP is transported and 
synthesised locally (Trapp et al., 1988).  It is possible that a cytoplasmic pool of HspB5 is 
synthesised and incorporated into the myelin sheath and a targetted pool is retained until it 
is required.  Indeed, a cytoskeletal component neurofilament M (NF M) mRNA translation 
has been shown to be induced by loss of contact of Schwann cells that have been placed in 
culture and deprived of axonal contact (Kelly et al., 1992).  Additionally in spite of the 
prescence of NF M mRNA in Schwann cells during development, NF M protein is not a 
significant Schwann cell constituent (Fabrizi et al., 1997).    
4.4.2.  Sequence analysis of HspB5 mRNA 
  Selective transport of mRNA is not restricted to proteins such as MBP that would 
otherwise adhere non specifically to other cellular membranes.  Transport of mRNAs   154 
encoding other proteins has been reported in various cell types (Ainger et al., 1997).  
Targetting and localisation generally requires the prescence of specific sequences or 
secondary structural motifs.  A 21 nucleotide transport sequence (RTS) is necessary and 
sufficient for transport of mRNA in different cells and in oligodendrocytes.  The RTS is 
found in both the untranslated regions (UTR) or in the coding region of the mRNA.  














          Mouse               HspB5      5’ UTR      TGGGTGTGGACAGAGAGCTAG 
             Consensus sequence                   GCCAAGGAGCCAGAGAGCAUG 
 
Table 4.3. RTS homology in mRNAs known to be transported.  All sequences 
are from mature RNAs. The species and location of the RTS homology are indicated.  
HspB5 mRNA sequence showing homology to RTS is also indicated.  ARC, activity 
related cytoskeleton associated protein; Ca N, N type calcium channel α1; GABAR(A), 
gaba amino butyric acid receptor α subunit; GFAP, glial fibrillary acidic protein; MOBP, 
myelin associated/oligodendrocytic basic protein; NOS, nitric oxide synthase; RC3, 
neurogranin (Adapted from Ainger et al., 1997). 
 
   
  The full length RTS was not present in the HspB5 mRNA sequence, but almost complete 
homology was observed in the 5’UTR with a decanucleotide sequence present in the 
concensus RTS (rts1) (Figure 4.7).  This may be sufficient in mediating RNA transport of 
HspB5, as many of the mRNAs containing the RTS have almost complete homology to 
one of the decanucleotide sequences.   155 
4.4.3.  Protein expression of HspB5 in oligodendrocytes.   
  HspB5 staining as observed by IHC displayed an intricate nature of HspB5 expression, 
not only in the perikaryon, but also in oligodendrocyte processes and myelin tracts.  The 
level of myelination in the hippocampus is relatively sparse in comparison to heavily 
myelinated structures such as the corpus callosum.  It is not clear which neurons are 
myelinated, however oligodendrocyte expression has recently been investigated in the 
mouse hippocampus (Vinet et al., 2010).  Interestingly this study identified three 
morphologically distinct sub populations of oligodendrocytes using mice expressing eGFP 
under an oligodendrocyte specific promoter. These subtypes were shown to be 
differentially distributed in the various layers of the hippocampus. 
  The hippocampal staining of HspB5 (Figure 4.8) shows overlap with the majority of the 
identified oligodendrocyte subpopulation as described by Vinet et al. (2010).  Interestingly 
this suggests that HspB5 may potentially be a useful general marker for oligodendrocytes 
in the hippocampus.  The HspB5 staining in the hippocampus does not display the typical 
organisation observed in structures such as the corpus callosum with cell bodies forming 
tandem arrays in close register, but cell bodies are distributed throughout the hippocampus.  
The lacunosum molecular layer shows some oligodendrocytes lining up together, but the 
separation of the cell bodies is greater than that observed in other white matter regions.  
The staining pattern observed shows resemblance to the chondroitin sulphate proteoglycan 
NG2 expressing (NG2) progenitor cells.  These cells are oligodendrocyte precursor cells 
(OPC) that are thought to give rise to oligodendrocytes.  Transgenic mice expressing CNP 
EGFP were shown to co localise with a population of NG2 cells in addition to mature 
oligodendrocytes in the hippocampus (Mangin et al., 2008).  As HspB5 co localised with 
CNP in the hippocampus it can be speculated that some of these distinctive cells are also 
NG2 cells.  NG2 progenitor cells are anatomically placed close to neuronal cells.  They 
have a small cell bodies and thin radiating processes (Lin and Bergles, 2002).  Their 
processes are usually intertwined with neuronal dendrites and they are anatomically 
associated with interneurons in the hippocampus (Mangin et al., 2008).  This observation is 
consistent with the remarkable similarities of NG2, CNP and HspB5 staining with 
interneuronal proteins such as CB1 (cannabinoid receptor 1) (Katona et al., 1999).  NG2 
cells in the gray matter generally remain quiescent, although these cells are OPC’s they   156 
also have the potential to differentiate into interneurons in the hippocampus (Belachew et 
al., 2003, Aguirre et al., 2004).  Vinet et al. (2010), showed that NG2 cells co localised 
faintly with CNP EGFP expressing cells, however olig 2 expression in these cells was high 
(91.4%) indicating the probable immature oligodendrocytic nature of these cells (Vinet et 
al., 2010).   
4.4.4.  HspB5 co localises with CNP a non compact myelin protein 
  Co localisation of HspB5 and CNP was observed in all regions analysed.  Both HspB5 
and CNP labelled white matter tracts throughout the tissue sections.  Additionally HspB5 
staining was stronger in the cell bodies, whereas CNP staining, although present in cell 
bodies, was masked by intense staining of the surrounding myelin fibres (Figure 4.7).  Co 
localisation was clearly observed in the cell bodies of the dorsal hippocampus, showing 
perinuclear expression as well as expression in processes of oligodendrocytes (Figure 4.8 
B (inset)).   
  Colocalisation of HspB5 with CNP not only confirms expression of HspB5 in 
oligodendrocytes, but also allows functional assumptions to be made.  CNP, like HspB5 is 
expressed  in oligodrendrocytes in the CNS and also in Schwann cells in the peripheral 
nervous system.  It is found to be localised to the cytoplasmic membrane of 
oligodendrocytes and Schwann cells consistent with a role in membrane synthesis and 
maintanence as well as signal transduction within these cells (Trapp et al., 1988, Lee et al., 
2005b). 
  CNP expression shows significant overlap with that of HspB5, it is expressed in all white 
matter containing structures, such as the corpus callosum, the optic nerve and the spinal 
cord.  It is also present in the outer rod segment of the visual system where major 
membrane reorganisation occurs in response to visual input (Heath and Hindman, 1986).  
CNP is not a major component of myelin in comparison to MBP and PLP, however is still 
relatively abundant (Kurihara and Tsukada, 1967, Olafson et al., 1969).  It is found 
associated with the non compact myelin compartment, and is observed in paranodal loops, 
inner and outer loop and tongue structures, incisure like membranes and in periaxonal 
regions (Trapp et al., 1988).     157 
  Up to 40% of CNP is thought to associate with the detergent insoluble membrane fraction 
containing lipid rafts (Kim and Pfeiffer, 1999).  HspB5 has also been shown to bind 
membrane lipids in vitro (Cobb and Petrash, 2000).  The binding capacity is dependent on 
the lipid composition, with a higher binding capacity associated with a higher amount of 
sphingolipids and lower amounts of phosphotidylethanolamine (PE) related lipids (Grami 
et al., 2005).  As the white matter is enriched in sphingolipids, it is likely the HspB5 
associates with membranous structure such as lipid raft. 
  HspB5 and CNP associate with both the actin (microfilament) and tubulin (micotubule) 
cytoskeleton (Dyer et al., 1995).  CNP acts as a microtubule associated protein (MAP) 
linking tubulin with the plasma membrane (Bifulco et al., 2002), whereas HspB5 binds to 
microtubules via MAP’s (Fujita et al., 2004).  CNP is able to induce MT polymerisation, 
and direct the formation of branched process outgrowth (Lee et al., 2005b) and HspB5 
stabilises the MT (Fujita et al., 2004).  The overlapping functions of both proteins suggests 
that HspB5 may also be involved in lipid raft mediated signalling, affecting myelin 
cytoskeletal components, as suggested for CNP (Hinman et al., 2008). 
  Along with the potential role of HspB5 in maintaining myelin structure by 
interaction/regulation of the cytoskeleton, HspB5 may be crucial in regulating a cellular 
stress response and conferring protection.  Indeed, proteolytic stress in oligodendroglial 
cell line induces aggresome formation containing tau, HspB5 and ubiquitin, close to the 
microtubule organising centre (MTOC) (Bauer and Richter Landsberg, 2006).  
  Myelinated axons have been shown to be protected from oxidative stress in comparison to 
non myelinated axons.  The known function of HspB5 in redox homeostasis and its 
potential localisation to lipid rafts in oligodendrocytes places it in a key position where 
cross talk between neuronal and oligodendrocytes can occur, allowing protective responses 
to be regulated by this protein.  Additionally the abundance of HspB5 may reflect the 
intrinsic vulnerabilities of oligodendrocytes and the need for a molecular chaperone that is 
able to modulate many cellular responses.   
  Oligodendrocytes are more susceptible to stress and injury such as ischemic insult in 
comparison to other glial cells (Husain and Juurlink, 1995) this is likely associated with 
increase ROS generation    Rat glial cultures preloaded with DCFH (5 (and 6) carboxyl 
2’,7’ dichlorodihydrofluorescein) an indicator of oxidative stress showed pronounced   158 
fluorescence signal in oligodendroglial cells with little signal in astrocytes, (Juurlink, 
1997).  This was attributed to a higher burden of oxidative stress in oligodendrocytes 
compared to astrocytes as established by measuring ROS activity under normal culture 
conditions (Thorburne and Juurlink, 1996).  Oligodendrocytes are the major store of iron in 
the CNS (Connor, 1994).  The levels of glutathione (GSH), an antioxidant enzyme, were 
also measured and were significantly lower in oligodendrocytes compared to astrocytes 
(1mM vs. 5mM).  Combined with a high iron content such a combination makes 
oligodendrocytes potentially more susceptible to ROS generation.  ROS have pronounced 
effects on lipids, for example de esterification of membrane phospholipids by ROS with 
the subsequent release of free fatty acids which can be further oxidized by ROS (Deby and 
Goutier, 1990).  With myelin membranes composed of high amounts of lipid, modulation 
of ROS levels would seem to be important for maintaining myelin function, and could be 
one of the potential roles for HspB5 in oligodendrocytes.   
  Additionally a role for zinc has been proposed in the compaction of the mature myelin 
sheath (Riccio et al., 1995, Tsang et al., 1997).  Interestingly the chaperone activity of 
HspB5 has been shown to be increased in the presence of zinc (Coi et al., 2008).  This 
raises the potential for HspB5 to be involved in modulating myelin proteins during 
compaction and facilitating correct structure and localisation by way of chaperone activity. 
4.5.  Summary 
  Oligodendroglial expression of HspB5 was investigated by immunohistochemistry in 
mouse brain sections and co localisation of HspB5 was observed with CNP.  Detailed 
analysis of in situ hybridisation (emulsion radiography) showed mRNA localisation over 
cell bodies as previously shown in Chapter 3 as well as specific expression along processes 
emanating from the cell body in a similar fashion to that observed for MBP.  Sequence 
analysis revealed the prescence of a putitive RTS domain in the HspB5 mRNA sequence 
suggesting targeted transport and expression of HspB5, perhaps similar to what is known 
about MBP.  The schematic shown in Figure 4.12 summarizes expression of HspB5 in 
oligodendrocytes and also includes a description of specific, potential roles of HspB5 in 
oligodendrocytes. 
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Figure 4.12. Proposed expression/function of HspB5 in oligodendrocytes.  A schematic 
drawing which illustrates the expression of HspB5 in oligodendrocytes and also depicts 
potential roles.  HspB5 mRNA and protein are found within the cell body and in the 
myelin sheath of oligodendrocytes.  (1) mRNA may be translated on free ribosomes, in a 
similar fashion to CNP before being targetted to non compact myelin.  (2) mRNA may be 
transported in RNA granules to specific regions.  (3) mRNA may be transcribed by free 
ribosomes or polysomes at the site of function.  (4) HspB5 protein may interact with lipid 
rafts allowing crosstalk between myelin subdomains. (5) Localised synthesis or targetted 
proteins may interact with lipid rafts in regions where axo glial crosstalk and signalling 
events can be initiated/regulated.  (6) HspB5 protein binds and stabilises microfilaments, 
and may be involved in membrane maintanence and synthesis.  (7) HspB5 protein interacts 
with microtubules, likely through accessory proteins (MAPs) to modulate the cytoskeleton. 
(8) HspB5 protein and mRNA could potentially be targetted to compact myelin, by similar 
mechanisms as described for MBP.  HspB5 may also be involved in counteracting 
oxidative stress and having a general chaperone role in these specialised oligodendrocyte 
sub compartments.   
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5.1.  Introduction 
  Chapter 3 has highlighted the constitutive expression of HspB1, HspB5, HspB6 and 
HspB8 under physiological conditions in the adult mouse CNS.  These four sHsps have 
varying expression levels in distinct anatomical regions of the CNS, and are also 
differentially associated within cell types and sub compartments of the brain (as shown in 
Chapter 3 and 4).  HspB1 and HspB8 displayed selective expression in a subpopulation of 
motor neurons in the ventral horn of the spinal cord (Figure 3.4 and 3.8) and HspB5 and 
HspB6 were enriched in the myelin compartment of brain fractions (Figure 3.12).  
Furthermore, HspB5 mRNA expression was localized to the cell bodies and processes of 
oligodendrocytes (Chapter 4) suggesting mRNA targeting and a potential for local 
translation of this sHsp in the myelin compartment.  HspB5 also showed co localisation 
with CNP, a non compact white matter protein, suggesting HspB5 expression in the white 
matter could be selective to the non compact myelin compartment as discussed in Chapter 
4.  The constitutive expression of sHsps in neuronal and non neuronal cells suggests they 
are important for the normal function of these cells.  This is further supported by the fact 
that mutations in sHsps give rise to myopathies and neuropathies (see Introduction; Table 
1.3).   
  Given that proteinopathies are to some extent associated with brain region  and cell 
specific pathology, it is conceivable that the 4 sHsps could be involved in modulating 
disease processes such as protein aggregation, oxidative stress and inflammation, as 
described in the general introduction.  The sHsps are up regulated in response to insults 
and stresses in both neuronal and glial cells (Goldbaum and Richter Landsberg, 2001, 
Dabir et al., 2004) and have indeed been shown to modulate pathologies in several in vivo 
and in vitro studies of chronic neurodegeneration (Wilhelmus et al., 2006a, Ousman et al., 
2007, Sharp et al., 2008).  To investigate the change in sHsp expression and the potential 
contribution to chronic neurodegeneration in a model characterized by intracellular 
aggregates, this chapter will focus on expression of the sHsps in the R6/2 mouse model of 
HD. 
  The R6/2 transgenic mice recapitulate and display many of the symptoms and clinical 
features observed in HD patients.  These include impaired motor coordination, tremor, 
changes in open field activity and progressive weight loss (Menalled and Chesselet, 2002).     162 
For this reason it is considered a useful ‘model’ for understanding the pathological changes 
and dysfunction that occurs prior to cell death (Turmaine et al., 2000) and has revealed a 
number of potentially important and specific details on changes and mechanisms essential 
to pathology in human disease (Zucker et al., 2005, van der Burg et al., 2008).   
  Many studies have focused on the events that occur in the late stage of neurodegenerative 
disease.  It is now becoming apparent that the changes that occur early during chronic 
neurodegeneration, before the manifestation of clinical symptoms are important in disease 
progression and may provide a pivotal step for therapeutic intervention.  Post mortem 
studies in HD suggest that the appearance of motor and cognitive symptoms occur in the 
absence of overt neuronal loss thus impaired cognition is likely caused by cellular 
dysfunction (Vonsattel et al., 1985).  Synaptic dysfunction and reduced/increased 
excitability that change neuronal plasticity are likely candidates that underlie the cellular 
dysfunction observed (Murphy et al., 2000, Milnerwood et al., 2006).   
  Altered levels of neurotransmitter receptors (Cha et al., 1998) and changes in mRNA 
expression are apparent in the striatum and cortex of the R6/2 mice at 6 weeks.  cAMP 
regulated genes are downregulated, whereas some genes are up regulated e.g. DNA repair 
enzymes (Luthi Carter et al., 2000, Sugars et al., 2004).  Dysregulation is not only limited 
to the transcript level, but changes in protein expression and post translational regulation 
are also observed.   
  Interestingly, the expression of some molecular chaperones and co chaperones such as 
Hsp70, Hsp40 and α SGT (small glutamine rich tetratricopeptide repeat domain protein) 
are reduced by about 40 % at 14 weeks of age.  This is thought to be a consequence of 
recruitment into httEx1 positive inclusions as shown by co localisation studies (Hay et al., 
2004).   
   The brains of R6/2 mice have been reported to weigh approximately 20% less than wild 
type animals at 12 weeks (Mangiarini et al., 1996).  This marked reduction does not 
correlate with cell death, as limited cell loss is observed in this model.  In the cortex and 
the striatum a small number of neurons were shown to undergo “dark cell degeneration” 
(Turmaine et al., 2000), but progressive and substantial loss of orexin neurons was 
observed in the lateral hypothalamus (Petersen et al., 2005). However, this was not 
ascribed to the gross reduction in brain volume seen in the R6/2 mice.  The reduction could   163 
be a result of atrophy of individual neurons as the cell bodies of MSNs were shown to 
shrink by ~20% (Klapstein et al., 2001).  Interestingly, axonal atrophy was found to be a 
prominent feature of degenerating myelinated axons, with axoplasms showing a 15% 
reduction in diameter (Wade et al., 2008).  Additionally pre symptomatic changes in the 
white matter of HD patients have also been reported suggesting white matter pathology 
and volume loss may precede neuronal dysfunction and cell death (Ciarmiello et al., 2006).  
These observations indicate an additional importance of changes in the white matter and 
hence place two of the sHsps (HspB5 and HspB6) to a perhaps vulnerable glial cell type.    
5.2.  Aims 
  The aim of this chapter is to analyse expression of the 4 sHsps constitutively expressed in 
the mouse CNS under normal conditions (HspB1, HspB5, HspB6 and HspB8) in the R6/2 
mouse model of HD.  As early and progressive changes appear to be important in the 
pathogenesis of disease, three time points will be analysed to encompass the breadth of 
disease progression (Carter et al., 1999, Morton et al., 2000).  Expression will be analysed 
at an early (pre symptomatic; 4 weeks), mid (cognitive and behavioural abnormalities; 9 
weeks), and late (symptomatic; 17 weeks) stage of disease.  As HD is suggested to occur 
via selective dysfunction in certain brain regions, we investigated expression of sHsps in 
the striatum and cortex and compared this to the cerebellum. This provides a way to 
investigate preferentially affected regions (cortex and striatum) to one that is spared from 
pathology until very late in the disease (cerebellum) in addition to age matched wild type 
controls.  The white matter specific expression of HspB5 in non compact myelin and the 
white matter changes that have been documented in HD patients and the R6/2 animals as 
described above, provoke the need to investigate the expression of this sHsp in a white 
matter rich region.  Indeed, the cerebellum provides an ideal brain region to investigate the 
potential changes of the white matter specific HspB5.   
5.3.  Results 
5.3.1.  sHsps in soluble brain fractions at early and mid stages of disease 
  Cortex, striatum and cerebellum samples were microdissected from R6/2 transgenic (tg) 
and wild type (wt) littermates. Tissue from 4 and 9 week old animals was subjected to   164 
mechanical homogenization in a detergent (NP 40) based lysis buffer and spun at low 
speed (6000rpm) to pellet nuclei and the resultant supernatant was used for analysis 
(section 2.3.3).  40 g of protein from each sample was resolved on SDS PAGE and 
western blotting was used to analyse expression of the four sHsps expressed in the CNS.  
The pixel intensity values were normalized to protein loading (section 2.8.4) and the 
average intensity of the bands was plotted for the three brain regions.  Differences in pixel 
intensity between time points do not correspond to difference in protein levels, but are 
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5.3.1.1.  HspB1 
  Protein expression of HspB1 within the frontal cortex, striatum and the cerebellum was 
quantified by western blotting.  Figure 5.1 shows the protein expression of HspB1 at early 
(4wks) and mid stage (9wks) of the disease.  Representative western blots are shown 
below each graph.  HspB1 does not show any significant differences in expression between 














Figure 5.1. HspB1 protein expression in supernatant fractions at early (4wk) and mid 
(9 wk) stage of disease.  40 g of protein from frontal cortex, striatum and cerebellum 
homogenates were resolved by SDS PAGE and expression of HspB1 was measured by 
incubating membranes with an antibody against HspB1 followed by a fluorescently 
labelled secondary antibody which was detected by infrared fluorescence.  Intensity values 
were measured using Odyssey Infrared Scanner software and normalized to protein loading 
and expressed as pixel intensity per mm
2.  Expression of HspB1 is shown in distinct brain 
regions at A, 4 and B, 9 weeks.  (A) No changes in HspB1 expression were observed in tg 
animals in any brain region studied at 4 weeks.  (B) There were also no changes in HspB1 
expression in tg animals in the three brain regions analyzed at 9 weeks.  Representative 
blots are shown below the corresponding graph (n = 6).  One way analysis of variance 
(ANOVA), followed by Newman Keuls post hoc test was used to determine significance 
between wt and tg samples within regions and between brain regions (p, <0.05), error bars 
represent SEM.  FC (frontal cortex); STR (striatum); CER (cerebellum); WT (wild type); 
TG (transgenic). 
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5.3.1.2.  HspB5  
  Next, protein expression of HspB5 within the frontal cortex, striatum and the cerebellum 
was quantified by western blotting.  HspB5 showed statistically higher levels of expression 
in the cerebellum and striatum of wt animals relative to the frontal cortex (Figure 5.4).  
This may be a reflection of white matter/oligodendrocyte density in this region.  Indeed, as 
shown in Figure 5.17, MBP expression is higher in the cerebellum and striatum compared 
to the cortex.  Figure 5.2 represents the protein expression of HspB5 at early (4wks) and 
mid stage (9wks) of the disease.  Representative western blots are shown below each 
graph.  HspB5 expression showed a trend towards reduction in tg animals in all three brain 
regions at 4 weeks.  This was more pronounced at 9 weeks, and was statistically significant 












Figure 5.2. HspB5 protein expression in supernatant fractions at early (4wk) and mid (9wk) stage 
of disease.  40 g of protein from frontal cortex, striatum and cerebellum homogenates were resolved by 
SDS PAGE and expression of HspB5 was measured by incubating membranes with an antibody against 
HspB5 followed by a fluorescently labelled secondary antibody which was detected by infrared 
fluorescence.  Intensity values were measured using Odyssey Infrared Scanner software and normalized 
to protein loading and expressed as pixel intensity per mm
2.  Expression of HspB5 is shown in distinct 
brain regions at A, 4 and B, 9 weeks.  (A) HspB5 protein levels were decreased in tg animals in all three 
brain regions at 4 weeks.  (B) Downregulation of HspB5 was more pronounced at 9 weeks in all three 
brain regions and was statistically significant in the frontal cortex at the later time point.  Representative 
blots are shown below corresponding graph (n = 6).  One way analysis of variance (ANOVA), followed 
by Newman Keuls post hoc test was used to determine significance between wt and tg samples within 
regions and between brain regions (*p, <0.05; **p, <0.01; ***p, <0.001), error bars represent SEM. FC 
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5.3.1.3.  HspB6  
  Protein expression of HspB6 within the frontal cortex, striatum and the cerebellum was 
also quantified by western blotting.  Figure 5.3 represents the protein expression of HspB6 
at early (4wks) and mid stage (9wks) of the disease. HspB6 shows a different profile to 
that seen for HspB1 and HspB5.  There was no detectable expression of HspB6 in the 
frontal cortex at 4 weeks in both tg and wt animals (Figure 5.3 A).  Immunoreactivity was 
observed in the striatum and cerebellum at this time point, however there were no changes 
in expression between wt and tg animals.  At 9 weeks, the expression profile of HspB6 was 
very different to that seen at 4 weeks (Figure 5.3 B).  Immunoreactivity was now absent in 
the cerebellum and present in the frontal cortex, albeit low in comparison to the striatum.  
The differences observed were due the differential detergent extractabilities of this sHsps, 

















Figure 5.3. HspB6 protein expression in supernatant fractions at early (4wk) and mid (9wk) stage of 
disease.  40 g of protein from frontal cortex, striatum and cerebellum homogenates were resolved by SDS 
PAGE and expression of HspB6 was measured by incubating membranes with an antibody against HspB6 
followed by a fluorescently labelled secondary antibody which was detected by infrared fluorescence.  
Intensity values were measured using Odyssey Infrared Scanner software and normalized to protein loading 
and expressed as pixel intensity per mm
2.  Expression of HspB6 is shown in distinct brain regions at A, 4 and 
B, 9 weeks.  (A) HspB6 immunoreactivity was absent in the frontal cortex at 4 weeks and there were no 
changes in expression in tg animals in the striatum and cerebellum.  (B) At 9 weeks immunoreactivity was 
absent in the cerebellum and there were no changes in expression in tg animals in the frontal cortex.  
Representative blots are shown below corresponding graph (n = 6).  One way analysis of variance 
(ANOVA), followed by Newman Keuls post hoc test was used to determine significance between wt and tg 
samples within regions and between brain regions (p, <0.05), error bars represent SEM. FC (frontal cortex); 
STR (striatum); CER (cerebellum); WT (wild type); TG (transgenic). 
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5.3.1.4.  HspB8 
  Finally, protein expression of HspB8 within the frontal cortex, striatum and the 
cerebellum was quantified using western blotting at early (4wks) and mid stage (9wks) of 
the disease (Figure 5.4).  Again, representative western blots are shown below each graph.  
A decrease in HspB8 protein expression was observed at 4 weeks in the striatum, whereas 
the frontal cortex and cerebellum did not show any changes (Figure 5.4 A). There were no 
significant differences between wt and tg animals in any of the brain regions analysed at 9 
weeks (Figure 5.4 B).  HspB8 also showed statistically higher levels of expression in the 




















Figure 5.4. HspB8 protein expression in supernatant fractions at early (4wk) and mid 
(9wk) stage of disease.  40 g of protein from frontal cortex, striatum and cerebellum 
homogenates were resolved by SDS PAGE and expression of HspB8 was measured by 
incubating membranes with an antibody against HspB8 followed by a fluorescently 
labelled secondary antibody which was detected by infrared fluorescence.  Intensity values 
were measured using Odyssey Infrared Scanner software and normalized to protein loading 
and expressed as pixel intensity per mm
2.  Expression of HspB8 is shown in distinct brain 
regions at A, 4 and B, 9 weeks.  (A) HspB8 protein levels were decreased in tg animals in 
the striatum at 4 weeks.  (B) There was no change in HspB8 expression at 9 weeks in the 
three brain regions analysed.  Representative blots are shown below corresponding graph 
(n = 6).  One way analysis of variance (ANOVA), followed by Newman Keuls post hoc 
test was used to determine significance between wt and tg samples within regions and 
between brain regions (*p, <0.05; **p, <0.01; ***p, <0.001), error bars represent SEM. FC 
(frontal cortex); STR (striatum); CER (cerebellum); WT (wild type); TG (transgenic). 
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5.3.2.  sHsp expression at mid (9wk) and late (17wk) stages of disease  
  The samples analysed in section 5.3.1 were detergent (NP 40) extracted supernatant 
fractions and as established in section 3.3.2.2 the sHsps show differential detergent 
extractabilities in synaptosomal fractions.  It was likely that the protein levels of the sHsps 
in these samples were not representative of the total protein levels, especially as HspB6 did 
not produce any immunoreactivity in some samples.  The sHsps did indeed partition 
differentially in NP 40 extracted brain homogenates such that the extracted protein was not 
representative of total protein (see section 2.3.5 for method and Appendix 3).  To 
determine changes in total levels of sHsps, tissue from the cortex, striatum and cerebellum 
was microdissected from R6/2 tg animals and age matched wt littermates and  
homogenized to produce a fraction representative of total brain protein (section 2.3.3).  
Tissue was only available from mid (9 weeks) and late (17 weeks) stages of disease. 
  40 g of the total homogenate samples from the cortex, striatum and the cerebellum were 
resolved on SDS PAGE and western blotting was used to analyze expression of the sHsps.  
GFAP and MBP expression was also analysed to investigate astrogliosis and expression of 
a marker protein of the white matter. The average intensity of the bands was plotted for the 
three brain regions and the intensity values were normalized to protein loading (section 
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5.3.2.1.  HspB1 
  HspB1 did not show any significant difference in expression in the cortex and the 
striatum at 9 weeks, although the cerebellum shows significantly higher levels of HspB1 in 
tg animals (Figure 5.5 A).  At 17 weeks there were no significant differences in expression 





















Figure 5.5. HspB1 protein expression at mid (9wk) and late (17wk) stage of disease. 
40 g of protein from frontal cortex, striatum and cerebellum homogenates were resolved 
by SDS PAGE and expression of HspB1 was measured by incubating membranes with an 
antibody against HspB1 followed by a fluorescently labelled secondary antibody which 
was detected by infrared fluorescence.  Intensity values were measured using Odyssey 
Infrared Scanner software and normalized to protein loading and expressed as pixel 
intensity per mm
2.  Expression of HspB1 is shown in distinct brain regions at A, 9 and B, 
17 weeks. (A) No changes in HspB1 expression were observed in tg animals in the frontal 
cortex and striatum at 9 weeks.  However HspB1 was up regulated in the cerebellum of tg 
animal.  (B) There were no changes in HspB1 expression at 17 weeks in tg animals in the 
three brain regions analysed.  Representative blots are shown below corresponding graph 
(9 wks, n = 3; 17 wks, n = 4).  One way analysis of variance (ANOVA), followed by 
Newman Keuls post hoc test was used to determine significance between wt and tg 
samples within regions and between brain regions (**p, <0.01), error bars represent SEM.  
FC (frontal cortex); STR (striatum); CER (cerebellum); WT (wild type); TG (transgenic). 
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5.3.2.2.  HspB5  
  HspB5 showed a very similar expression profile to that seen in Figure 5.2.  There was a 
clear and significant downregulation of HspB5 in tg animals in all three brain regions at 9 
weeks.  This downregulation was statistically significant in the striatum and the cerebellum 
(Figure 5.6 A).  This observation was more pronounced at 17 weeks and was statistically 
significant in all three brain regions analysed (Figure 5.6 B).  HspB5 showed statistically 
higher levels of expression in the cerebellum and striatum of wt animals relative to the 



















Figure 5.6. HspB5 protein expression at mid (9wk) and late (17wk) stage of disease. 
40 g of protein from frontal cortex, striatum and cerebellum homogenates were resolved 
by SDS PAGE and expression of HspB5 was measured by incubating membranes with an 
antibody against HspB5 followed by a fluorescently labelled secondary antibody which 
was detected by infrared fluorescence.  Intensity values were measured using Odyssey 
Infrared Scanner software and normalized to protein loading and expressed as pixel 
intensity per mm
2.  Expression of HspB5 is shown in distinct brain regions at A, 9 and B, 
17 weeks.  (A) The amount of HspB5 protein expression decreased in tg animals in all 
three brain regions at 9 weeks.  This was statistically significant in the striatum and 
cerebellum.  (B) HspB5 protein expression was also significantly decreased in tg animals 
in all three brain regions at 17 weeks.  Representative blots are shown below 
corresponding graph (9 wks, n = 3; 17 wks, n = 4).  One way analysis of variance 
(ANOVA), followed by Newman Keuls post hoc test was used to determine significance 
between wt and tg samples within regions and between brain regions (*p, <0.05; **p, 
<0.01; ***p, <0.001), error bars represent SEM. FC (frontal cortex); STR (striatum); CER 
(cerebellum); WT (wild type); TG (transgenic). 
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5.3.2.3.  HspB6  
  There were no significant differences in HspB6 expression between wt and tg animals in 
the three brain regions at both 9 and 17 weeks (Figure 5.7).  However, HspB6 showed 
statistically higher levels of expression in the cerebellum and striatum of wt animals 
relative to the frontal cortex at 9 weeks (Figure 5.7), similar to HspB5 (Figure 5.6) and 
MBP (Figure 5.17), potentially reflecting the white matter expression of this sHsp as 
described in chapter 3.  Additionally, in these total homogenate samples all brain regions 
showed HspB6 immunoreactivity in contrast to the detergent extracted supernatant 
samples as shown in Figure 5.3.  The presence of three HspB6 isoforms and their 
specificity by pre absorption with antigen was previously established in Chapter 3 (Figure 
3.11).  However a fourth band was distinguishable as shown by the asterisks (Figure 5.7 
B).  The relatively similar electrophoretic motilities of the fourth band and the 18kDa 
isoform makes it very difficult to separate both in samples with high levels of HspB6, 
however in samples were there is less HspB6 such as the frontal cortex, the fourth band is 
better visible.  The presence of four isoforms is in keeping with the literature as four 
isoforms (three phosphorylated and one not) have been identified in bovine heart (Beall et 



























Figure 5.7. HspB6 protein expression at mid (9wk) and late (17wk) stage of disease.  
40 g of protein from frontal cortex, striatum and cerebellum homogenates were resolved 
by SDS PAGE and expression of HspB6 was measured by incubating membranes with an 
antibody against HspB6 followed by a fluorescently labelled secondary antibody which 
was detected by infrared fluorescence.  Intensity values were measured using Odyssey 
Infrared Scanner software and normalized to protein loading and expressed as pixel 
intensity per mm
2.  Expression of HspB6 is shown in distinct brain regions at A, 9 and B, 
17 weeks.  (A) No changes in HspB6 expression were observed in tg animals in the three 
brain regions at 9 weeks.  (B) There were also no changes in HspB6 expression in tg 
animals in the three brain regions analyzed at 17 weeks. Representative blots are shown 
below the corresponding graph (9 wks, n = 3; 17 wks, n = 4). One way analysis of variance 
(ANOVA), followed by Newman Keuls post hoc test was used to determine significance 
between wt and tg samples within regions and between brain regions (*p, <0.05; **p, 
<0.01), error bars represent SEM. FC (frontal cortex); STR (striatum); CER (cerebellum); 
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5.3.2.4.  HspB8 
  HspB8 did not show any significant differences in expression between wt and tg animals 
in the three brain regions at both time points (Figure 5.8).  The profile seen in total 
homogenate samples is very similar to that seen in supernatant fraction as described earlier 
in the chapter with higher expression in the cerebellum compared to the frontal cortex and 





















Figure 5.8. HspB8 protein expression at mid (9wk) and late (17wk) stage of disease. 
40 g of protein from frontal cortex, striatum and cerebellum homogenates were resolved 
by SDS PAGE and expression of HspB8 was measured by incubating membranes with an 
antibody against HspB8 followed by a fluorescently labelled secondary antibody which 
was detected by infrared fluorescence.  Intensity values were measured using Odyssey 
Infrared Scanner software and normalized to protein loading and expressed as pixel 
intensity per mm
2.  Expression of HspB8 is shown in distinct brain regions at A, 9 and B, 
17 weeks.  (A) No changes in HspB8 expression were observed in tg animals in the three 
brain regions at 9 weeks.  (B) There were also no changes in HspB8 expression in tg 
animals in the three brain regions analyzed at 17 weeks.  Representative blots are shown 
below corresponding graph (9wk, n = 3; 17wks, n = 4).  One way analysis of variance 
(ANOVA), followed by Newman Keuls post hoc test was used to determine significance 
between wt and tg samples within regions and between brain regions (*p, <0.05; **p, 
<0.01; *p, <0.001), error bars represent SEM. FC (frontal cortex); STR (striatum); CER 
(cerebellum); WT (wild type); TG (transgenic). 
 
 
A  B 
*** 
***  0.09 
   *   175 
5.3.3.  Summary of sHsp protein expression in HD (R6/2 mouse model) 
  The protein data obtained for the sHsps in detergent (NP 40) extracted supernatant 
fractions (time points in italics) and non detergent extracted total homogenate samples 
(time points in bold) in the frontal cortex, striatum and the cerebellum are summarized in 
Table 3.1.  HspB1 did not show any changes in expression in tg animals in any of the brain 
regions and time points, apart from an up regulation in total homogenate samples of the 
cerebellum at 9 weeks.  A similar change in expression was not observed in detergent 
extracted supernatant samples.  HspB5 was significantly downregulated in all three brain 
regions at all time points analysed apart from the frontal cortex and cerebellum in 4 week 
supernatant fractions.  HspB6 did not show any changes in expression in tg animals in any 
of the brain regions and time points.  HspB8 did not show any changes in expression in tg 
animals in any of the brain regions and time points, apart from a downregulation in 
supernatant samples of the striatum at 4 weeks, suggesting compartment shifting. 
 
 
Frontal cortex  Striatum  Cerebellum   
4wk  9wk  9wk  17wk  4wk  9wk  9wk  17wk  4wk  9wk  9wk  17wk 
HspB1  -  -        -  -        -  -      
HspB5  -                -       
HspB6  /  -        -  -        -  /       
HspB8  -  -          -        -  -       
 
Table 5.1. Summary of sHsp expression at early (4wk) mid (9wk) and late (17wk) 
stages of disease.  HspB1 shows protein up regulation in homogenate samples of the 
cerebellum at 9wks.  HspB5 displays decrease in protein expression in all regions 
analysed, at all time points.  This downregulation suggests a global change in expression of 
this sHsp.  HspB6 does not show any changes in expression.  HspB8 shows protein 
downregulation in supernatant fractions of the striatum at 4wks.  This highlights the 
selective downregulation of HspB5, a white matter specific sHsp, in R6/2 tg animals.  
(Time points in: italics = detergent extracted supernatant fractions; bold = non detergent  




  sHsp data from the two extraction protocols summarized in Table 5.1 highlight the 
selective downregulation of HspB5.  The HspB5 data was plotted as a percentage of wild 
type control samples from each brain region and time point.  The collective data displays 
not only a selective downregulation of this sHsp in all brain regions analysed, but also   176 
shows a progressive downregulation over time, particularly in the cerebellum (Figure 5.9).  













Figure 5.9. HspB5 expression at early (4wk), mid (9wk) and late (17wk) stages of 
disease.  HspB5 immunoreactivity in tg animals was plotted as a percentage of age 
matched wt samples (100%) from the corresponding brain region.  HspB5 shows a 
decrease in protein expression in all regions analysed, most progressively in the 
cerebellum.  Error bars represent SEM. S (supernatant fraction); H (homogenate sample) 
FC (frontal cortex); STR (striatum); CER (cerebellum). 
 
5.3.4.  Dot blot analysis of HspB5 on late stage striatal samples 
  To ascertain if the selective and progressive downregulation of HspB5 was due to an 
association or sequestration of HspB5 with aggregated protein as suggested for other 
molecular chaperones (Stenoien et al., 1999, Wyttenbach et al., 2000, Hay et al., 2004), a 
dot blot or filter trap protocol was used (section 2.9).  This method allows aggregated 
proteins or proteins associated with aggregates to be trapped on the surface of a 
nitrocellulose acetate membrane.  As the most significant changes in HspB5 
downregulation were observed at late stage in the disease, 17 week striatal homogenate 
samples were used in the dot blot assay.  40 g and 20 g of 17 week striatal homogenates 
from tg and wt animals were filtered through the membranes.  The potential presence of   177 
HspB5 in htt exon1 positive aggregates was determined by detecting a signal by enhanced 
chemiluminescence (ECL).  Htt exon1 showed immunoreactivity as measured by ECL in 
samples from tg animals as expected (Figure 5.10 A).  Additionally, immunoreactivity was 
absent in wt samples as these did not express htt exon1.  HspB5 did not show any 
immunoreactivity in material trapped on the nitrocellulose from the tg homogenate 
samples (Figure 5.10 B).  In order to confirm that the dot blot protocol had worked, and 
that this membrane did contain aggregated proteins, an anti ubiquitin antibody was used as 
a positive control to re probe the same membrane, as the aggregates are normally 
ubiquitinated (Meade et al., 2002).  As expected ubiquitin immunoreactivity was present in 












Figure 5.10. Dot blot analysis of HspB5 on late stage striatal samples 
40 g and 20 g of 17 week striatal homogenates were passed through nitrocellulose acetate 
membranes.  Immunoreactivity against HspB5, htt exon1 and ubiquitin was measured by 
ECL. 1, 2, and 3 represent samples from different animals.  Samples were loaded as 
duplicates (top row) and one subsequent dilution was loaded below.  Samples from wt 
animals were loaded in the same manner as tg animals.  (A) Tg samples containing 
aggregates were immunopositive for Htt exon1 using the S830 antibody.  As expected, 
immunoreactivity was not present in samples from wt animals.  (B) HspB5 did not show 
any immunoreactivity on the nitrocellulose membrane.  (C) The HspB5 membrane was re 
probed with an ubiquitin antibody.  As expected, ubiquitin immunoreactivity was observed 
in tg animals but not in wt animals, confirming the presence of aggregates captured on this 
membrane.  
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5.3.5.  R6/2 brain and synaptosomal fractions 
  The above observation indicates that the loss of HspB5 which we have characterized as 
being selectively expressed in white matter is not a consequence of incorporation or 
association with mtHtt aggregates.  To determine where the disease related changes in 
HspB5 expression were occurring, total brain homogenate and synaptosomal fractions 
(section 2.10) from R6/2 tg and wt littermates were used to investigate expression of 
HspB5 in different brain compartments (Figure 5.11 A).  These fractions as also described 
in chapter 3, consist of total homogenate, P1 pellet containing cell body/nuclei, myelin and 
synaptosome fractions.  Additionally the synaptosomal fraction is further sub fractionated 
allowing the distinct synaptic compartments to be teased apart.  The pH6 insoluble fraction 
represents paired pre  and post synaptic densities and the soluble fraction represents 
plasma membrane proteins.  The pH8 insoluble fraction enriches for the PSD and the 
soluble fraction for the presynaptic compartment.  The white matter (myelin) enrichment 
of this sHsp as previously determined (Figure 3.13) suggests the selective downregulation 
of HspB5 is also occurring in the white matter.  Indeed HspB5 expression showed the 
greatest reduction (5 fold) in the myelin fraction consistent with its association with the 
white matter (Figure 5.11 A).   
  The distribution and disease related changes of endogenous full length htt protein and 
Exon1 fragments were next analysed to investigate if there was any overlap with HspB5 
expression.  Htt displayed immunoreactivity in all brain compartments tested, but was 
predominantly present in the synaptosomal compartment (Figure 5.11 B).  It displayed a 
predominantly pre synaptic profile in the synaptosome sub compartments, as it was 
present in both the insoluble and soluble fractions at pH6 and the majority of the protein 
appeared solubilised at pH8 (Figure 5.11 B).  Although there was a trend towards 
decreased levels of htt in tg animals compared to wt animals in the synaptosomal 
compartment and sub compartments, this was not statistically significant (n = 4).  
  Wild type animals did not show immunoreactivity against exon1 as expected (data not 
shown), whereas tg animals showed enrichment of exon 1 in the cell body/nuclei 
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5.3.6.  Ubiquitinated inclusions in HD tissue 
  The previous observations illustrate selective HspB5 downregulation in the white matter 
which is not associated with incorporation into aggregates.  Brain fractions also show a 
relative lack of Exon1 immunoreactivity in the myelin compartment.  However, inclusions 
have been demonstrated in glial cells in R6/2 animals (Shin et al., 2005).  To investigate if 
inclusions were present in non neuronal cells with a particular focus in the white matter, 
the presence of inclusion bodies was analysed immunohistochemically (section 2.11) in wt 
and tg animals using an anti ubiquitin antibody, as ubiquitinated proteins are a feature of 
inclusions as also demonstrated by dot blot analysis (Figure 5.10).  Wt animals did not 
show any inclusion bodies in the sections analysed (Figure 5.12 Ai and ii).  Tg animals 
contained ubiquitinated inclusion bodies in neuronal cell bodies as observed in the CA1 
cell body layer (Figure 5.12 Bii).  Cytoplasmic inclusions were also present in the 
surrounding neurophil (Figure 5.12 Bi and ii).  Upon close inspection of white matter brain 
structures in tg animals, cells were identified that contained ubiquitin positive inclusions. 
Due to the location of these cells in the white matter and being present in tandem arrays, 
they were likely to be oligodendrocytes.  The inclusions were smaller and showed less 
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5.3.7.  Immunohistochemical analysis of HspB5 expression 
   Homogenate samples from R6/2 tg animals showed a selective downregulation of the 
white matter specific HspB5 protein (Table 5.1).  To confirm this finding and provide 
detailed anatomical information, tissue sections from wt and tg animals were prepared and 
processed as detailed in section 2.11 for immunohistochemical analysis. Coronal tissue 
sections between 0.86mm and 0.26mm relative to Bregma were used to analyse expression 
in the striatum and cortex.  Sections between  1.58mm and  2.06mm relative to Bregma 
were used to analyse expression in the hippocampus and corpus callosum.  Sections 
between  5.80mm and  6.24mm relative to Bregma were used to analyse expression in the 
cerebellum.  All tissue sections from tg and wt animals were processed in parallel and 
developed in DAB solution for the identical length of time. 
  Staining in the striatum, cortex, cerebellum and corpus callosum was analysed (Figure 
5.13).  Wt animals displayed a darker staining pattern in all brain regions (Figure 5.13 A) 
in comparison to tg animals (Figure 5.13 B).  In all sections analysed, staining of the cell 
bodies was similar in both wt and tg animals.  
  Sections containing cortex and striatum displayed a reduction in staining of the cortex, 
external capsule (white matter tract) and fiber bundles in the striatum of tg animals (Figure 
5.13 B i) in comparison to wt animals (Figure 5.13 A i).  Higher magnification images of 
the striatum showed the presence of white matter fiber bundles in both wt and tg animals, 
but staining in tg animals was fainter, indicating a reduction of HspB5 protein (Figure 5.13 
B ii) in comparison to wt animals (Figure 5.13 A ii).  HspB5 staining in the cerebellum 
also displayed a similar reduction in immunoreactivity in tg animals (Figure 5.13 B iii).  
Staining was observed between the cell bodies of the granule cell layer and was more 
pronounced in the white matter layer of the cerebella lobule (Figure 5.13 A iii).  The 
corpus callosum also showed a reduction of HspB5 protein expression in the fiber tracts of 
tg animals (Figure 5.13 B iv).  Staining of oligodendrocyte cell bodies did not appear 
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5.3.8.  Expression of HspB5 and CNP by immunofluorescence 
  We previously showed co localisation of HspB5 with another white matter specific 
protein CNP which is selectively expressed in the non compact myelin compartment 
(Chapter 3).  To investigate if the changes in expression were selective to HspB5 or if they 
were also apparent in another white matter protein expressed in the same myelin 
compartment (non compact), double immunofluorescence labelling was used to analyse 
the expression of HspB5 and CNP in the same tissue sections. Tissue from tg and wt 
animals were processed and imaged in parallel.  All microscopy settings were kept the 
same between wt and tg animals on equivalent sections and magnifications (section 2.14). 
  Staining in the cortex, striatum, corpus callosum and cerebellum was analysed.  HspB5 
staining was reduced in tg animals in all regions analysed (Figure 5.14 Bi/Di and 5.15 
Bi/Di) as also described above (Figure 5.13).  CNP staining in the same tg sections (Figure 
5.14 B/Dii and 5.15 B/Dii) did not show any changes in expression in comparison to wt 
animals (Figure 5.14 Aii/Cii and 5.15 Aii/Cii).     
5.3.9.  HspB5 expression in oligodendrocyte cell bodies (cell count)   
  Oligodendrocyte cell body staining was apparent and appeared not different between wt 
and tg animals.  To determine the number of HspB5/CNP positive cells, hippocampal 
sections were analysed as this brain region allowed HspB5/CNP positive cell bodies to be 
clearly distinguished amongst the myelinated processes (Chapter 4).  Myelinated tracts 
such as the corpus callosum were not analysed as CNP cell body staining was masked 
among intense fiber tract staining.  The number of CNP/HspB5 positive cells with DAPI 
staining were manually counted under x20 magnification in the CA1, CA3 and dentate 
gyrus of the hippocampus in four animals (Figure 5.16 A) (section 2.14.3).  There were no 
statistically significant differences between HspB5/CNP positive cell bodies in wt and tg 
animals in any of the hippocampal regions (Figure 5.16 B) suggesting reduction of HspB5 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.16. HspB5/CNP positive cells count in tg and wt animals.  Coronal brain sections from late stage 
(17 weeks) wt and tg animals from the dorsal hippocampus were analysed for CNP positive cell bodies that 
were also HspB5 positive.  (A) A representative example of how cell counting was conducted is shown from 
the DG.  Cell bodies that were distinguishable as CNP positive were highlighted with a circle using software 
tools in Leica Application Suite Advanced Fluorescence software.  The position of circles was automatically 
transferred to the equivalent images showing HspB5 immunofluorescence, DAPI stain and an overlay of all 
the images.  (B) Cell bodies were counted in the CA1, CA3 and the DG.  There were no statistically 
significant differences between wt and tg animals in the hippocampus.  (n = 4 animals (3 fields per animals: 
CA1/CA3/DG)). 
A 
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 5.3.10.  White matter changes in R6/2 tissue  
5.3.10.1.  MBP expression in brain homogenate samples 
  Although HspB5 was downregulated in the white matter of tg animals, no changes in the 
staining of the non compact myelin protein CNP were observed in the same tissue.  This 
suggested that the decrease of HspB5 in non compact myelin was selective and likely not a 
consequence of general changes in the non compact myelin compartment.  To investigate 
if the compact myelin compartment was affected during disease, myelin basic protein 
(MBP) expression was investigated in wt and tg animals.  MBP did not show any 
significant changes in protein expression at 9 weeks or 17 weeks in the three brain regions 
analysed (Figure 5.17). 
5.3.10.2.  MBP expression in R6/2 tissue sections 
 MBP expression is restricted to the processes by virtue of selective targeting of protein 
and/or local translation of targeted RNA (Barbarese et al., 1995), accordingly the 
biochemical investigation described above was extended and MBP immunoreactivity 
analysed in tissue sections.  MBP displayed intense staining of the external capsule with 
white matter fibers extending into the cortex.  Fiber bundles in the striatum were also 
immunopositive for MBP (Figure 5.18 A i).  Higher magnification image of the striatum 
showed intense MBP expression in fiber bundles as well as fine myelinated processes 
forming a meshwork throughout the striatum (Figure 5.18 A ii).  Staining in the cerebellum 
was observed in the white matter layer of the cerebella lobule as well as some fine staining 
emanating into and between the cell bodies of the granule cell layer (Figure 5.18 A iii).  A 
clear difference in MBP immunoreactivity between wt and tg animals was not apparent in 
any of the brain regions analysed (Figure 5.18 B).  However quantification of the staining 
























Figure 5.17. MBP expression at mid and late stage of disease. 
40 g of protein from the frontal cortex, striatum and the cerebellum were resolved by 
SDS PAGE and expression of MBP was detected by infrared fluorescence.  Intensity 
values (pixels/ mm
2) were measured by Odyssey Infrared Scanner software.  (A) No 
changes in MBP expression were observed in tg animals in the three brain regions at 9 
weeks.  (B) There were also no changes in MBP expression in tg animals in the three brain 
regions analyzed at 17 weeks. Representative blots are shown below corresponding graph 
(9wk, n = 3; 17wks, n = 4).  Student’s t test was used to determine significance (p, <0.05), 
error bars represent SEM. FC (frontal cortex); STR (striatum); CER (cerebellum); WT 













































Figure 5.18. Immunohistochemical analysis of MBP in R6/2 tissue.  Coronal brain sections from wt and 
tg animals were subjected to immunohistochemistry for detection of MBP immunoreactivity.  No obvious 
changes in intensity as judged by relative staining or distribution of MBP were observed in tg animals (B) 
compared to wt (A) animals.  (A) (i) MBP immunoreactivity was observed in the cortex, ec and striatum 
(CPu).  (ii) Staining in the CPu was localized to white matter rich fiber bundles along with white matter 
processes forming a fine meshwork throughout the CPu.  (iii) Immunoreactivity in the cerebellum was 
localized mainly to the wml with some processes extending into the granular cell layer.  (B) (i) MBP 
immunoreactivity did not appear different in the cortex and ec of tg animals.  (ii) MBP expression in the fiber 
bundles of the CPu did not show an obvious difference in staining.  (iii) Staining of the cerebellum of tg 
animals appeared consistent with staining in wt animals.  Images are representative of staining from 4 
animals.  External capsule (ec), caudate putmen (CPu), molecular layer (ml), granular layer (gl), white matter 




5.3.10.3.  Luxol fast blue staining in R6/2 tissue  
  Although there were no clear changes in CNP and MBP expression and/or staining, 
indicating other myelin specific proteins were not affected in R6/2 tg animals, to observe 
myelination in wt and tg animals, brain sections were analysed by Luxol fast blue (LFB) 
staining (Section 2.12).  Tissue from tg and wt animals was processed in parallel.  LFB 
showed staining of the corpus callosum and cingulate gyrus (Figure 5.19 A i).  White 
matter fiber bundles were stained by luxol fast blue in the striatum (Figure 5.19 A ii),   191 
staining of the white matter layer of the cerebellum with some staining in the granular 
layer (Figure 5.19 A iii).  All white matter tracts were stained in both wt and tg animals.  
On a qualitative level, tg animals appeared to have lighter LFB staining compared to wt 
animals (Figure 5.19 B) however a difference in all animals could not be conclusively 
established.  As suggested for MBP staining, quantification of the LFB staining would 






























Figure 5.19. Luxol fast blue (LFB) staining in R6/2 tissue.  Coronal brain sections from late stage (17 
weeks) wt and tg animals were subjected to LFB staining for detection of white matter.  All white matter 
structures were stained with LFB and no conclusive changes in the white matter of tg animals (B) compared 
to wt animals (A) were observed.  (A) (i) The cc and cg were intensely stained by LFB. (ii) Staining in the 
CPu was localized to white matter rich fiber bundles.  (iii) Staining in the cerebellum was localized mainly to 
the wml with some staining extending into the granular cell layer.  (B) (i) There were no clear changes in the 
white matter structures of the cc and cg in tg animals.  (ii) Staining of fiber bundles of the CPu did not appear 
different.  (iii) White matter staining did not appear different in the cerebellum of tg animals.  Images are 
representative of staining from 4 animals (17 weeks).  Granular layer (gl), white matter layer (wml), caudate 
putmen (CPu), corpus callosum (cc), cingulated gyrus (cg). Scale bar, 50 m.   192 
5.3.11. GFAP expression in R6/2 HD tissue  
5.3.11.1.  Limited GFAP expression changes in brain homogenate samples 
  Induction of the sHsps was not observed in this disease context; however sHsp up 
regulation in a number of neurodegenerative diseases has been associated with expression 
in astrocytes and astrogliosis, as describe in the general introduction (section 1.6.2.2).  In 
order to investigate the level of astrogliosis in R6/2 animals, and see if this correlated with 
a lack of sHsp induction, GFAP expression was investigated biochemically at mid (9 
weeks) and to late (17 weeks) stage of disease.  
  GFAP did not show any significant changes in protein expression at 9 weeks in the three 
brain regions (Figure 5.20 B).  At 17 weeks, tg animals showed an increase in GFAP 
expression in the frontal cortex, but there were no changes in expression in the striatum 


















Figure 5.20. GFAP expression at mid and late stage of disease.  40 g of protein from the frontal 
cortex, striatum and the cerebellum were resolved by SDS PAGE and expression of GFAP was 
detected by infrared fluorescence.  Intensity values (pixels/ mm
2) were measured by Odyssey 
Infrared Scanner software.  (A) No changes in GFAP expression were observed in tg animals in the 
three brain regions at 9 weeks.  (B) GFAP levels were increased in tg animals in the frontal cortex, 
but no changes were observed in the striatum and cerebellum at 17 weeks.  Representative blots are 
shown below corresponding graph (9wk, n = 3; 17wks, n = 4).  Differences in pixel intensity at 9 
and 17 weeks do not correspond to difference in protein levels between time points, but are 
reflective of differences in individual blots and normalization to protein loading.  Student’s t test 
was used to determine significance (*p, <0.05), error bars represent SEM. FC (frontal cortex); STR 
(striatum); CER (cerebellum); WT (wild type); TG (transgenic).  
B   193 
5.3.11.2.  GFAP expression in R6/2 tissue sections 
  GFAP expression analysis was extended by immunohistochemical analysis of late stage 
(17 week) tissue.  GFAP staining in wt animals was observed in the cortex and the external 
capsule (Figure 5.21 A i).  Astrocytes were present in the striatum and were mainly 
localized to the white matter fiber bundles (Figure 5.21 A ii).  GFAP positive cells were 
distributed throughout the corpus callosum and cingulate gyrus (Figure 5.21 A iii) as well 
the hippocampus (Figure 5.21 A iv).   GFAP immunoreactivity and astrocytic cell 
morphology in tg animals did not indicate a pronounced astrogliosis when compared to wt 
animals (Figure 5.21).  However, close examination of some sections, such as the striatum 
(Figure 5.21 B ii.) suggest a modest increase in the number of astrocytes.  In conjunction 
with up regulation of GFAP in the frontal cortex (Figure 5.20 B) this suggests the 
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5.3.12. mRNA expression of HspB5 is not decreased (QT PCR) 
  HspB5 downregulation in the white matter of tg animals was not due to sequestration into 
Htt Ex1 aggregates or due to overt changes in myelin structure and content.  Htt Ex1 is 
able to dysregulate many genes, raising the possibility of HspB5 being targeted in a similar 
way.  HspB5 gene expression was therefore investigated.  mRNA was extracted for QT 
PCR analysis from the cortex and cerebellum of tg and wt animals at 9 weeks of age and 
from the cortex, striatum and the cerebellum at 17 weeks (section 2.5).  HspB5 gene 
expression data was normalized to ATP5b expression.  ATP5B was determined to be a 
suitable housekeeping gene based on its expressional stability in different brain regions 
(Benn et al., 2008).  ATP5b primer specificity was confirmed by running 5 l of QT PCR 
product on an agarose gel.  A single band of the predicted size for cDNA amplification was 
observed (Figure 5.22 A).  HspB5 primer specificity had previously been established in 
Chapter 3.  HspB5 transcript levels did not change in the cortex and cerebellum at 9 weeks 
(Figure 5.22 B).  There were no changes in expression in the cortex, striatum and 
cerebellum of tg animals at 17 weeks (Figure 5.22 C).  The relative mRNA expression of 
HspB5 was consistent with high protein expression in the cerebellum (Figure 5.2/5.6) 
however this was not the case for the frontal cortex and striatum.  At the protein level, 
HspB5 showed higher expression in the striatum compared to the frontal cortex; however 






























Figure 5.22. mRNA expression of HspB5 in HD tissue at 9 and 17 weeks (QT PCR). 
Transcript analysis by QT PCR of HspB5 in the cortex, striatum and cerebellum of wt and 
R6/2 tg animals was conducted.  HspB5 data was normalised to ATP5b expression.  (A) 
ATP5b primer specificity was confirmed by the presence of a single band (lane 1) of the 
predicted size for cDNA amplification.  Negative control sample lacking cDNA template 
did not produce any bands (lane 2).  (B) There were no significant changes in tg animals 
compared to wt animals at 9 weeks in the frontal cortex and cerebellum.  (B) There were 
also no significant changes in tg animals compared to wt animals at 17 weeks in any of the 
three brain regions analysed.  (n = 5; Student’s t test was used to determine significance (p, 
<0.05), error bars represent SEM). 
 
 
5.4.  Discussion 
  The aim of this chapter was to investigate the expression of the four sHsps that have 
shown to be constitutively expressed in the mouse CNS under normal conditions (Chapter 
3), in a mouse model of chronic neurodegeneration.  The R6/2 mouse model of HD, 
characterized by intracellular protein aggregates (Morton et al., 2000, Meade et al., 2002) 
was used, and chosen tissue from specific brain regions at different time points were 
investigated to reflect the different stages in disease progression (Carter et al., 1999, 
Morton et al., 2000) and compare anatomically susceptible brain regions. 
  In addition to providing insight into when a change occurs, the use of time points 
associated with distinct phases of disease also allows some speculation into the possible 
relevance of the changes during pathogenesis (Freeman and Morton, 2004).    
A  B  C   L    1   2  
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5.4.1.  Changes in sHsp protein expression 
  Protein expression of HspB1, HspB5, HspB6 and HspB8 was analysed at early (4wk) and 
mid (9wk) stage of disease in detergent extracted tissue, and at mid (9wk) and late (17wk) 
stage in non detergent extracted homogenates.  The striking observation from these results 
was the selective downregulation of the white matter specific HspB5 in all regions and 
time points analysed (Table 5.1).  HspB5 loss was apparent at 4 weeks and showed a 
progressive almost 80% decline over the disease time course (Figure 5.12). The global 
changes in HspB5 expression suggest disease specific alterations that are brain region 
independent, but cell type (oligodendrocyte) specific.  Because the pixel intensity for each 
blot is normalized to protein loading, the relative differences between brain regions could 
also be compared.  The physiological (basal) levels of HspB5 in tissues of R6/2 wt animals 
appeared higher in the striatum and the cerebellum compared to the frontal cortex (Figure 
5.6).  This is indeed reflective of the higher levels of myelination in these regions 
compared to the frontal cortex, as shown by MBP expression (Figure 5.17) and is 
consistent with the white matter expression of HspB5 (see Chapter 4).  Additionally 
HspB8 consistently showed higher levels of protein expression in the cerebellum of wt 
animals compared to the frontal cortex and striatum.  Combined with the finding that 
HspB1 is induced at 9 weeks in the cerebellum it is possible that these sHsps contribute to 
the protection of the cerebellum from dysfunction in R6/2 animals (Mangiarini et al., 
1996).                 
  Interestingly, in a study comparing the gene expression profiles of 3 types of primary 
neurons expressing mutant htt or ataxin 1, it was found that Hsp70 protected neurons and 
was up regulated selectively in the granule cells of the cerebellum.  Insensitivity to 
degeneration of the cerebellum was lost by siRNA knockdown of Hsp70, whereas cortical 
neurons affected in human HD gained resistance by overexpressing Hsp70 (Tagawa et al., 
2007).  It was therefore concluded that Hsp70 levels are a critical factor for determining 
vulnerabilities to mutant htt among neuronal subtypes.  This lends support to the potential 
protective role of the sHsps in the cerebellum, potentially involved in protein folding 
processes associated with the larger ATP dependent Hsp70 and Hsp40. 
  HspB1 and HspB8 form heterogeneous oligomeric complexes under physiological 
conditions (Sun et al., 2004) and show a great deal of overlap and similarity in expression   198 
and cellular localization, as shown in Chapter 3.  MRNA expression of both HspB1 and 
HspB8 was shown to localize to a subpopulation of motor neurons in the spinal cord 
(Chapter 3).  HspB1 protein expression in other neuronal populations has also been 
extensively documented (Armstrong et al., 2001a), and given the overlapping expression 
of HspB8 with HspB1 suggests it is also expressed in similar cell types as HspB1.  HspB1 
expression in the cerebellum has allowed its use as a marker for Purkinje cells (Armstrong 
et al., 2009) and thus potentially places both of these sHsps in a suitable cell type to confer 
neuroprotection in the face of a pronounced white matter deficit which is likely to impinge 
on myelinated neuronal populations.  Indeed, HspB1 has been shown to be protective in 
mice containing a mutation in HspB5 (R120G) (Ito et al., 2003).  
  In addition to HspB5, HspB6 is also enriched in the white matter (Chapter 3).  However 
this sHsp does not show a change in expression levels in R6/2 compared to wt animals.  
Enrichment of both HspB5 and HspB6 in the white matter suggests important functions in 
this compartment.  In the case of HspB5, although these functions have not yet been 
determined a number of potential functions have been proposed, such as cytoskeleton 
stabilization and lipid raft mediated signalling, by virtue of localization to the non compact 
myelin in oligodendrocytes (Chapter 4).  The selective and early downregulation of HspB5 
suggests that the remaining protein may be directed towards general and essential 
functions such as maintaining myelin integrity and structure as shown for CNP (Yin et al., 
1997) thus other potential functions may be negatively affected.  If HspB5 is involved in 
signalling events by association with lipid rafts, the downregulation could have a direct 
impact on neuronal glia cross talk, and may be a potential mechanism for neuronal 
dysfunction as a consequence of early myelin/oligodendrocyte dysfunction.  Dysfunction 
could then be increased in regions such as the frontal cortex and striatum; with neuronal 
cells in these regions show more vulnerability (Sieradzan and Mann, 2001).  The above 
suggests white matter dysfunction may contribute to early pathological events in R6/2 
animals.  It would therefore be of interest to analyse HspB5 expression in detergent 
extracted pellet samples in conjunction with supernatant samples to investigate if, in 
addition to the downregulation, a shift in compartment is also observed.  
  Additionally, unpublished preliminary data from our lab has also demonstrated a trend 
toward lower levels of HspB5 in the R6/1 mouse model of HD.  Additionally preliminary   199 
analysis of human Vonsattel stage II brain tissue suggest variable expression of HspB5 in 
HD tissue compared to controls (see Appendix 4).  
5.4.2.  HspB5 is not sequestered into mtHtt aggregates 
  Downregulation of a number of molecular chaperones (Hdj1, Hdj2, Hsp70, α SGT (small
 
glutamine rich tetratricopeptide repeat containing proteins) and β SGT) has previously 
been reported in the brains of R6/2 animals (Hay et al., 2004).  Some of these chaperones, 
including Hsp70 were found to co localise with intra nuclear polyQ aggregates despite 
their predominately cytosolic localisation.  The downregulation was proposed to occur via 
post translational mechanisms, inducing sequestration into Htt Ex1 aggregates or an 
increase in protein turn over (Hay et al., 2004).  This suggested the possibility that HspB5 
was also being modulated by similar mechanisms in particular an association with 
aggregates as it was previously shown that sHsps promote removal of protein aggregates 
by incorporating into insoluble protein complexes and, with the assistance of large ATP 
dependent molecular chaperones such as Hsp100, promote refolding of substrates from 
such insoluble complexes (Haslbeck et al., 2005, Jiao et al., 2005).   
  However, dot blot analysis showed that HspB5 was not redistributed into the SDS 
insoluble htt aggregates (Figure 5.10).  Nevertheless it appears that the downregulation 
was selective to the myelin compartment as determined in brain fractions, with an 
approximately 5 fold reduction in tg animals compared to wt animals (Figure 5.11 A).  
Although HspB5 did not associate with SDS insoluble Htt aggregates as determined by dot 
blot analysis, the distribution of endogenous htt protein and htt Ex1 were investigated in 
brain and synaptosome sub compartments to determine if these proteins were present in 
the same compartments as HspB5 as it would suggest that their interaction could contribute 
to the down regulation of HspB5, by the toxic loss of function of Htt and/or indeed gain of 
function of mtHtt.  The distribution of htt and htt Ex1 were very different to HspB5.  Htt 
was mainly associated with the synaptosomal compartment and displayed a presynaptic 
protein profile, although our observations also support both a pre and post synaptic 
localization.  This was consistent with its global expression and also its association with 
the presynaptic compartment shown previously (DiFiglia et al., 1995, Wood et al., 1996).  
However, some immunoreactivity was present the myelin fraction.  Htt Ex1 was enriched   200 
in the P1 pellet, consistent with an intra nuclear presence; though it did not show 
immunoreactivity in the myelin fraction, supporting the lack of association of HspB5 with 
htt aggregates.  It is therefore unlikely that HspB5 directly interacts with htt Ex1 and 
affects its misfolding and aggregation.  This is also suggested by experiments performed 
by A. Wyttenbach and A. J. Morton who did not find co localisation of HspB5 with htt 
Ex1 inclusion bodies in R6/2 tg animals (A. Wyttenbach, personal communication). 
  The localization of inclusion bodies in tissue sections was investigated with an anti 
ubiquitin antibody.  In addition to intra nuclear and cytoplasmic inclusions in neuronal 
cells of tg animals, some inclusion bodies in the white matter (cc) of tg animals were 
observed under high magnification.  The immuno positive cells were likely 
oligodendrocytes as they were part of a chain of cells forming tandem arrays, which typify 
these cells in the white matter.  The inclusions present were small in comparison to 
neuronal inclusions in the same tissue.  In a study by Shin et al. immunogold labelling of 
aggregates revealed nuclear htt aggregates in glial cells that were smaller than neuronal 
nuclear inclusions (Shin et al., 2005), consistent with our own observations at the light 
microscopic level.  The ubiquitous expression of the Exon1 transgene in different brain 
regions (Mangiarini et al., 1996), indicates that the relative expression is likely similar in 
different cell types.  The minor amount of inclusions in the white matter is therefore 
indicative of the intrinsic protection of this compartment against inclusion body formation.   
   Shin et al. (2005) also reported that only a few glial cells contained inclusions in R6/2 
animals; however this increased with age and also correlated with disease progression.  
Indeed, wt glial cells were reported to protect neurons against mtHtt mediated toxicity in a 
co culture system, whereas glia expressing mtHtt increased neuronal vulnerability (Shin et 
al., 2005).  Transgenic mice generated to express mtHtt in astrocytes were shown to 
develop age dependent neurological phenotype, motor function deficits and died earlier 
than wt and control tg mice (Bradford et al., 2009) implying an important role for 
astrocytes in HD pathology.  
  In the R6/2 mouse model, intra nuclear inclusions and cytoplasmic aggregates are 
apparent at 4 weeks (Morton et al., 2000).  This appearance of aggregates coincides with 
the decrease in expression of HspB5 at 4 weeks.  As aggregate formation increases, HspB5 
expression decreases, as we have shown at 9 weeks and 17 weeks.  It may be speculated   201 
that changes in normal neuronal oligodendrocyte crosstalk (Simons and Trajkovic, 2006) 
could results in neuronal susceptibility to inclusion formation, or indeed the opposite may 
be the case whereby neuronal polyQ aggregation and inclusion formation impacts on 
oligodendrocyte function.  Human glioblastoma and neuroblastoma co cultures that were 
stably expressing mutant fALS SOD1 were shown to demonstrate functional cross talk by 
the production and molecular exchange of cytokines and subsequent induction of caspase 
pathways impacting on the function of both cell types (Ferri et al., 2004).  This theme of 
glia/neuron cross talk is increasingly established in many diseases (Marchetti et al., 2005, 
Rossi and Volterra, 2009). 
5.4.3.  White matter specific changes in HD  
  Involvement of the white matter in neurodegenerative disease is relatively understudied, 
despite indications that this compartment is affected in neurodegenerative diseases such as 
AD and PD (Duan et al., 2006).  White matter abnormalities are being increasingly 
reported and studied in HD patients.  A recent study examining changes in the corpus 
callosum (cc) by diffusion tensor imaging (DTI) revealed early microstructural changes 
indicative of white matter dysfunction, that occurred prior to measurable atrophy and more 
than a decade before onset of motor symptoms (Rosas et al., 2010).  The cc is the primary 
cortical projection system and connects the two hemispheres.  This study suggested a role 
for progressive white matter alterations for clinical symptoms to occur and a contribution 
to cognitive deficits by altered cortical circuitry (Rosas et al., 2010).  Alterations in the cc 
have been reported in a number of neuro psychiatric and neurological disorders including 
dementia (Stricker et al., 2009) and multiple sclerosis (MS) (Lowe et al., 2006) relating to 
altered cortical connectivity.  Early white matter changes in HD patients were found to 
correlate with early neurological dysfunction and appear to precede striatal cell loss (Sapp 
et al., 1997)(Sapp et al., 1997).  An increase in the number of degenerating myelinated 
fibers was observed in another study, although myelin thickness did not change (Wade et 
al., 2008)(Wade et al. 2008). 
   Additionally it has been reported that so called “normal appearing white matter” 
(NAWM) as detected by magnetic resonance imaging (MRI) in MS patients, is in fact 
abnormal when imaged by non conventional MRI techniques  (Moore et al., 2008).      202 
Increasing evidence for white matter damage and dysfunction is also observed in AD and 
has been correlated with cognitive decline (Duan et al., 2006).  The early changes in 
HspB5 suggest HspB5 may be a good indicator or marker for white matter dysfunction in 
HD and perhaps other proteinopathies that show changes in the white matter associated 
with pathology, as discussed in section 4.1.2. 
5.4.4.  Myelin sub compartment specific downregulation of HspB5  
  Immunohistochemical analysis also showed global downregulation of HspB5 in the white 
matter of tg animals.  Additionally the staining pattern suggested that HspB5 expression 
was selectively reduced in the white matter fiber tracts even relative to cell bodies.  As 
previously described in Chapter 4, HspB5 showed colocalisation with CNP a white matter 
specific protein selectively expressed in the non compact myelin subdomain.  We analysed 
expression of both proteins in the same tissue by double immunofluorescence to elucidate 
if HspB5 downregulation was due to a compartment effect.  If so, a difference in CNP 
immunofluorescence would also be observed in tg animals compared to wt.   
As expected, HspB5 showed reduced immunofluorescence staining in tg animals in all 
regions analysed.  However, CNP staining did not appear any different in tg compared to 
wt animals, supporting the specific down regulation of HspB5 relative to a more general 
change in the non compact myelin compartment.   
  Although there appeared to be no difference in HspB5 immunoreactivity in 
oligodendrocyte cell bodies of tg animals compared to wt, it was possible that the 
reduction in HspB5 expression was occurring as a result of a reduction in the number of 
oligodendrocytes.  HspB5/CNP double stained, positive cells were counted in the 
hippocampus, as myelination in this region is relatively sparse in comparison to heavily 
myelinated structures such as the cc, thus allowing cell bodies to be distinguished.  This 
analysis did not reveal any difference in CNP stained oligodendrocyte cell body number in 
tg animals compared to wt.  The downregulation of HspB5 could not be attributed to a 
reduction in the number of the cells producing this protein, but was therefore likely to be 
due to a reduction in the number of myelin fibers/sheaths expressing HspB5.  Although we 
did not observe any changes in the number of HspB5/CNP positive oligodendrocytes in the 
hippocampus, oligodendrocyte numbers have been shown to increase in HD in response to   203 
myelin breakdown and dysfunction.  No changes in CNP positive oligodendrocyte number 
in the hippocampus were observed, but increased numbers were observed in the striatum.  
The differences were correlated to when regions were myelinated in development, 
highlighting a susceptibility of regions myelinated early during development (striatum) 
(Bartzokis et al., 1999, Bartzokis et al., 2007).  This suggests that the lack of change in 
HspB5/CNP positive cell number in the hippocampus may not reflect changes in other 
regions.  We were unable to determine the number of HspB5/CNP positive cells in other 
brain regions due to masking of cell bodies by myelin fiber tracts. 
  MBP expression was also analysed to investigate whether other white matter proteins 
were altered.  MBP is a major white matter protein expressed in the compact myelin sub 
compartment (Maier et al., 2008).  Total protein and immunohistochemical analysis did not 
show any changes in tg animals compared to wt animals suggesting the compact myelin 
compartment was not affected.  However, although this indicates normal MBP content and 
distribution, abnormalities cannot be ruled out.  MBP is able to stain all myelinated 
structures in normal and multiple sclerosis tissue, however a rabbit antiserum (anti EP) that 
recognized the synthetic peptide QDENPVV, which corresponds to human MBP residues 
82 88 was shown to selectively immunostain abnormal appearing oligodendrocyte 
processes and cell bodies in areas associated with MS plaques and showed no 
immunoreactivity in normal tissue (Matsuo et al., 1997).  The use of such antisera would 
indicate pathological changes in the white matter that otherwise appear normal. 
  Luxol fast blue (LFB) is a lipid binding dye, and due to the large proportion of lipids and 
lipoproteins in myelin membranes, it is able to differentiate the gray matter from the white 
matter. This dye is routinely used to investigate myelin loss/changes in acute and chronic 
conditions such as ischemia, AD and MS (Gilmore et al., 2009, Ihara et al., 2010).  LFB 
staining did not detect any clear changes in white matter staining in tg animals, although 
there was an indication for lighter staining in tg animals.  However to tease apart subtle 
changes quantification of the staining intensities is required (Ihara et al., 2010).  
5.4.5.  Potential contribution of HspB5 to inflammation and gliosis 
  Gliosis is not a prominent feature in the R6/2 mouse model, but this observation may be a 
result of limited studies in this area (Schwab et al., 2009). There are occasional reports   204 
indicating gliosis (Reddy et al., 1998, Lin et al., 2001) in HD mouse models, but thorough 
studies are missing. The involvement of inflammation in HD had been documented 
showing increased activation of the complement system (a component of the innate 
immune system), microglial activity and up regulation of inflammatory cytokines (Sapp et 
al., 2001, Dalrymple et al., 2007).  In both HD patients and R6/2 mice expression of 
ferritin in microglia was reported to increase and microglial cells appeared dystrophic in 
that they had thick, twisted processes (Simmons et al., 2007).  More recently, a study 
analysing cytokine levels in plasma samples from HD mutation carriers showed increases 
in IL 6 in pre manifest HD carriers, and increased IL 6 and IL 8 expression in post 
mortem striatal tissue of HD patients.  In addition, IL 8, IL 4, IL 10, and TNF α levels 
were also significantly increased with disease progression (Bjorkqvist et al., 2008).  This 
study suggests the initial pro inflammatory cytokine production as a consequence of the 
innate immune response is strongly linked to disease progression.   
  HspB5 has been implicated in the immune response.  Loss of HspB5 (knockout) was 
shown to increase T cell and macrophage secretion of Th1 pro inflammatory cytokine 
production (IL 2, TNF α, IL 12) (Ousman et al., 2007).  It is plausible that a similar 
immune response as observed in human HD tissue and in HspB5 knockout mice could 
occur in R6/2 animals associated with the reduction of HspB5.  
  We investigated levels of the astrocytic protein GFAP, an indicator of gliosis and found 
no significant differences in GFAP expression at 9 weeks in the three brain regions 
analysed.  At 17 weeks there was a significant, but modest up regulation in the frontal 
cortex, but the striatum and the cerebellum did not show any changes.  The modest up 
regulation at late stage of disease suggests mild astrogliosis.  The limited gliosis observed 
may be a consequence of the lack of induction of the sHsps, as the sHsps have been shown 
to be expressed and up regulated in glial cells as part of an astrocytic response during 
neurodegenerative disease such as AD and Parkinson disease with dementia (PDD) 
(Renkawek et al., 1999).  It must also be noted that the R6/2 model may not show all the 
pathologic phenotypes associated with HD.  Several studies indicated that due to the fast 
and aggressive progression of polyQ pathology in this model, the CNS may compensate 
for the protein misfolding stress and even show resistance to external stress responses 
(Hansson et al., 2001a, Hansson et al., 2001b).  For example, the striatal neurons of R6/2   205 
mice that had been subjected to oxidative stress induced by dopamine, 6 
hydroxydopamine, or malonate were found to be more resistant to this insult in comparison 
to age matched wt littermates (Hansson et al., 2001a, Petersen et al., 2001). 
5.4.6.  Changes in sHsp mRNA expression  
  Changes in HspB5 expression could not be attributed to association with htt aggregates or 
overt changes in myelin, so mRNA analysis was conducted to determine if the down 
regulation was a consequence of transcriptional regulation.  The promoter region of HspB5 
contains a number of sites that bind transcription factors that have been shown to be 
sequestered by mutant htt, reducing transcription of the genes (Figure 5.23).  For example 
mtHtt can dissociate Sp1 from specific gene promoters, decreasing transcription of Sp1 
genes, but the overall levels of Sp1 do not change (Yu et al., 2002).  The disruption to gene 
expression by mtHtt is not general to all genes containing binding sites for affected 













Figure 5.23. Transcription factor binding sites in the promoter region of HspB5. 
The promoter of HspB5 contains binding sites for many transcription factors.  Each 
transcription factor responsive element is represented by an individual symbol in the 
correct relative location to the TATA box.  Transcription factor binding sites that are 
potentially affected by mtHtt are circled in blue (Adapted from (Mineva et al., 2005). 
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  HspB5 mRNA expression was normalized to ATP5B.  There were no changes in HspB5 
transcript levels in any of the brain regions analysed at mid and late stage of disease.  This 
confirmed that down regulation was not due to transcriptional changes and suggests that 
HspB5 gene expression is not dysregulated by mtHtt.  This leaves the possibility that the 
down regulation is a consequence of post transcriptional and/or translational 
modifications.   
  Additionally, polyQ aggregation is known to alter transport events (Sinadinos et al., 
2009).  However, limited inclusion formation in oligodendrocytes argues against this point 
as the mechanism for HspB5 downregulation, suggesting alternative mechanisms are at 
play.  Indeed, fast axonal transport is inhibited by nanomolar polyQ protein levels even 
when no aggregates are biochemically or microscopically detectable (Szebenyi et al., 
2003). 
  In Chapter 4, it was suggested that HspB5 mRNA was transported to myelinating 
processes in a similar fashion to MBP.  As it has been shown that mtHtt perturbs axonal 
transport in neurons (Morfini et al., 2005), and that such events can occur without the 
presence of aggregates, suggests this could also occur in oligodendrocytes as microtubule 
transport is an important process for targeting mRNA and proteins to the correct myelin 
compartments.  This raises the possibility of HspB5 mRNA being transcribed and 
packaged into granules, but not targeted to its correct destination and thus remaining in a 
repressed state. This could be determined by carrying out dipped in situ hybridization 
experiments on wt and tg tissue sections to see if there is a difference in mRNA 
localization and potentially a retention to the cell bodies (Medrano and Steward, 2001).  
Altered transport could therefore explain the reduction of HspB5 staining in the myelin 
fiber tracts. Mechanistic experiments using oligodendrocyte cell cultures models with/out 
polyQ expression could also be used to address this hypothesis. 
  It is also likely that HspB5 is in fact being translated, but that there is an increase in 
turnover and degradation of this protein due to altered signalling events.  Htt is localized to 
plasma membranes and has been described in lipid rafts.  Additionally mtHtt has also been 
shown to associate more readily with neuronal lipid rafts.  The critical role that lipid rafts 
have in cell signalling could mean that in HD there are multitudes of signalling changes 
emanating from lipid rafts that may alter cellular processes such as promoting turnover of   207 
proteins (Valencia et al., 2010). Yet another possibility emanates from the finding that htt 
has been associated with Ago2 (Argonaute) and is localized to P bodies (Savas et al., 
2008).  P bodies are a class of somatic cytoplasmic RNP's, termed cytoplasmic RNA 
processing bodies that contain non translated mRNAs and proteins involved in mRNA 
degradation and translational control (Barbee et al., 2006).  MtHtt may perturb mRNA 
processing/trafficking or post transcriptional regulation, or alterations in the normal 
function of htt may confer silencing or reduction of some genes at a translational level by 
associating with structures such as P bodies. 
  Transient decreases of HspB5 have been reported in in vivo studies of mechanical stress 
(Mitton et al., 1997).  The transient changes were suggested to occur as a result of 
increased degradation rather than transcriptional changes.  The increase back to basal 
levels was suggested to be due to increasing levels of mRNA synthesis.  It may be that the 
initial down regulation of HspB5 early in the disease is a white matter response to mtHtt, 
but the increased disease progression and the toxic functions of htt do not allow protein 
levels to return to normal, resulting in changes to the myelin compartment that likely 
impinge on neuronal function.  
5.4.7.  Potential implications of the selective loss of HspB5  
  The data so far is supportive of disease related changes of a white matter specific sHsp 
(HspB5), without overt changes to other white matter proteins and myelin.  It is plausible 
that there are pathological changes occurring in the white matter that require ultrastructural 
analysis.  However our findings suggest a possible myelin dysfunction and not loss that 
may contribute to R6/2 pathogenesis.  The regional susceptibilities observed in HD 
correlate with brain regions that are myelinated early during development such as the 
striatum, whereas regions that are myelinated later in development are much less affected 
(e.g. the hippocampus).  In HD the specific degeneration of myelinated projection neurons 
with sparing of interneurons gives weight to the involvement of myelin abnormalities in 
HD pathogenesis (Bartzokis et al., 2007).  Myelin breakdown and homeostatic re 
myelination events have been described in HD patients.  A consequence of this is an 
increase in oligodendrocyte number and iron levels, which are thought to contribute to HD 
pathogenesis by production of ROS (Bartzokis et al., 2007).  HspB5 has antioxidant   208 
properties and is able to bind to Cu
2+ with picomolar affinity, thus inhibiting Cu
2+ induced 
oxidation and preventing ROS generation (Ahmad et al., 2008).  Redox abnormalities and 
ROS damage in HD have been widely reported (reviewed in (Browne and Beal, 2006), 
thus it is plausible that loss of HspB5 could also contribute to increased oxidative stress. 
   A deviation of HspB5 from its suggested roles in the myelin compartment (Chapter 4) as 
a consequence of reduced expression, could impart dysfunction in oligodendrocytes and 
subsequent dysfunction in ensheathed axons via cross talk between cell types.  Cross talk 
may not be restricted to intracellular events, as HspB5 has also been reported in the 
extracellular space (Wilhelmus et al., 2006c) which could also be important for signalling 
between cells.  Additionally such a location could contribute to, or provide a route for 
modulation of an inflammatory response.  
5.5.  Summary 
  This chapter has described the expression profile of the sHsp family in the R6/2 mouse 
model of HD.  A progressive and selective loss of HspB5 protein is observed in R6/2 tg 
animals in all brain regions.  This white matter specific change occurs early in disease and 
suggests a key role for oligodendrocytes and the white matter in HD pathogenesis.  
Changes in the white matter are likely to impinge on the function of associated neuronal 
cells via cross talk and may trigger increased susceptibilities to damage and stress.  
  The loss of HspB5 protein is not a consequence of sequestration into SDS insoluble 
aggregates or due to a reduction in transcript levels.  This suggests that post transcriptional 
changes are the likely cause of the downregulation.  Whether this occurs via disrupted 
mRNA targeting or increased protein degradation has yet to be determined.  The schematic 
shown in Figure 5.24 summarizes a model on the potential roles of HspB5 










Figure 5.24. Proposed expression/function of HspB5 in the R6/2 model of HD.  A schematic 
drawing which illustrates the expression of HspB5 in oligodendrocytes and shows the changes observed 
in the R6/2 mouse model of HD.  (1) HspB5 mRNA is translated and the protein is targetted to the 
myelin sheath.  (1a) Increased degradation of HspB5 may reduce HspB5 levels.  (2) Htt loss of function 
may perturb transport of  RNA granules and proteins.  (3) Htt loss of function and association with 
RNA granules may disrupt tr anslational control resulting in a decrease in HspB5 mRNA that is 
transcribed by free ribosomes or polysomes at the site of function.  (4) Reduced local synthesis or 
reduction in targetted proteins may change interactions with lipid rafts in regions where axo glial 
crosstalk and signalling events can be initiated/regulated.  Soluble mtHtt may alter signalling events by 
association with lipid rafts.  Additionally perturbations in axonal frunction by mtHtt such as 
mitochondrial dysfunction, increase in oxidative stress (ROS), inhibition of proteosomal and autophagic 
pathways and transcriptional dysregulation could impact on oligodendrocyte/myelin function by altered 
cross/talk and induction of stress signals.  (5) Reduction of HspB5 binding and association of soluble 
mtHtt with the cytoskeleton may disrupt membrane maintenance, synthesis, transport and signalling 
events. The decrease in HspB5 protein levels will impact on all the functions and processes that this 
sHsps is potentially involved in (as described in chapter 4). 









Chapter 6: A coordinated and selective 
small heat shock protein response in 
non neuronal cells in the ME7 model of 
Prion Disease   211 
6.1.  Introduction 
  The previous chapter investigated the expression of the sHsps in the R6/2 model of HD 
associated with intracellular protein misfolding.  In order to investigate expression of the 
sHsps in a rodent model of extracellular protein deposition and to provide a comparison 
with responses seen in HD, the ME7 mouse model of Prion disease was used. The ME7 
model has several features that are consistent with generic features associated with 
extracellular misfolding diseases such as deposition of abnormal protein deposits in the 
extracellular environment, gliosis, and inflammation (Jellinger, 2009).  Intracerebral 
inoculation of ME7 brain homogenate into C57BL/6J mice leads to chronic 
neurodegeneration associated with progressive hippocampal pathology (Cunningham et al., 
2003).  Other brain regions, such as the thalamus are also affected during disease (Bruce et 
al., 1991, Kim et al., 1999, Cunningham et al., 2005).  In addition to intracerebral 
inoculation, ME7 pathology can also be established by a number of routes, such as 
intraperitoneal (i.p.) and intravenous (i.v.) inoculation (Taylor et al., 1996).  Infected 
animals have disease duration of approximately 24 weeks post infection and develop 
neurodegeneration over a defined timeline as described previously (section 1.9.3 a).   
6.1.1.  ME7 pathology 
  The ME7 model shows activated microglia, marked astrogliosis, vacuolation, spongiform 
degeneration and neuronal loss associated with the post translational modification of 
cellular prion protein (PrP
c) leading to the conformationally altered isoform, PrP
sc.  These 
pathological changes occur at distinct time points over the duration of disease.  Three time 
points have been routinely used to dissect disease progression and investigate changes that 
occur early (8 weeks  pre symptomatic), mid (13 weeks) and late (20 weeks  symptomatic) 
in disease. Much of this is based on behavioural dysfunction, in addition to changes 
associated with pathological events (Dell'Omo et al., 2002, Chiti et al., 2006, Gray et al., 
2009).   
  ME7 induced infection is associated with hippocampal pathology, with gliosis, PrP
sc 
deposition, selective synaptic degeneration in the stratum radiatum and CA1 neuronal loss 
(Betmouni et al., 1996, Deacon et al., 2001, Cunningham et al., 2003).  The selective cell 
loss of CA1 neurons in ME7 animals suggests susceptibility of certain hippocampal   212 
regions to neurodegeneration and is indicative of cellular and regional differences that may 
confer vulnerabilities to pathological changes (Gray et al., 2009).  The intrinsic 
susceptibility of CA1 pyramidal cells to pathological insult over and above the CA3 and 
DG is not selective to this model of prion disease and has been reported in a number of 
conditions such as ischemic insult (Schmidt Kastner and Freund, 1991).  The CA1 region 
has been reported to be one of the first regions to develop pathological markers of AD in 
human brains (West et al., 2000).  Additionally in vivo models of tauopathy have 
correlated disease pathology to neuronal loss in the CA1 (Spires et al., 2006).  CA1 
vulnerabilities have also been linked with aging.  Measurements of survival signalling 
mediated through AKT (protein kinase B) activation was found to be significantly reduced 
in CA1 nuclear regions compared to CA3 while expression of the pro apoptotic 
transcription factor FOXO3a was increased in the CA1 compared to the CA3 (Jackson et 
al., 2009). 
  The defined anatomical pathways, neuronal circuitry and region susceptibilities of the 
hippocampus (see Figure 6.1) provides a tool for investigating ME7 induced hippocampal 
degeneration that lends itself to tractable dissection of roles played by molecules, cells and 
network connections (Lein et al., 2004, Thompson et al., 2008). 
  A major feature of prion diseases as well as in this model is the prominent astrocytic 
response (Kordek et al., 1997, Cunningham et al., 2003).  As the sHsps have been shown 
to be up regulated in astrocytes associated with disease responses in human tissue 
(Renkawek et al., 1999, Wilhelmus et al., 2006c), this would predict that HspB1, HspB5, 





























Figure 6.1. Illustration of the neuronal projections within the hippocampus: The 
Hippocampal Network.  The hippocampus forms a uni directional network.  Inputs from the 
Entorhinal Cortex via the Perforant Path (PP –split into lateral and medial) form connections with 
the Dentate Gyrus (DG) and CA3 pyramidal neurons.   CA3 neurons also receive input from the 
DG via the mossy fibers (MF) and send axons to CA1 pyramidal cells via the Schaffer Collateral 
Pathway (SC).  Additionally, CA3 neurons project to CA1 cells in the contralateral hippocampus 
via the Associative Commissural pathway (AC).  CA1 neurons send axons to the Subiculum (Sb).  
The synapses in the stratum radiatum (circle) formed of presynaptic inputs from CA3 Schaffer 
collateral and post synapses of the apical dendrites of CA1 pyramidal neurons are vulnerable and 
degenerate in ME7 induced pathology.  
 
 
6.2.  Aims 
 The aim of this chapter is to analyse expression of the 4 sHsps constitutively expressed in 
the mouse CNS under physiological conditions (HspB1, HspB5, HspB6 and HspB8) in the 
ME7 mouse model of prion disease.  Microdissected hippocampal tissue will be analysed 
at; early (8 weeks), mid (13 weeks), and late (20 weeks) stage of disease to reflect different 
stages of disease progression associated with distinct pathological events.  
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6.3.  Results 
6.3.1.  Progressive changes in sHsp expression in ME7 prion disease. 
  Protein expression of the 4 sHsps expressed in the CNS was initially investigated at mid 
(13 weeks) and late (20 weeks) stage of disease, with a view to extend this to an earlier 
time point, if major changes were observed at mid stage of disease.  40 g of protein from 
each sample was resolved on SDS PAGE and western blotting was used to analyse 
expression of the four sHsps expressed in the CNS.  The pixel intensity values were 
normalized to protein loading (section 2.8.4) and the average intensity of the bands was 
plotted for the three brain regions.  Differences in pixel intensity between time points do 
not correspond to differences in protein levels, but are reflective of differences in 
individual blots and subsequent normalization to protein loading. 
   215 
6.3.1.1. HspB1 
  There were no significant differences in the protein levels of HspB1 in ME7 compared to 
NBH animals in any of the hippocampal regions at 13 weeks (Figure 6.2 A).  At 20 weeks 
HspB1 was up regulated in the CA1 region of the hippocampus.  A significant up 
regulation was also observed in the DG, although the change was not as large as seen in 





















Figure 6.2. HspB1 protein expression in the hippocampus of NBH and ME7 animals 
at 13 and 20wks (pi).  40 g of protein from CA1, CA3 and DG homogenates were 
resolved by SDS PAGE and the expression of HspB1 was measured by incubating 
membranes with an antibody against HspB1 followed by a fluorescently labelled 
secondary antibody which was detected by infrared fluorescence.  Intensity values 
(pixels/mm
2) were measured using Odyssey Infrared Scanner software.  Values were 
normalized to protein loading and expressed as pixels intensity per mm
2.  Expression of 
HspB1 is shown in distinct hippocampal regions at A, 13 and B, 20 weeks.  (A) No 
changes in HspB1 protein expression were observed in ME7 animals compared to NBH in 
the 3 hippocampal regions at 13 weeks.  (B) HspB1 was significantly up regulated in the 
CA1 and the DG at 20 weeks. Representative blots are shown below the corresponding 
graph (n = 4).  Student’s t test was used to determine significance (*p, <0.05), error bars 
represent SEM.
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6.3.1.2. HspB5  
  There were no significant differences in the protein expression of HspB5 in ME7 and 
NBH animals in all 3 regions of the hippocampus analysed at 13 weeks (Figure 6.3 A).  At 
20 weeks, the protein expression of HspB5 was up regulated in the CA1 region of the 
hippocampus in ME7 animals; however the p value was 0.05 and therefore did not reach 
the threshold of significance (Figure 6.3 B). 
 
 









Figure 6.3. HspB5 protein expression in the hippocampus of NBH and ME7 animals 
at 13 and 20wks (pi).  40 g of protein from CA1, CA3 and DG homogenates were 
resolved by SDS PAGE and protein expression of HspB5 was measured by incubating 
membranes with an antibody against HspB5 followed by a fluorescently labelled 
secondary antibody which was detected by infrared fluorescence.  Intensity values were 
measured using Odyssey Infrared Scanner software and normalized to protein loading and 
expressed as pixel intensity per mm
2.  Expression of HspB5 is shown in distinct 
hippocampal regions at A, 13 and B, 20 weeks.  (A) No changes in HspB5 protein 
expression were observed in ME7 animals compared to NBH in the 3 hippocampal regions 
at 13 weeks.  (B) At 20 weeks, HspB5 showed a trend towards up regulation in the CA1 
region, although this was not significant.  Representative blots are shown below the 
corresponding graph (n = 4).  Student’s t test was used to determine significance (p, 
<0.05), error bars represent SEM. 
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6.3.1.3. HspB6  
  There were no significant differences in HspB6 protein expression between ME7 and 
NBH animals in all regions of the hippocampus at 13 weeks and 20 weeks (Figure 6.4 A 
















Figure 6.4. HspB6 protein expression in the hippocampus of NBH and ME7 animals 
at 13 and 20wks (pi).  40 g of protein from CA1, CA3 and DG homogenates were 
resolved by SDS PAGE and protein expression of HspB6 was measured by incubating 
membranes with an antibody against HspB6 followed by a fluorescently labelled 
secondary antibody which was detected by infrared fluorescence.  Intensity values 
(pixels/mm
2) were measured using Odyssey Infrared Scanner software.  Values were 
normalized to protein loading and expressed as pixels intensity per mm
2.  Expression of 
HspB6 is shown in distinct hippocampal regions at A, 13 and B, 20 weeks.  As previously 
shown in Chapter 3 and 5, the 3 band (asterisks) represent isoforms of HspB6.  (A) No 
changes in HspB6 protein expression were observed in ME7 animals compared to NBH in 
the 3 hippocampal regions at 13 weeks.  (B) There were also no significant changes in 
expression at 20 weeks. Representative blots are shown below the corresponding graph (n 
= 4).  Student’s t test was used to determine significance (p, <0.05), error bars represent 
SEM. 
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6.3.1.4. HspB8   
  HspB8 protein expression was significantly up regulated in the CA1 at 13 week in ME7 
animals compared to NBH (Figure 6.5 A).  This change concurred with the hippocampal 
region and time point associated with synaptic degeneration in this model (Cunningham et 
al., 2003).  At 20 weeks, HspB8 up regulation in the CA1 was more pronounced and a 
statistically significant increase in HspB8 protein expression was also apparent in the DG 














Figure 6.5. HspB8 protein expression in the hippocampus of NBH and ME7 animals 
at 13 and 20 wks (pi).  40 g of protein from CA1, CA3 and DG homogenates were 
resolved by SDS PAGE and protein expression of HspB8 was measured by incubating 
membranes with an antibody against HspB8 followed by a fluorescently labelled 
secondary antibody which was detected by infrared fluorescence.  Intensity values 
(pixels/mm
2) were measured using Odyssey Infrared Scanner software.  Values were 
normalized to protein loading and expressed as pixels intensity per mm
2.  Expression of 
HspB8 is shown in distinct hippocampal regions at A, 13 and B, 20 weeks. (A) HspB8 
protein expression was up regulated in the CA1 region of the hippocampus in ME7 
animals compared to NBH at 13 weeks.  (B) Additionally, HspB8 was also significantly 
up regulated in the CA1 and the DG at 20 weeks. Representative blots are shown below 
the corresponding graph (n = 4).  Student’s t test was used to determine significance (*p, 
<0.05; **p, <0.01), error bars represent SEM. 
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  In summary, three out of four sHsps that are otherwise constitutively expressed in the 
brain were up regulated in the hippocampus of ME7 animals at late stage of disease.  
HspB1 and HspB8 protein levels were up regulated in the CA1 and DG and HspB5 
showed a clear trend towards up regulation in the CA1.  HspB8 was also up regulated in 
the CA1 at 13 weeks.  These changes correlate with early synapse loss and neuronal death 
in the CA1 region. No change in protein expression was observed for HspB6.   
6.3.2. mRNA expression of the sHsps (QT PCR) 
  mRNA was extracted for QT PCR analysis from the CA1, CA3 and DG of ME7 and 
NBH animals at 8, 13 and 20 weeks of age pi (section 2.5).  sHsp gene expression data was 
normalized to the housekeeping gene, GAPDH (section 2.5.3).  Additionally, mRNA 
expression of the other 6 members of the sHsp family that are not constitutively expressed 
in the CNS (Quraishe et al., 2008) showed no change in mRNA expression in ME7 
animals compared to controls (data not shown).  
  There were no statistically significant changes in the mRNA expression of HspB1 and 
HspB5 at 8, 13 and 20 weeks in ME7 compared to NBH animals in the hippocampus 
(Figure 6.6 A & B).  Interestingly, although there were no changes in the protein levels of 
HspB6 in ME7 animals, this sHsps showed a strong up regulation of mRNA in the DG at 8 
weeks.  There were no changes at 13 weeks, however all regions of the hippocampus 
showed up regulation of HspB6 mRNA at 20 weeks pi (Figure 6.6 C).  HspB8 mRNA 
expression remained unchanged at 8 and 13 weeks, however, although not statistically 
significant, an upward trend in ME7 animals was apparent at 20 weeks (Figure 6.6 D).  
This disparity between protein and transcript expression highlights post transcriptional 
















































Figure 6.6. mRNA expression of the sHsps in microdissected hippocampal regions over a time course 
(QT PCR).  Transcript analysis by QT PCR of the sHsp relative to GADH control in RNA extracted form 
distinct hippocampal regions (CA1, CA3 and DG).  (A) There were no significant changes in the mRNA 
expression of HspB1 in ME7 animals compared to NBH animals at any of the time points analysed.  (B) 
There were no significant changes in HspB5 mRNA expression in ME7 animals compared to NBH animals 
at any of the time points analysed.  (C) HspB6 mRNA expression was up regulated in the DG of ME7 
animals at 8 weeks.  There were no changes in any of the hippocampal regions at 13 weeks, however all three 
regions showed up regulation of HspB6 mRNA at 20 weeks.  (D) There were no significant changes in ME7 
animals compared to NBH animals at any of the time points analysed.  (8wks n = 3, 13/20wks n = 5/6).  N 
numbers represent independent injection experiments.  Student’s t test was used to determine significance, 




D   221 
6.3.3.  Specificity of HspB8 immunoreactivity determined by immunocytochemistry 
in cell culture 
  HspB8 protein analysis by western blotting was conducted using a non commercial 
antibody (kindly provided by Dr. Wilbert Boelens).  This antibody was reported to be 
unsuitable for immunohistochemical analysis.  Therefore an alternative non commercial 
HspB8 antibody (kindly provided by Dr. Mohan Roa) that was reported by the provider to 
be suitable for immunohistochemical analysis, but not western blotting was tested.  Indeed, 
we did not observe immunoreactivity by western blotting (data not shown).   
  To determine specificity of this antibody, HeLa cells were transfected with constructs 
expressing human HspB1 (Hsp25), HspB6 (Hsp20) and HspB8 (Hsp22) (section 2.13).  
Cells overexpressing these sHsps were fixed on coverslips and processed for 
immunocytochemistry (section 2.13.).  HspB8 immunoreactivity was absent in cells 
transfected with HspB1, HspB6 and untransfected cells. HspB8 immunoreactivity was 
selectively detectable in cells transfected with HspB8 using the non commercial HspB8 
antibody (obtained from Dr. Mohan Roa) (Figure 6.7).  Of note was the appearance of 
bright immunoreactive dots reminiscent of aggregates in the perinuclear regions in some 
cells, only found in HspB8 transfected cells (see Figure 6.7 A and B). This antibody was 
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6.3.4.  Immunohistochemical analysis of sHsp expression in ME7 and NBH tissue   
  Hippocampal samples from ME7 infected animals showed a selective up regulation of 
HspB1 and HspB8, and a trend towards up regulation of HspB5 protein levels at late stage 
of disease.  To substantiate this finding, tissue sections from ME7 and NBH animals were 
prepared and processed for immunohistochemical analysis as detailed in section 2.11.  
Coronal tissue sections between  1.22mm and  2.30mm relative to Bregma were used to 
analyse expression of HspB1, HspB5 and HspB8 in the hippocampus.  Age matched tissue 
sections from ME7 and NBH animals were processed in parallel and developed in DAB 
solution.                                                              
  HspB1, HspB5 and HspB8 all showed staining and up regulation in the hippocampus in 
late stage ME7 tissue compared to NBH tissue (Figure 6.8 to 6.10).  The cellular staining 
of these 3 sHsps displayed astrocytic morphology 
 6.3.4.1. Immunohistochemical analysis of HspB1 expression in ME7 and NBH tissue 
  HspB1 immunoreactivity in NBH animals (20wks) was readily detected in the 
hippocampus, and showed staining of the vasculature (Figure 6.8 A/C).  This was marked 
by discrete staining of microvascular structures.  As shown previously, in situ 
hybridization used to investigate HspB1 expression showed mRNA localization to the 
dorsal and lateral ventricles (Figure 3.4 a).  These ventricles are lined by ependymal cells 
and the protein stain of HspB1 is suggestive of expression in this cell type.  It is also 
possible that the staining reflects expression in astrocytic end feet that form connections 
with endothelial cells (Figure 6.8 A and C).  Beyond this there was little or no other 
staining in the hippocampus and none attributable to neurons and glia. 
  In contrast, HspB1 immunoreactivity was greatly increased in the hippocampus of ME7 
animals at 20 weeks (Figure 6.8 A and C).  This increase was present in the CA1, CA3 and 
DG.  The morphology of the stained cells was indicative of expression in astrocytes.  
HspB1 immunoreactivity was not uniformly distributed throughout the hippocampus, but 
HspB1 immunopositive cells formed a layer above (stratum oriens) and below (stratum 
radiatum) the CA1 pyramidal cell layer.  A similar layer of HspB1 positive cells were 
present in the molecular layer of the dentate gyrus and also in the polymorphic layer of the 
dentate gyrus.  The cellular staining was not discrete but showed diffuse localisation   224 
around the cell body and main processes indicative of expression throughout the astrocytic 





















Figure 6.8. Immunohistochemical analysis of HspB1 in the hippocampus of 20 week 
NBH and ME7 animals.  Coronal sections from NBH and ME7 animals at 20 weeks pi 
were processed for immunohistochemistry with an anti HspB1 antibody.  (A) HspB1 
immunoreactivity was associated with the vasculature of NBH animals.  (B) Increased 
immunoreactivity was observed in the hippocampus of ME7 animals.  (C) Higher 
magnification images of the CA1 region of NBH animals showed HspB1 
immunoreactivity associated with blood vessels.  (D) HspB1 immunoreactivity was present 
in the SRad, with minimal staining of the LMol layer.  Inset illustrates the diffuse nature of 
HspB1 staining in ME7 animals.  The staining pattern was suggestive of expression in 
astrocytic cells.  Images are representative of staining from 4 different animals.  
Hippocampal regions: stratum oriens (SOr),  stratum pyramidal (Spy), stratum radiatum 
(SRad), lacunosum molecular (LMol), Molecular layer of Dentate Gyrus (MoDG), 
granular layer of Dentate Gyrus (GrDG), Polymorphic layer of Dentate Gyrus (PoDG).  
Scale bar: A/B, 100 m; C/D, 50 m.   225 
6.3.4.2. Immunohistochemical analysis of HspB5 expression in ME7 and NBH tissue 
  HspB5 immunoreactivity in NBH animals was selective and limited to white matter 
structures such as the corpus callosum, as described in Chapter 5.  Staining of the 
characteristic oligodendrocytes present in the lacunosum molecular layer were also 
observed (Figure 6.9 A and C).  HspB5 immunostaining increased consistent with an 
increased expression in the hippocampus of ME7 animals (Figure 6.9 B and D). The 
cellular staining pattern was not as distinctive as the staining observed for HspB1, but 
similarly the morphology of the cells was suggestive of expression in astrocytes.  
Additionally, oligodendroglial staining in the lacunosum molecular did not appear any 
different in ME7 animals compared to NBH suggesting there were no overt white matter 
changes.  226 
















Figure 6.9. Immunohistochemical analysis of HspB5 in the hippocampus of 20 week 
NBH and ME7 animals.  Coronal sections from NBH  and ME7 animals at 20 weeks pi 
were subjected to immunohistochemistry for detection of HspB5. (A) HspB5 
immunoreactivity in NBH animals was associated with the corpus callosum.  Staining was 
also observed in oligodendrocyte cell bodies decorating the hippocampus (See also 
Chapter 4).  (B) Increased immunoreactivity in addition to oligodendrocytic staining which 
remained unchanged was present in the hippocampus of ME7 animals.   
(C) Higher magnification images of the CA1 region of NBH animals showed HspB5 
immunoreactivity in oligodendrocytes situated in the LMol.  (D) HspB5 up regulation in 
ME7 animals was suggestive of expression in astrocytic cells.  Images are representative of 
staining from 4 different animals.  Hippocampal regions: stratum pyramidal (Spy), stratum 
radiatum (SRad) and lacunosum molecular (LMol).  Scale bar: A/B, 100 m; C/D, 50 m. 
   227 
6.3.4.3. Immunohistochemical analysis of HspB8 expression in ME7 and NBH tissue 
  There was no specific HspB8 immunoreactivity in the hippocampus of NBH animals, a 
background staining of hue was apparent associated with the secondary antibody (Figure 
6.10.A and C).  However, HspB8 expression was up regulated in the hippocampus in ME7 
animals (Figure 6.10 B and D).  The staining pattern was similar but more intense to that 
seen for HspB5 with immunoreactivity throughout the hippocampus.  The cellular 
























Figure 6.10. Immunohistochemical analysis of HspB8 in the hippocampus of 20 week 
NBH and ME7 animals.  Coronal sections from NBH and ME7 animals at 20 weeks pi 
were subjected to immunohistochemistry for detection of HspB8. (A) and (C) Specific 
immunoreactivity was absent in the hippocampus of NBH animals.  (B) HspB8 
immunoreactivity was up regulated in the hippocampus of ME7 animals.  (D) Higher 
magnification images of the CA1 region showed up regulation of HspB8 in cells with 
astrocytic morphology.  Images are representative of staining from 4 different animals.  
Hippocampal regions: stratum pyramidal (Spy), stratum radiatum (SRad) and lacunosum 
molecular (LMol).  Scale bar: A/B, 100 m; C/D, 50 m.   228 
HspB6 expression was not analysed by immunohistochemistry as this sHsps did not show 
any change in protein expression by western blotting. 
6.3.5.  sHsp co localization with GFAP (immunofluorescence) 
  To determine if the sHsp immunopositive cells were astrocytes, double 
immunofluorescence labelling of coronal brain sections was used to analyse the expression 
of the sHsps and GFAP, a robust astrocytic marker.   
6.3.5.1. HspB1 expression in astrocytes 
  HspB1 expression was investigated at 13 weeks.  Protein expression at this time point 
was no different in ME7 animals compared to NBH animals by western blotting, however 
2 ME7 animals out of 4 displayed a modest increase in a restricted number of GFAP 
positive cells in ME7 animals at 13 weeks.  These HspB1 positive cells were present in the 
molecular layer of the dentate gyrus with a few cells decorating the stratum radiatum 
(Figure 6.11 A ii).  GFAP expression was compact within distinct thick astrocytic 
processes emanating from the cell body.  HspB1 also showed expression and co 
localisation with GFAP in these processes (Figure 6.11 B ii), but in addition a fine and 
diffuse decoration extending from these processes was also observed (Figure 6.12).  This 
staining suggests expression of HspB1 throughout the astrocytic cell, extending into the 
extremities of astrocytic processes consistent with either expression of a soluble protein or 
one associated with cytoskeletal elements that define the cortical structure of the astrocyte.  
  HspB1 expression was also analysed at 20 weeks.  Immunoreactivity in NBH animals 
showed staining of the vasculature that was not associated with GFAP.  A background 
staining of hue was also observed which was associated with non specific secondary 
antibody immunoreactivity (Figure 6.13 Ai/ Bi).  HspB1 immunoreactivity co localised 
with GFAP in 20 week ME7 animals, consistent with the notion that the up regulated 
staining was associated with astrocytes (Figure 6.13 Ai/ Bi).  Expression was not 
homogeneous and displayed variability between astrocytic cells as well as being absent 
from astrocytes in the lacunosum molecular layer of the hippocampus.  This was not 
reflected by GFAP staining which was consistent throughout the hippocampus.  All HspB1 
positive cells were GFAP positive, however all GFAP positive cells were not HspB1 


















Figure 6.11. Double immunofluorescence staining of HspB1 and GFAP in 13 week 
NBH and ME7 animals.  (Ai) HspB1 expression in the hippocampus of NBH animals.  
(Aii) HspB1 immunoreactivity was increased in a small number of GFAP positive cells in 
ME7 animals.  These HspB1 positive cells decorated the MoDG, with some staining 
observed in the SRad.  (Bi) HspB1 expression in the CA1 of ME7 animals was selective to 
a few GFAP positive cells.  (Bii) Higher magnification images illustrate the diffuse and 
extended nature of the HspB1 staining in these astrocytes (B).  Images are representative of 
staining from 2 out of 4 animals.  Hippocampal regions: stratum pyramidal (Spy), stratum 
radiatum (SRad) and lacunosum molecular (LMol). Scale bar: A, 200 m; Bi, 50 m; Bii, 
20 m.   230 
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Figure 6.12. Localization of HspB1 and GFAP immunoreactivity in the CA1 of ME7 
animals at 13 week.  HspB1 co localisation with GFAP was investigated by confocal 
microscopy analysis of immunostaining.  HspB1 (green) immunopositive cell in the CA1 
region of the hippocampus showed complete co localisation (yellow) with GFAP staining 
(red).  Additionally, HspB1 staining was shown to surround the main processes and cell 
body of the astrocyte displaying the distinctive bushy appearance of protoplasmic 
astrocytes.  GFAP positive cells were also observed that showed no HspB1 
immunoreactivity (arrow).  Cell bodies were stained with DAPI (blue).   
 











































Figure 6.13. Double immunofluorescence staining of HspB1 and GFAP in the 
hippocampus of 20 week NBH and ME7 animals.  (Ai/Bi) HspB1 expression in NBH 
animals was restricted to blood vessels and was distinct from GFAP staining.  (Aii/Bii) 
Up regulation in ME7 animals showed co localisation with GFAP positive cells.  HspB1 
staining is restricted away from the lacunosum moleculare.  Representative staining in 
hippocampal sections (A) and CA1 (B) are shown for control (NBH) and ME7 animals.  
Images are representative of staining from 4 different animals.  Hippocampal regions: 
stratum pyramidal (Spy), stratum radiatum (SRad) and lacunosum molecular (LMol). Scale 
bar: A, 200 m; B, 50 m.   232 
6.3.5.2. HspB5 expression in astrocytes 
  HspB5 expression was investigated immunohistochemically at 13 weeks.  No changes in 
expression were observed (data not shown).  HspB5 immunoreactivity in NBH animals 
was associated with oligodendrocytic cell bodies decorating the CA1, lacunosum 
moleculare, CA3 and dentate gyrus of the hippocampus. Oligodendrocytic expression is 
consistent with the expression observed in the R6/2 HD mouse model.  Chapter 4 and 5 
described HspB5 expression in oligodendrocytes in the hippocampus, thus this is an 
important stain to be considered.  There was no co localisation with GFAP staining in 
NBH animals and HspB5 expression was exclusively associated with the white matter 
(Figure 6.14 Ai/Bi).  At 20 weeks HspB5 was up regulated in the hippocampus of ME7 
animals (Figure 6.14 A ii), however this was not associated with the cells that expressed 
HspB5 constitutively (oligodendrocytes), but a new set of cells namely astrocytes as shown 
by co localisation with GFAP staining (Figure 6.14 B ii).  Tomato lectin, a marker of 
microglial cells was used to investigate expression of HspB5 in microglia.  HspB5 did not 
show co localisation with tomato lectin staining in NBH or ME7 animals indicating that 
the increased immunostaining in ME7 was specific to astrocytes (Figure 6.15).  
 


















Figure 6.14. Double immunofluorescence staining of HspB5 and GFAP in the hippocampus of 
20 week NBH and ME7 animals.  (Ai/Bi) HspB5 expression in NBH animals was present in 
distinctive and intensely stained cell bodies distributed throughout the hippocampus, characteristic 
of oligodendrocytes.  This staining did not co localise with GFAP staining.  (Aii) HspB5 
immunostaining was increased in ME7 animals.  (Bii) A strong oligodendrocytic background 
staining was present; however the signal was dominated by astrocytic staining in ME7 animals.  
The increased HspB5 staining seen in ME7 animals co localised with GFAP positive cells.  
Representative staining in hippocampal sections (A) and CA1 (B) are shown for control (NBH) and 
ME7 animals.  Images are representative of staining from 4 animals.  Hippocampal regions: 
stratum pyramidal (Spy), stratum radiatum (SRad) and lacunosum molecular (LMol). Scale bar: A, 




























Figure 6.15.  HspB5 up regulation is not associated with microglial cells.  HspB5 
immunostaining in NBH shows tight staining of oligodendrocytes (see chapter 4). This 
staining that persists in the NBH hippocampus was distinct from increased staining in ME7 
animals. Neither showed co localisation with cells positive for tomato lectin.  Images are 
representative of staining from 4 animals showing. Hippocampal regions: stratum 
pyramidal (Spy), stratum radiatum (SRad) and lacunosum molecular (LMol). Scale bar: 
CA1, 100 m; CA3, 50 m.  
 
 
6.4.3.3. HspB8 expression in astrocytes 
  HspB8 expression was up regulated in ME7 animals compared to NBH at 20 weeks and 
showed co localisation with GFAP staining (Figure 6.16).  Expression was increased in all 
regions of the hippocampus.  The 13 week analysis remains to be done.   
   

















Figure 6.16. Double immunofluorescence staining of HspB8 and GFAP in the 
hippocampus of 20 week NBH and ME7 animals.  (Ai/Bi)  HspB8 expression in NBH 
animals was not associated with GFAP expression. (Aii) HspB8 showed up regulation in 
ME7 animals.  (Bii) The increased expression of immunoreactivity in ME7 animals 
displayed co localisation with GFAP positive cells. Representative staining in 
hippocampal sections (A) and CA1 (B) are shown for control (NBH) and ME7 animals.  
Images are representative of staining from 4 animals.  Hippocampal regions: stratum 
pyramidal (Spy), stratum radiatum (SRad) and lacunosum molecular (LMol). Scale bar: A, 
200 m; B, 50 m. 6.4.  Discussion 
  The ME7 mouse model of prion disease, characterized by extracellular PrP
sc protein 
aggregates was used to analyse expression of the sHsps.  HspB1, HspB5 and HspB8 
protein expression was up regulated in the hippocampus of ME7 animals at late stage of 
disease, however there were no changes in HspB6 protein expression.  The changes in 
protein expression were not regulated at the transcriptional level as the 3 sHsps that were 
up regulated at the protein level showed no changes in mRNA expression.  However 
HspB6 mRNA was significantly up regulated in the hippocampus in ME7 animals at late 
stage.  The disparity between protein and transcript suggests the up regulation of the sHsps 
is a consequence of translational regulation or indeed reduced protein degradation to 
increase steady state protein levels.  
  It is unclear why HspB6 up regulation of mRNA is observed in the absence of protein 
changes.  However, stress induced HspB6 protein expression has been shown to be 
induced in a number of studies.  HspB6 expression in AD tissue showed no change by 
western blotting, but elevated reactivity was found in astrocytes surrounding SPs, perhaps 
suggesting involvement or modulation of the disease process (Wilhelmus et al., 2006c).  
HspB6 was found to be up regulated in the hippocampus of newborn piglets in response to 
hypoxia (David et al., 2006).  It was also shown to be transiently up regulated in two 
phases in a model of experimental ischemia reperfusion injury.  This was attributed to an 
initial glial response to ischemic insult, followed by CA1 neuronal apoptosis (Niwa et al., 
2009).  HspB6 protein staining was associated with the apical dendrites of CA1 pyramidal 
cells after ischemic insult.  Phosphorylated HspB6 has been reported to be protective 
against apoptosis by direct interactions with Bax, a pro apoptotic protein.  It has been 
proposed that this interaction prevents Bax translocation from the cytosol to the 
mitochondria, preventing Cytochrome C release.  However, in this study, phosphorylation 
of HspB6 was observed after CA1 pyramidal cell death as determined by TUNEL staining 
(Niwa et al., 2009).  Although we have not investigated HspB6 expression 
immunohistochemically, in light of the above, it would be important to do so to understand 
HspB6 expression at a cellular level and potential changes in its distribution.     237 
6.4.1.  sHsp expression and astrogliosis  
  Immunohistochemical investigation supported the increased expression of 3 sHsps 
observed by western blotting.  However, it has also highlighted a disparity between the two 
methods.  The three sHsps showed no change in expression in the CA3 region by western 
blotting, but an up regulation in the CA3 was shown immunohistochemically.  This 
suggests the microdissection of the hippocampus may not accurately isolate the CA3 
region and raises the possibility that contamination from other brain regions, such as the 
fimbria, which are closely associated with the hippocampal structure, mask the changes 
seen immunohistochemically.  Indeed such a contamination, and the basal expression of 
HspB5 in the white matter may mask the subtle up regulation of HspB5 as seen 
immunohistochemically (Figure 6.9) and would explain the trend towards up regulation in 
ME7 animals, but the lack of significance. 
  Increased immunoreactivity of these sHsps was associated with expression in astrocytes 
as determined by co localisation with GFAP.  Immunohistochemical analysis of HspB1 
revealed additional complexity to the up regulation observed by western blotting.  At 13 
weeks HspB1 did not show any significant changes in protein expression.  However 
immunohistochemical analysis revealed a very distinctive staining of a subset of astrocytes 
at this time point.  HspB1 co localised with GFAP, which was consistent with an 
association with the cytoskeleton, but this co expression involved staining beyond the 
extremities of the GFAP immunoreactivity. This extended staining in the fine processes of 
a subset of astrocytes was reminiscent of staining of protoplasmic astrocytes, or 
experimentally dye filled astrocytes (Figure 6.11 and 6.12).  Protoplasmic astrocytes have 
between 1000 10000 processes that make connections with synapses and blood vessels.  
Dye filled astrocytes were also shown to have bushy processes that occupied separate 
territories thus allowing the most efficient surveillance of the microenvironment (Bushong 
et al., 2004). 
  In addition to the elaborate morphology of these cells, the staining observed at 13 weeks 
was restricted to a few astrocytes that selectively expressed HspB1 in the molecular layer 
of the DG and the stratum radiatum of the CA1.  At 20 weeks the staining of the HspB1 
positive cells was not as elaborate as seen at 13 weeks, however was again restricted to a 
subpopulation of astrocytes displaying a similar extended staining pattern beyond GFAP   238 
expression.  This was perhaps a consequence of the increase in number of astrocytes at 20 
weeks, reducing the territory of each cell.  All HspB1 positive cells were GFAP positive, 
but only a subset of GFAP positive cells showed increased HspB1 immunoreactivity.  The 
lacunosum molecular layer of the hippocampus containing distal dendrites was effectively 
devoid of HspB1 astrocytic staining, whereas the proximal dendrites of the stratum 
radiatum, where synapse loss is observed, showed abundant HspB1 staining.  The pattern 
of staining is suggestive of a selective astrocytic response during disease associated with a 
compartment specific degeneration. 
  Expression of HspB8 in the CA1 subfield at 13 weeks by western blotting and the 
selective expression of HspB1 in this region in a few animals, suggest a potential 
involvement of these sHsps in cellular processes that may directly underlie the synaptic 
loss that precedes CA1 cell loss at this time point.  In contrast, HspB1 positive astrocytes 
in the molecular layer of the DG may represent an astrocytic response to PrP
sc deposition 
in this region.  HspB5 and HspB8 also showed co localisation with GFAP at late stage of 
disease.  HspB5 and HspB8 expression was very similar to GFAP expression and did not 
display the elaborate staining observed for HspB1.  Additionally, HspB5 and HspB8 
immunoreactivity was present throughout the hippocampus and was not associated with a 
subpopulation of astrocytes.  HspB5 did not show any immunohistochemical changes in 
expression in ME7 animals at 13 weeks and HspB8 expression is yet to be determined.   
  The sHsp response and up regulation in ME7 animals displays a distinct and staged 
response in astrocytes indicative of different phases of reactivity or astrocytosis.  The 
selective up regulation of HspB1 and HspB8 at an early time point may be a distinct 
response to the synaptic loss and degeneration that occurs at 13 weeks.  It is very 
interesting that the few animals displaying HspB1 immunoreactivity at 13 weeks show 
differential expression in the CA1 region, which coincides with the area where synaptic 
loss occurs (stratum radiatum).  The sHsp response at a late stage, when a concerted up 
regulation of the sHsps is observed may be a co coordinated continuation of the early 
response, or a cumulative astrocytic response as a consequence of astrogliosis.   
  Astrocytes are a heterogeneous population of cells with at least 9 morphological variants 
described (Matyash and Kettenmann, 2009).  Early neuro anatomists recognised two 
morphologically distinct glial cell populations in the white and gray matter, termed   239 
protoplasmic and fibrous astrocytes.  However astrocytes were further subdivided into 9 
classes based on differential yet complementary labeling methods – mice expressing 
GFAP GFP transgenically or astrocytes stained against GFAP and S100β (Matus and 
Mughal, 1975, Nolte et al., 2001, Emsley and Macklis, 2006).  Therefore, in a given brain 
region, several types of astrocytes coexist together and cannot be simply classified as 
protoplasmic and fibrous astrocytes (Emsley and Macklis, 2006).  Although astrocytes 
have been distinguished on a morphological basis, no thorough comparison of the 
physiological behaviour of these cells has been made (Matyash and Kettenmann, 2009).  
Morphologically undistinguishable astrocytes have also been found to exhibit different 
physiological behaviour (Houades et al., 2008).  Interestingly the hippocampal CA1 layers 
display differences in morphology and orientation of astrocytes, which lends weight to the 
astrocytic subpopulation specific expression of HspB1.  The astrocytes in the stratum 
lacunosum moleculare are small, with uniform radially orientated processes, astrocytes in 
the stratum radiatum are much bigger and polarised (Nixdorf Bergweiler et al., 1994).  The 
different populations of astrocytes that co exist in the hippocampus have been shown to 
differ in their AMPA receptor subunit expression and show distinct coupling capabilities 
(Matthias et al., 2003, Wallraff et al., 2004). 
  The selective neuronal death of CA1 neurons has been presumed to reflect the inherent 
vulnerability and connectivity of neuronal populations in this region (Ouyang et al., 2007).  
It has been reported that CA1 astrocytes were more sensitive to ischemia than DG 
astrocytes.  Oxidative stress was suggested to contribute to selective changes in CA1, 
because CA1 astrocytes show early increases in mitochondrial free radicals and reduced 
mitochondrial membrane potential.  These changes were not seen in the DG astrocytes 
(Ouyang et al., 2007).  It is clear that distinct subpopulations of astrocytes co exist in the 
brain and the functional implications of the regional and local heterogeneity is displayed 
by the sensitivity or contribution of some subpopulations such as those in the CA1 to 
disease processes (Hewett, 2009).  These observations suggest that the selective sHsp 
response in astrocytes, particularly in relation to HspB1 expression, could represent a 
distinct population that may be responding to early pathological changes, and the 
combined sHsp response in late stage of disease is a coordinated regional astrocytic 
response.    240 
  Interestingly, an increase in   calpain activation in astrocytes of late stage prion disease 
has been reported (Gray et al., 2006).  It has also been shown that calpain inhibitors of   
and m calpain increase HspB5 phosphorylation via p38 MAP and intracellular calcium 
signalling.  Phosphorylation of Ser 59 seems to be crucial for its cytoprotective effects 
(Aggeli et al., 2008).  This suggests that the astrocytic changes at late stage of disease 
would indeed impact on the phosphorylation of the sHsps and likely promote large sHsp 
homo  and heter oligomeric complex formation, supporting a chaperoning role in this 
disease context potentially as a distinct event from the selective up regulation at 13 weeks.   
6.4.2.  Biological significance of astrocytic expression   
  Expression and up regulation of the sHsps in glial cells, particularly in the context of 
disease settings have been reported in a number of studies (Dabir et al., 2004, van Noort, 
2008).  Activation of astrocytes may be involved in up regulating expression of the sHsps 
in an attempt to prevent or deal with the deposition of protein aggregates (Renkawek et al., 
1999, Wilhelmus et al., 2006c), or it may be an intrinsic defence mechanism used by the 
astrocytes to protect them, or indeed other cells such as neurons, from pathological insult. 
  HspB5 has been identified as a major component of Rosenthal fibers (RF), intra 
cytoplasmic inclusions within astrocytes.  In human brains, reactive astrocytes around 
infarcts were GFAP and HspB5 positive.  It was also noted that the population of HspB5 
positive cells were heterogeneous, in that more astrocytes were GFAP positive than HspB5 
positive (Iwaki et al., 1992).  This suggested that there may be many different adaptive 
responses in astrocytes during pathology and ‘reactive’ astrocytes are clearly not 
homogenous. This observation indicates that the selective expression of HspB1 in a 
subpopulation of astrocytes may represent a different class of ‘reactive’ astrocytes in the 
hippocampus in addition to the astrocytes that express HspB5 and HspB8.  It may also 
reflect a response to PrP
sc deposition, which accumulates in the hilus of the dentate gyrus, 
followed by the CA3 and CA1.  It is also likely that the local microenvironment is different 
between the hippocampal regions and therefore triggers changes in some astrocytes, but 
not all.  Gliosis, as mentioned previously coincides with aggregate deposition in ME7 
animals.  This suggests that the presence of extracellular aggregates and/or membrane 
bound PrP
sc triggers a glial response as these cells are constantly in surveillance of their   241 
local microenvironment and up regulation of sHsps would be consistent with a protective 
role.  
  Another interesting avenue arises from the potential for astrocytes to process and assist in 
the generation of the PrP
sc species.  The potential for astrocytic contribution to the PrP
sc 
load comes from a number of studies.  PrP
c expression is required for the conversion to 
PrP
sc (Bueler et al., 1993, Sailer et al., 1994).  PrP mRNA is present in high amounts in 
neurons (Harris et al., 1993), but has also been reported in astrocytes and oligodendrocytes 
in the brains of postnatal hamsters and rats (Moser et al., 1995) suggesting involvement of 
glial cells in prion replication.  Transgenic mice devoid of murine PrP
c were generated to 
express hamster PrP
c transgenes driven by the GFAP promoter.  These mice developed 
severe disease and accumulated high levels of PrP
sc after inoculation with hamster scrapie 
(Raeber et al., 1997).  As astrocytes are involved in neuronal maintenance (Mucke and 
Eddleston, 1993), astrocytic dysfunction could result in neuronal dysfunction and toxicity.  
In view of the misfolding event involved in PrP
c conversion to PrP
sc, such an involvement 
of astrocytes could be the basis for sHsp up regulation.  Interestingly HspB5 was shown to 
be a potent copper chelator, binding with picomolar affinity.  This was associated with a 
decrease in the production of ROS (Ahmad et al., 2008).  PrP
c is a copper binding protein 
and it is likely involved in protecting against oxidative stress or acting as a copper buffer 
(Davies and Brown, 2008).  The up regulation of sHsps may be a general response to the 
increased burden of such metals and oxidative stress in an attempt to maintain the normal 
homeostatic balance or in the case of prion disease a compensatory role due to the loss of 
PrP
c function.  Interestingly, increased expression of HspB1 has been shown to reduce iron 
levels and increase the reduced (antioxidant) form of glutathione (Arrigo et al., 2005b).  
6.4.3.  An extracellular presence of the sHsps? 
  The sHsps have been associated with extracellular functions such as regulating the 
inflammatory response and they have been associated with protein aggregates and plaques 
in the extracellular environment (Wilhelmus et al., 2006c).  The evidence although limited, 
supports an extracellular presence and function of the sHsps that is associated with a 
pathological context.     242 
  HspB1 is a circulating protein marker of increased malignancy in breast cancer and has 
been found in the serum of cancer patients (Fanelli et al., 1998).  HspB5 and HspB1 
expression has also been shown to occur close to PrP
sc plaques in astrocytes and microglia 
(Renkawek et al., 1992).  Due to the lack of a signal sequence targeting sHsps to the 
extracellular space, it has been proposed that sHsps may be released into the extracellular 
environment by non conventional means, such as by exosomes or via the lysosomal 
pathway (Graner et al., 2007) as they have been found extracellularly in the absence of cell 
lysis/necrosis (Fanelli et al., 1998).  This supports the idea that non neuronal cells may 
liberate sHsps in a targeted and selective manner.  The presence of sHsp positive astrocytes 
that potentially secrete HspB1 and other sHsps into the extracellular environment is an 
interesting concept and would provide a mechanism to confer neuroprotection via 
chaperone functions associated with sHsps or indeed modulation of an inflammatory 
response.  Although the halo like expression of HspB1 in astrocytes initially suggested the 
possibility of an extracellular presence, it is clear that this morphology is characteristic of 
protoplasmic astrocytes and indeed represents the spatial field a single astrocyte can 
encompass (Bushong et al., 2004).   
6.4.4.  sHsps and the inflammatory response 
  The sHsps have been shown to be involved in regulating the inflammatory response 
(Roelofs et al., 2006, van Noort, 2008).  The inflammatory response in autoimmune de 
myelination was shown to be exacerbated in HspB5 knock out mice.  This sHsp was 
demonstrated to be a potent negative regulator of the inflammatory response, acting as a 
brake on several inflammatory pathways in the CNS and immune system.  Knockout mice 
showed higher levels of pro inflammatory cytokine secretion leading to intense CNS 
inflammation (Ousman et al., 2007).  Thus HspB5 may modulate the inflammatory 
response during prion disease and sensitise the cells against further insults. Extracellular 
HspB8 has also been shown to bind to TLR4 (Toll like receptor 4) (Roelofs et al., 2006).  
This again is supportive of a role in the inflammatory process and also gives weight to the 
extracellular presence of the sHsps.   
  Il 10 has been shown to play a prominent role in prion disease regulation.  Il 10 deficient 
mice were found to be highly susceptible to developing prion disease after inoculation with   243 
RML or ME7 brain homogenate and showed a marked shortening of the incubation time in 
both strains.  Lack of Il 10 led to an early expression of TNF α, sensitising mice to prion 
pathology (Thackray et al., 2004).  Although microglia are primarily thought to be 
involved in the inflammatory response, astrocytes and oligodendrocytes are also a source 
of inflammatory mediators and may contribute to inflammation during disease (McKinnon 
et al., 1993, Omari et al., 2005, Fernandez et al., 2007).  Indeed, HspB1 can induce IL 10 
in human monocytes; this was dependent on the activation of the p38 MAPK pathway.  
Activation of other kinase pathways by HspB1 such as ERK1/2 (extracellular signal 
related kinase) and JNK1/2 (c Jun N terminal kinase) resulted in inflammatory cytokine 
production (TNF α) (Fanelli et al., 1998). 
  The inflammatory response seen during ME7 induced prion disease is atypical in nature 
with a predominantly anti inflammatory cytokine profile (see general introduction). Given 
the implications of the sHsps in modulation of inflammatory processes outlined above, it is 
possible to suggest that the sHsps may contribute to and maintain the atypical anti 
inflammatory response in this model of neurodegeneration.  
 6.4.5.   Potential negative consequences of sHsps up regulation 
  The results indicate that the sHsps are responding to a disease with extracellular 
aggregates in a different way to a disease with intracellular aggregates.  The precise roles 
of these sHsps is not clear and although it is likely that the up regulation is beneficial and 
slows disease progression due to the functions attributed to this group of molecular 
chaperones, this does not exclude the possibility of a detrimental effect in this disease 
context.  It was recently shown that extracellular HspB5 was involved in the fragmentation 
of amyloid fibrils.  This role was thought to enhance production of further fibrils by 
providing a mechanism for seed formation and nucleation (Raman et al., 2005).  The 
decrease in fibrils resulted in increased toxicity, consistent with small oligomeric species 
being more toxic (Stege et al., 1999, Raman et al., 2005).  This raises the possibility that 
the up regulation of the sHsps, particularly HspB5 at late stage of disease may enhance the 
neurodegenerative process by inducing the formation of toxic PrP
sc species.  Liberation of 
such species could tip the scale in favour of neuronal cell death.   244 
  Mutations in the sHsps (B1, B5 and B8) that result in hereditary neurodegenerative 
diseases result in compromised structural stability resulting in the aggregation of these 
sHsps.  It is unclear whether the disease phenotype is due to gain of function induced by 
aggregate toxicity, or a loss of chaperone capacity (Carra et al., 2005).  However it is 
evident that the basal levels of the sHsps are important for normal protein homeostasis and 
up regulation is potentially important to restore or reduce the imbalance under conditions 
of stress.  Oligodendrocytes are also able to mount a stress response and HspB1 and 
HspB5 have been shown to be up regulated in oligodendrocytic cells in addition to 
astrocytes in a number of disease/stress contexts (Aquino et al., 1997, Duvanel et al., 
2004).  Although there were no overt changes in HspB5 staining of oligodendrocyte cell 
bodies and myelin in the hippocampus, it is likely that there is some contribution of this 
cell type in neuroprotection via axonal support and cross talk with axons and astrocytes.  
An interesting possibility that may confer neuroprotection to some hippocampal regions is 
the varying levels of myelination.  The DG, CA3 and lacunosum molecular layer of the 
hippocampus show greater MBP, CNP and HspB5 staining in comparison to the CA1 
region.   
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6.5.  Summary 
  This chapter has described the expression profile of the sHsp family in the ME7 mouse 
model of prion disease that is characterized by extracellular protein deposits.  HspB1, 
HspB5 and HspB8 were up regulated in the hippocampus of late stage ME7 animals.  
Additionally HspB1 (although not significant) and HspB8 were up regulated in the CA1 
region at 13 weeks.  The sHsps response was attributable to the selective expression in 
astrocytes, likely driven via a reactive response in these glial cells.  This up regulation was 
not transcriptionally regulated, suggesting translational mechanism were modulating the 
sHsps levels.  The consequence of the induced astrocyte expression of sHsps during 
disease progression remains unclear.  However the sHsps may play roles both intra and 
extracellularly in modulating neuro inflammation and neuro protection/degeneration via 
cell cell communication.  To test more specific hypothesis in relation to the protective 
effects of sHsps in the future, ME7 homogenate could be injected into HspB1, B5 or B8 
knockout (that are available) or double knockout mice, and disease outcomes could be 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 7: General discussion   248 
  Prior to this study the expression of the sHsps had not been systematically studied in the 
mouse CNS.  The importance of understanding the physiological expression of this family 
of molecular chaperones in the CNS arises from mutations in a few members that perturb 
motor neuron function and an association of the sHsps with neurodegenerative diseases.  
Therefore, the expression of the 10 members of the sHsp family was first systematically 
and comparatively characterised under physiological (non disease) conditions in the mouse 
CNS.  This work established a baseline of expression and as described in Chapter 3, four 
members of the sHsp protein family (HspB1, HspB5, HspB6 and HspB8) were found to be 
constitutively expressed in the CNS (Quraishe et al., 2008).  The observations in this 
systematic study support reports in the literature, in which expression of the sHsps under 
non stress/disease conditions was predominantly associated with non neuronal cell types 
(Table 3.4) (Renkawek et al., 1992, Plumier et al., 1997).  HspB5 and HspB6 expression 
was predominantly localised to the white matter under physiological conditions.  
Enrichment of HspB5 in the white matter and potential expression in the non compact 
myelin compartment as described in Chapter 4, suggests a number of possible functions in 
this cell type.  Perturbations of these functions could contribute to dysfunction of the white 
matter/oligodendrocytes and impinge on neuronal cell function via alterations in the 
normal crosstalk between these cell types. 
  Our analysis does not preclude expression in neurons in the CNS and indeed HspB1 and 
HspB8 were selectively expressed in the large motor neurons in the ventral horn of the 
spinal cord, consistent with a role of HspB1 and HspB8 in these cells, which when 
perturbed due to mutations result in specific motor neuropathies (Evgrafov et al., 2004, 
Irobi et al., 2004).  Limited HspB1 expression has been reported in other neuronal 
populations in the CNS (Plumier et al., 1997, Armstrong et al., 2001a), however the 
constitutively higher and selective expression of HspB1 and HspB8, in a subset of motor 
neurons in the spinal cord as shown in Chapter 3 and other studies (Plumier et al., 1997, 
Irobi et al., 2004) may reflect a need of these neurons for additional chaperone capacity or 
associated sHsp functions such as redox regulation.  Indeed motor neurons in the ventral 
horns have been suggested to be more sensitive to oxidative stress associated with 
ischemia/reperfusion than neurons localised to other spinal cord regions (Kolesar et al., 
2009).  Furthermore, a region specific response of the spinal cord to oxidative stress has   249 
previously been reported in a model of transient ischemia followed by short periods of 
reperfusion (1 and 3 h) (Kolesarova et al., 2006) and in a model of repeated spinal cord 
ischemia (Pavel et al., 2001).  Additionally, oligodendrocytes have also been shown to be 
more susceptible to oxidative stress in comparison to astrocytes (Husain and Juurlink, 
1995).  The intrinsic vulnerabilities of these cell types to stress/injury suggest that higher 
basal levels of sHsps maybe required to buffer normal cellular mechanisms and maintain 
homeostasis.  Indeed, higher levels of constitutively expressed Hsc70 and HspB1 have 
previously been correlated with a higher defense capacity against chronic misfolding stress 
in motor neurons of the spinal cord compared to other neuronal populations such as the 
neurons of the substantia nigra and entorhinal cortex (Chen and Brown, 2007). 
  Expression of the sHsps are not only associated with oxidative stress and ischemia but 
also heat stress and osmotic stress.  Little is known about sHsp expression during 
conditions of chronic stress driven by intra/extracellular protein misfolding occurring 
during proteinopathies.  Hence to understand the involvement of the sHsps in both 
intra/extracellular protein misfolding contexts, we investigated the expression of the sHsps 
in a HD and a prion model of protein misfolding. 
  As both models are characterized by protein misfolding and aggregation it was 
hypothesized that there would potentially be convergent cellular mechanisms involving the 
sHsps at play during pathogenesis.  However, the different sHsp signatures as determined 
in Chapter 3 argue against this point and indeed, the data revealed opposing results in these 
two models.  
  As described in chapter 5, in the R6/2 mouse model of HD, characterised by intracellular 
aggregates, a selective and progressive downregulation of the white matter specific HspB5 
protein was observed in tg animals in all white matter compartments of the brain (Chapter 
5).  Although obvious white matter changes were not observed, the early and selective 
changes in HspB5 expression suggest a possible contribution of oligodendrocytes during 
HD pathogenesis.  The proposed localization of HspB5 in the non compact myelin 
compartment additionally places this sHsps in a key location for involvement in neuronal 
glial cross talk.  Indeed white matter abnormalities are routinely observed in HD patients 
(Jernigan et al., 1991).   250 
   In the ME7 mouse model of prion disease HspB1, HspB5 and HspB8 protein expression 
was up regulated in astrocytes.  For HspB1 this was associated with a subpopulation of 
astrocytes in the hippocampus detectable at an early time point.  HspB5 and HspB8 
expression was observed in all GFAP positive astrocytes. 
  The changes observed in each model and potential implications for sHsp function were 
discussed in Chapters 5 and 6.  However the disease specific sHsp responses raise some 
interesting questions and correlate with some key differences in these models i.e. the 
location of aggregates, astrogliosis and the inflammatory response. 
7.1.  Protein aggregation and astrogliosis 
  sHsp expression changes could be due to protein misfolding itself, and its localization.  
The presence of extracellular aggregates in ME7 animals may be “sensed” by glial cells 
resulting in gliosis and up regulation of the sHsps.  However the selective expression of 
HspB8 in the CA1 at 13 weeks and expression of HspB1 in a subpopulation of astrocytes 
restricted to the stratum radiatum suggests this early astrocytic response is unlikely to be a 
consequence of extracellular deposition as PrP
sc deposition in this region of the 
hippocampus is sparse at this time point (Cunningham et al., 2003).  It is more likely a 
result of the early synaptic dysfunction and loss that occurs in the CA1 region at this time 
point (Cunningham et al., 2003). 
  Interestingly, the differential astrocytic response in the stratum radiatum and lacunosum 
moleculare layers of the CA1 could be associated with the distinct innervations of these 
layers in the hippocampal formation.  The stratum radiatum receives inputs from CA3 
pyramidal neurons; these synapses are selectively lost during ME7 induced pathology.  
The entorhinal cortex projects to the subiculum and to both the CA1 and CA3 and the 
terminals of these fibers projecting to CA1 and CA3 are present in the stratum lacunosum 
moleculare (van Groen et al., 2003).  Group II metabotropic glutamate receptors (mGluRs) 
which modulate neuronal excitability and synaptic transmission are highly expressed in the 
terminal field of inputs from the entorhinal cortex in the stratum lacunosum moleculare of 
the CA1 compared to other regions (Ohishi et al., 1998).  The distinct nature of these 
inputs compared to the stratum radiatum, may indicate that a distinct set of astrocytes are 
involved in their surveillance.  Indeed, astrocytes in this region of the hippocampus are   251 
morphologically different from the astrocytes in the stratum radiatum (Nixdorf Bergweiler 
et al., 1994; Ogata and Kosaka, 2002) which would support the potential for differential 
induction of the sHsps and other response depending on the affected synapses.   
  It can be speculated that up regulation of sHsps in the CA1 is associated with possible 
changes in the microenvironment, synaptic dysfunction and degeneration in the CA1 in 
particular the stratum radiatum and may mean a protective response is induced to protect 
against the cell loss that occurs there at late stage of disease.  Indeed, in ALS astrocytes are 
thought to interact with motor neurons in a complex manner.  Tg mice expressing mutant 
SOD 1 (a model of ALS) were shown to release fibroblast growth factor 1 (FGF 1) to 
induce local astrocyte activation by signalling through the FGF 1 receptor leading to the 
expression of antioxidant and cytoprotective enzymes such as heme oxygenase 1 to 
prevent motor neuron degeneration (Pehar et al., 2005, Vargas et al., 2005).  However 
FGF 1 activation of astrocytes has also been reported to promote motor neuron apoptosis 
(Cassina et al., 2005).  Further, in the brains of AD patients, reactive astrocytes selectively 
expressing nitric oxide synthase (NOS) were found at the place of clear and overt neuronal 
loss, particularly in the entorhinal cortex layer II and CA4 (Simic et al., 2000). 
  The sHsp induction at the late stage of disease may represent a distinct astrocytic 
response during disease, separate to that seen at earlier time points, and is perhaps due to 
the accumulation of PrP
sc which is deposited throughout the hippocampus at late stage 
(Cunningham et al., 2003).  The heterogeneity of astrocytes in the hippocampus as 
discussed in chapter 6 would support such a differential response associated with different 
stages and events during pathogenesis. 
  An astrogliosis associated with synaptic/cell loss and extracellular misfolding in the ME7 
model suggests that in a model where there is very limited cell loss, as in the R6/2 model 
(Turmaine et al., 2000) astrogliosis may not be a prominent feature.  Indeed in the R6/2 
animals we did not observe an astrogliosis to the same extent as in the ME7 model.  
However the limited astrogliosis in the frontal cortex as shown by western blotting 
suggests cortical astrocytes may be more sensitive to disease related changes in the cortex.   
  Protein aggregation within neuronal cells in R6/2 animals could mean that astrocytes are 
unable to ‘sense’ these aggregates and therefore do not response by way of astrogliosis.  
Additionally the limited number of aggregates in glial cells suggests they are able to deal   252 
with misfolding events much more efficiently than neurons and therefore do not become 
activated. This would be consistent with the limited astrogliosis we observe in R6/2 
animals, with up regulation at late stage of disease only in the frontal cortex.    
7.2.  Inflammation 
   Our studies show changes of sHsp expression in non neuronal cells that are potentially 
an important source of aspects of the innate immunity (McKinnon et al., 1993, Omari et 
al., 2005).  As suggested in previous chapters the astrocytic up regulation of the sHsps in 
the ME7 animals and downregulation of HspB5 in R6/2 tg animals may contribute to and 
modulate the inflammatory response in either disease.  Overall an anti inflammatory 
response is observed in the ME7 model (Cunningham et al., 2005).  Increased expression 
of the sHsps could act as an inflammatory “break” by promoting the production of anti 
inflammatory cytokines such as IL 10 as discussed in chapter 6.  
  The contribution and nature of an inflammatory response in R6/2 animals is not clear as a 
number of studies show differing reports with opposing changes in gliosis associated with 
R6/2 tg animals (Ma et al., 2003, Simmons et al., 2007).  In a recent study, stimulation by 
LPA of isolated macrophages or microglia from mouse models of HD including R6/2 has 
been shown to induce the production of pro inflammatory cytokine IL 6.  The serum levels 
of cytokines in end stage R6/2 animals have been reported to be elevated, included Il 6, IL 
10, and IL 1β (Bjorkqvist et al., 2008).  The mouse model data was show to be consistent 
with cytokine production in human serum samples in the same study.  Opposed to this, no 
changes in the levels of pro inflammatory cytokines were observed in end stage R6/2 tg 
animals (A. Wyttenbach, personal communication). 
  However, in view of the anti inflammatory response potentially associated with up 
regulation of the sHsps in the ME7 model, it can be postulated that R6/2 tg animals may 
produce a pro inflammatory cytokine profile.  HspB5 involvement in modulating 
inflammatory pathways also points towards a potential pro inflammatory profile, 
particularly as loss of this protein was found to exacerbate the pro inflammatory response 
in a mouse model of EAE (Ousman et al., 2007).  Thus it will be important to elucidate the 
nature of the inflammatory profile in R6/2 animals, or indeed the way in which they 
respond to additional insults (e.g. peripheral infection).    253 
7.3.  Potential mechanisms for sHsp regulation   
  Although the sHsp response in intra vs. extracellular proteinopathies is distinct, both 
models show a common convergent feature in that mRNA expression does not underpin 
changes in protein expression. Transcript analysis of the sHsps in R6/2 and ME7 animals 
showed that this was not the mechanism regulating the changes in expression.  These 
observations raise the question; how is sHsp expression modulated in R6/2 and ME7 
animals?  It is most probable that post translational regulation such as increased or 
decreased protein turnover, underpin the changes observed.  To address the likelihood of 
increased/decreased sHsp degradation, in vitro culture systems could be utilised.  Cell 
models of prion (Gu et al., 2002) and HD (Wyttenbach et al., 2001) have been used to 
investigate disease related changes and such models could be used to analyze changes in 
the sHsps e.g. pulse chase experiments under conditions of UPP/autophagy inhibition.  
Interestingly decreased expression of HspB1 has been suggested to contribute to Machado 
Joseph disease (MJD), an autosomal dominant spinocerebellar degenerative disease caused 
by expanded polyQ tract within the ataxin 3 gene (Wen et al., 2003).  This led to analysis 
of the mechanisms involved in downregulation of HspB1 expression.  In cell models of 
MJD expressing mutant ataxin 3, HspB1 levels were found to be significantly reduced 
compared to cells expressing normal ataxin 3 (Wen et al., 2003).  The changes in protein 
expression were not associated with transcriptional changes as determined by PCR. 
Therefore
 35S methionine pulse chase labeling was used to label newly synthesized 
proteins.  This data revealed reduced levels of 
35S labelled HspB1 in mutant cells 
compared to control cells indicating alterations in protein synthesis which were also not 
affected by HspB1 degradation by the UPP (Chang et al., 2009).  The authors noted that 
alterations in HspB1 expression were not reflective of general changes in protein synthesis 
and degradation as other proteins (Bcl 2 and Hsp70) did not show similar reduction in 
protein expression and were accumulated in the cell after proteasomal inhibition (Chang et 
al., 2009). 
  This study indicates that sHsps levels may be modulated by alterations in degradative 
pathways, likely mediated by the autophagy lysosomal pathway.  Indeed protein 
degradation pathways are altered during both prion disease and HD as described in the 
general introduction.  Htt aggregates in cell and mouse models have been suggested to   254 
induce autophagy (Ravikumar et al., 2004).  In prion pathology, neurons in the vicinity of 
tissue damage were found to contain PrP
sc in lysosomes, indicating that overloading 
endosomal/lysosomal function may correlate with regional pathology (Kovacs et al., 
2007).  Additionally PrP
sc has been shown to inhibit and impair the UPP in a number of 
cell lines (Kristiansen et al., 2007).  These observations suggest the potential for reduction 
of sHsp degradation in ME7 animals by impaired UPP.  The situation in the R6/2 model in 
this respect is less clear as the role of the UPP in HD is controversial.  However, it may be 
speculated that HspB5 degradation is increased via the UPP in R6/2 animals.   
  Another post translational modification that may be important for protein stability is 
phosphorylation.  The phosphorylation state of the sHsps is important in modulating their 
functional role.  The sHsps are rapidly induced at the transcriptional level following stress, 
but also undergo several post translational modifications that alter their functional roles for 
use as immediate response elements (Stetler et al., 2009).   
  As proposed for HspB5, induction of   calpain in late stage ME7 animals may decrease 
sHsp phosphorylation thereby altering oligomeric status and promoting a chaperone 
function.  It may be that the phosphorylation state of HspB1 and HspB8 at 13 weeks is 
different to HspB5 at late stage supporting a differential response.  Interestingly changes in 
the ERK/MAPK signalling pathways have been observed in a study analyzing the gene 
expression changes in mice infected with scrapie strains 22A, ME7 or 79a (Sorensen et al., 
2008).  An increase in MAPK signaling could promote the phosphorylation of the sHsps as 
they are downstream targets and would support a role in cytoskeletal regulation.  The need 
for cytoskeletal regulation and support is suggested by a study demonstrating 
colocalisation of  PrP
c and PrP
sc with GFAP in brain homogenates from healthy and 
scrapie (263 K) infected hamsters respectively (Dong et al., 2008), suggesting the PrP
sc 
species could alter cytoskeletal dynamics in prion infected animals resulting in GFAP up 
regulation.  GFAP up regulation in astrocytes is followed by changes in other cytoskeletal 
components such as vimentin and vinculin, resulting in remodeling of the actin 
cytoskeleton (Ostrow and Sachs, 2005).  Determining the phosphorylation and oligomeric 
state of the sHsps would further help discern their potential role during disease.   255 
7.4.  Potential for modulating sHsp levels 
  One of the key questions arising form this study is whether the sHsp are protective in 
these disease contexts?  A number of studies have investigated regulation of the sHsps 
during insults such as ischemia and excitotoxicity suggesting that the sHsps play a 
protective role (An et al., 2008, Stetler et al., 2008).  For example, transgenic mice 
overexpressing HspB1 that were subjected to kainate induced neurotoxicity were found to 
have reduced lesion size, less seizures and neuronal death in comparison to wild type 
controls (Akbar et al., 2003).  
  However, studies that have involved overexpression of the sHsps under chronic 
neurodegenerative conditions have not shown a similar protective effect.  For example, tg 
mice overexpressing HspB1 when crossed with R6/2 mice, showed no improvements in 
the R6/2 phenotype.  Additionally, HspB1 was unable to reduce oxidative stress and the 
lack of protection was associated with the presence of low molecular weight species and 
not large oligomeric species that were shown to be present in heat shocked brain lysates 
(Zourlidou et al., 2007), suggesting the importance of post translational regulation of the 
sHsps.  Overexpression of the large Hsps has similarly not led to neuroprotection.  For 
example Hsp70 mice were crossed into R6/2, resulting
 in only modest effects on disease 
progression (Hansson et al., 2003).  In contrast, the loss of Hsp70 by gene knockout was 
shown to exacerbate pathogenesis and reduce survival of R6/2 tg animals (Wacker et al., 
2009) clearly implicating this chaperone as a protective factor.  Interestingly Hsp70 
knockout mice did not produce an exacerbation of disease in the RML mouse model of 
prion disease, suggesting Hsp70 knockout mice were not responding generally to protein 
misfolding diseases but the response was selective to the HD context (Wacker et al., 2009).   
  Although the overexpression studies have not been able to show an improvement in 
neurodegenerative outcomes by overexpression of Hsps, it may be that the key Hsp has not 
been targeted or that indeed several Hsps need to be targeted (Sajjad et al., 2010).  Based 
on our data, and the proposal that white matter specific downregulation of HspB5 is a 
potential contributor to the HD pathology observed in R6/2 animals, it may be proposed 
that up regulation of HspB5 could have beneficial effects and alleviate the symptoms and 
potentially extend the life span of R6/2 animals.  Indeed loss of sHsps has important 
implications for normal cellular functions as illustrated by the study on heat shock factor 1   256 
(Hsf 1) knockout mice.  These mice have been shown to develop many of the 
characteristic symptoms of neurodegenerative diseases, such as severe astrogliosis, 
activated microglia, impaired UPP, oxidative stress and progressive myelin loss (Homma 
et al., 2007).  
  Genetically engineered knockout mice have been established for HspB1 (Huang et al., 
2007) and HspB5 (Brady et al., 2001).  HspB1 KO mice do not display morphological 
abnormalities; however HspB5 KO mice have muscle degeneration selective to the tongue 
and soleus (Brady et al., 2001; Huang et al., 2007).  These mice also display a modest 
ageing phenotype (personal communication, A Wyttenbach).  Such models could be used 
to answer the question whether the induction of the sHsps in ME7 animals is protective.  If 
so, an exacerbation and enhanced progression of disease is likely to be observed in sHsp 
knockout mice inoculated with ME7 brain homogenate. Similarly crossing HspB5 
knockout mice with R6/2 tg animals will provide indications to the role of HspB5 in this 
disease.  The potential for further exacerbation of pathology in R6/2 animals and an 
induced inflammatory response is supported by HspB5 knockout studies in an EAE model 
as discussed in Chapter 5 (Ousman et al., 2007). 
  An important consideration arising from our observations is the potential that the 
selective downregulation of HspB5 in oligodendrocytes, although very interesting may be 
an artifact of this disease model, for this reason it will be necessary to establish possible 
changes in HspB5 expression in other mouse models of HD.  Indeed, our preliminary 
results suggest a similar decrease in the R6/1 model of HD, however, analysis of human 
Vonsattel stage II brain tissue suggest variable expression of HspB5 in HD tissue 
compared to controls and no apparent loss of expression (M, U, Sajjad, unpublished data).  
This may reflect the distinctly higher levels of white matter in humans compared to rodents 
(Zhang and Sejnowski, 2000).  Analysis of more end stage human tissue and other HD 
mouse models is currently under way.   
  The striking sHsps signature suggests an important and differential effect in distinct 
proteinopathies.  This should be extended to systematically study the sHsp signature in PD, 
ALS and AD.  The emerging potential significance of non neuronal cells during chronic 
neurodegeneration is supported by this study.  The multitude of activities of the sHsps 
suggests that they could play various roles in the complexity of intra  and extracellular   257 
proteinopathies.  It is likely that misfolding events drive an induction or indeed a reduction 
of sHsp protein expression which may then modulate inflammatory pathways.  Or, 





























Figure 7.1. Modulation of cellular processes by the sHsps in extra vs. intracellular 
proteinopathies.  Misfolding events may drive changes in sHsp expression in both 
extracellular and intracellular proteinopathies.  These changes may modulate gliosis and 
inflammation.  Or, indeed misfolding may drive gliosis which in turn may modulate sHsp 
expression.  (A) In the R6/2 model, HspB5 downregulation may promote a pro 
inflammatory response (1) and inhibit an anti inflammatory response (2).  R6/2 phenotype 
and potential gliosis (pro inflammatory) may potentially be exacerbated in knockout 
animals crossed with R6/2 animals (3).  (B)Up regulation of sHsps in the ME7 model may 
promote an anti inflammatory response, or gliosis may modulate sHsp levels (1).  
Induction of sHsps may in turn inhibit or dampen a pro inflammatory response (2). sHsp 
knockout models inoculated with ME7 may alter the inflammatory response by potentially 
inhibiting the anti inflammatory response (3) and removing the inhibition on the pro 























































Figure A1. Example of standard curves from a QT PCR experiment.  Standard curves 
were made using cDNA from naïve tissue and were constructed from 5 fold serial dilutions 
(undiluted – 1:625) Duplicate reactions were performed at each starting concentration.  Ct 
threshold were automatically set at x1.0 standard deviation over cycle range. 
Figure A2. Example of a gene specific QT PCR experiment.  A gene specific reaction 
showing the Ct values at which a fluorescence signal becomes detectable.  Ct values for 
each sample are recorded as the Ct at which the fluorescence signal crosses the threshold. 
Figure A3. Example of melting curves from a QT PCR experiment.  Melting curves 
are shown from one experiment, depicting the fluorescence intensity and the melting point 
(Tm) of the amplicon. The presence of a single peak at the same Tm seen in the standards 
(standard melting curve not shown) supports specific amplification.  Additional peaks 
would suggest non specific priming and potential primer dimer formation. 
 
 
   260 





Synaptosomes Myelin P1 Homogenate Soluble Insoluble Soluble Insoluble
HspB1/Hsp25
HspB5/α α α αBC
HspB6/Hsp20
HspB8/Hsp22










Synaptosomes Myelin P1 Homogenate Soluble Insoluble Soluble Insoluble
HspB1/Hsp25





























Appendix 3  
Detergent extractability of the sHsps in brain homogenate. 
A simple fractionation protocol was adopted to investigate the detergent extractability of 
the sHsps in whole brain tissue.  This involved treating two halves of the same brain with 
different protocols.  A physiological buffer (100mM KCL, 20mM Hepes, plus compete 
protease inhibitor) was used to homogenize one half of the brain.  The other half of the 
brain was then homogenized in lysis buffer containing 1% NP 40 in order to mimic the 
protocol used for the 4 week and 9 week samples analysed in section 5.3.1.  The detergent 
extracted homogenate was centrifuged to produce a pellet (P1) and supernatant (S1) 
fraction.  S1 was further centrifuged to give a P2 and S2 fraction.  The S2 fraction was the 
equivalent of the samples analysed in section 5.3.1. 50 g of protein from each sample was 
resolved on SDS PAGE and western blotting was used to analyse expression of the sHsps 
(Figure A5).  
  The sHsps display differential detergent extractabilities in whole brain tissue (Figure A5).  
HspB1 is completely solubilised, and the majority of the protein is present in the S1 
supernatant fraction.  HspB5 is equally distributed between pellet and supernatant fractions   261 
from the first spin (P1 and S1), and is mostly present in the S2 fraction after the second 
spin.  HspB6 is triton insoluble and remains exclusively in the pellet (P1).  HspB8 is also 
equally distributed between the pellet and supernatant fraction after the first spin (P1 and 
S1), and is almost exclusively present in the S2 fraction after the second spin.   



















Figure A5. Detergent extractability of the sHsps.  50 g of protein were resolved by 
SDS PAGE and expression of the 4 sHsps was observed using a fluorescently labelled 
secondary antibody.  The sHsps display differential detergent extractabilities.  HspB1 is 
almost completely solubilised by NP 40, and is present in the initial supernatant fractions.  
HspB5 is distributed between pellet and supernatant fractions (P1 and S1), and is mostly 
present in S2 fraction after the second spin.  HspB6 is detergent insoluble and remains in 
the P1 pellet.  HspB8 is also distributed between the pellet and supernatant fractions (P1 
and S1), and in mostly present in S2 after the second low speed spin.  H (total brain 
homogenate in Hepes/KCL); P1 (1% NP 40 pellet 1); S1 (1% NP 40 supernatant 1); P2 
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Preliminary analysis of HspB5 protein expression in human Vonsattel stage II HD brain 
tissue.  Tissue was kindly provided by Dr. Richard Faull (University of Auckland, New 
Zealand) and Dr. Lesley Jones (University of Cardiff, UK). The tissue samples were 




















Figure A6.  Human frontal cortex  monoclonal HspB5 antibody.  C = control, HD: 















Figure A7. Human cerebellum   monoclonal HspB5 antibody.  C = control, HD: 
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Figure A10.  Human frontal cortex   immunofluorescence (green) for polyclonal HspB5 




















Figure A11. Human cerebellum   immunofluorescence (green) for polyclonal HspB5 
antibody.  Corresponding coomassie is shown below.  265 
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